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Résumé 
 
 
Le processus d'auto-assemblage est un phénomène naturel capable d'organiser des 
systèmes biologiques. Son utilisation par les chimistes comme procédé de synthèse a permis 
la formation de structures esthétiques et de systèmes supramoléculaires hautement complexes, 
avec des fonctions biologiques avérées. Depuis 1990, la stratégie d'auto-assemblage dirigée 
par des métaux a largement contribué à la conception et à la synthèse d'architectures discrètes. 
La formation de ces architectures spécifiques nécessite un contrôle minutieux des différents 
facteurs dirigeant le processus d'auto-assemblage. 
L'objectif de cette thèse est d'offrir un aperçu des règles dictant la formation des 
assemblages métalliques arène-ruthénium. Ceux-ci sont construits à l’aide de clips 
métalliques stables et de ligands polypyridiniques. La caractérisation des échanges 
dynamiques des ligands, au moyen d’une stratégie de marquage isotopique 1H/2D a démontré 
la stabilité et l'inertie relative de la structure rectangulaire. En outre, l'étude par résonance 
magnétique nucléaire, des espèces intermédiaires impliquées dans l'assemblage de cycles 
métalliques, a permis de mettre en exergue la nature dynamique de la liaison Ru-N en 
solution, avant la fermeture définitive des cycles métalliques. Cela nous a permis de décrire 
une voie de germination thermodynamique plausible avec une réactivité spécifique de ces 
assemblages métalliques. 
Par ailleurs, l’activité anticancéreuse prometteuse des complexes mononucléaires 
arène-ruthénium, ainsi que l’accumulation préférentielle de leurs espèces macromoléculaires 
dans les cellules cancéreuses, confèrent un potentiel antiprolifératif  très intéressant aux cages 
métalliques arène-ruthénium. Ainsi notre stratégie pour optimiser l'activité biologique des 
prismes métalliques comportait deux approches. Dans un premier temps, la fonctionnalisation 
des ligands pontés, a permis d’améliorer la sélectivité des composés actifs contre les cellules 
cancéreuses. Dans un second temps, la modification de la taille des ouvertures, de la cavité 
des cages métalliques, a permis de contrôler la libération d’un photosensibilisateur 
hydrophobe dans une lignée cellulaire humaine du cancer du côlon HT-29. 
 
 
 
Mots Clés 
 
 
Complexes arène-ruthenium, chimie supramoléculaire, auto-assemblage, cycles métalliques, 
Ligands N, processus dynamique, mécanismes réactionnels, complexes dinucléaires, 
complexes tétaranucléaires, complexes hexanucléaires, complexe hôte-invité, activité anti-
cancéreuse, administration de médicaments, thérapie photodynamique. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Summary 
 
 
The self-assembly process is a natural phenomenon with the ability to organize 
biological systems. Its development by chemists as a synthetic process allowed the formation 
of esthetical structures as well as highly complex supramolecular systems with remarkable 
biological functions. Since 1990, metal directed self-assembly strategy has largely contributed 
to the design and synthesis of discrete architectures. The formation of these specific 
architectures needs some control over the different factors ruling the coordination self-
assembly process. 
The aim of this thesis was to offer an insight into the rules dictating the formation of 
arene ruthenium metalla-assemblies built from stable dinuclear metalla-clips and polypyridyl 
linkers. The characterization of the dynamic ligand exchanges using the 1H/2D isotope 
labeling strategy showed relative stability and inertness of the final structure. In addition, the 
study of the intermediate species involved during the assembly of metalla-cycles by NMR 
experiments highlighted the dynamic nature of the Ru-N bond in solution before the final 
closure of the metalla-cycles. This helped us to describe a plausible thermodynamic 
germination pathway together with the specific reactivity of such metalla-assemblies. 
The promising anticancer-activities of the mononuclear arene ruthenium complexes 
along with the preferential accumulation of macromolecular species in the cancer cells led to 
more interest in the anti-proliferative potential of arene ruthenium metalla-cages. Our 
strategies in order to optimize the biological activity of arene ruthenium metalla-prisms were: 
Functionalization of the bridging linkers resulted in selectivity improvements of the active 
compounds towards target cancer cells; and the modification of the portal’s size of metalla-
cages to control the release of a hydrophobic photosensitizer on the human colon cancer cell 
line HT-29. 
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1        
Introduction 
 
	
 
 
 
 
1.1 Supramolecular Chemistry 
 
Supramolecular chemistry or "chemistry of molecular assemblies and intermolecular 
bonding" as described by Lehn,1 is a branch of chemistry "beyond the molecules".2 This 
concept is opposed to molecular chemistry by the type of chemical bonds involved, the 
preparation process and also in terms of the size and dimension of the formed molecule.3 
While molecular chemistry focuses more on the synthesis of a single molecule constructed via 
covalent bonds, supramolecular chemistry deals, however, with macromolecules assembled 
spontaneously from finite number of individual molecules. These molecules are hold together 
via a variety of intermolecular interaction of different strength.4 In nature, weak forces such as 
hydrogen bonds, Van der Waals and electrostatic interactions are responsible for the spatial 
organization of the majority of bio-macromolecules (DNA, RNA, Proteins…).5, 6 In 
chemistry, an ever-increasing number of elegant systems and discrete architectures with 
unique properties have been synthesized via metal-ligand coordination bond, strictly covalent 
bonds, weak interactions where sometimes two or both are gathered. This flexibility leads to 
unusual application in biology, physics and material science, allowing this new area of 
chemistry to be a highly interdisciplinary field.7, 8  
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Historically the concept of supramolecular chemistry was based on three principles.4  
The first one was proposed in 1893 by the Nobel laureate Alfred Werner (1913) who 
introduced the notion of coordination chemistry: electronically saturated molecules can still 
bind if they have "mutual affinity" to form "complexes".9, 10 The second principle concerns 
the molecular recognition, which was established in 1894 by the Nobel laureate Emil Fisher 
(1902) for introducing the "lock-and-key" concept.11 For the enzyme-substrate interactions, 
"binding must be selective", and the recognition requires size and shape complementarity.11, 10 
The third principle was proposed by the Nobel laureate Paul Ehrlich (1908) in 1906, who 
introduced the concept of receptor: molecules do not react if they do not bind.12, 10 All these 
three fundamental principles have certainly been developed over the years, but they remain 
the foundation of supramolecular chemistry. And noticeably, 1987 is a headlight date in this 
field, when three pioneers, Donald J. Cram, Jean-Marie Lehn, and Charles J. Pedersen, were 
awarded the Nobel Prize for Chemistry in recognition of their contribution to rationalize the 
general concept of supramolecular chemistry. The development of a series of rigid hosts like 
spheroids,13 cryptands2 and crown ethers14 able to recognize selectively a guest was 
highlighted as a major contribution to chemistry (Fig. 1). The breadth of supramolecular 
chemistry has progressively increased since then, and today is a mature field of science which 
gathers chemistry, physics and biology.8 
 
Figure 1. Some examples of supramolecular host molecules. 
 
1.1.1 General Concept in Supramolecular Chemistry 
 
As we described above, the germination process of supramolecular assemblies and the 
recognition "catch and  release" of a guest by a receptor, constitutes the main pillar of 
supramolecular chemistry.4, 8, 15, 16 In addition, supramolecular species assembled 
spontaneously from a number of different building blocks by recognition of each other 
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through thermodynamic preferences.17 This process called "self-assembly" is a successful 
synthetic tool which gives rise to the complex targeted structure in high yield as compared to 
conventional organic synthetic strategies.17, 18   
Molecular recognition, the "key-lock" concept described in the early 1894 by Emil 
Fisher, is a fundamental facet in the "host-guest" chemistry.11 A substrate or a "guest" 
molecule binds (interacts) selectively to a molecular receptor (host) to form a host-guest 
complex.19 The manner in which the molecules are able to identify each other is a form of 
self-assembling process. The chemical and the thermodynamic properties of the final complex 
should be unique and have different physicochemical properties as compared to the single 
starting units.8 
 
1.1.2 Molecular Self-Assembly 
 
 George M. Whitesides fixed the major elements leading to a successful self-assembly 
strategy. He summarized five characteristics related to supramolecular assemblies 
(components, interactions, reversibility or adjustability, environment, transport and 
agitation).17 
Components: The self-assembling supramolecular architecture results from the 
organization of a finite number of molecules or segment of macromolecules via an 
interaction, occurring through unfavorable entropy.17, 20 The shape complementarity of the 
molecules to recognize each other via a specific interaction is a crucial factor.21 
 Interactions: The forces responsible for the spatial arrangement of the different 
blocks vary from weak and noncovalent interaction (hydrogen bonds, Van der Waals forces, 
hydrophobic effects…) to relatively weak (coordination) bonds.4 The strength, the stability 
and the lability of the interaction presents the key-factor to predict the architecture and to 
determine the physicochemical properties of the final system.22, 23, 24 If George M. Whitesides 
described this intermolecular linkage as "balances of attractive and repulsive" interactions,17 
Lehn and Stang put forward the notion of the "interactional algorithms".8, 25  
Reversibility (or adjustability): The self-assembly is a kinetically reversible process. 
Before reaching the final closure, the reaction intermediates may pass through numerous 
correction and reorganization steps. The final system is thermodynamically stable.26, 27 
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Environment: Solvent,28 species and external stimuli such as light,16  pH,29 are able to 
direct the synthetic process pathway affecting the final geometries of the targeted molecule. 
For example, using a template synthesis to favor the formation of a specific shape and 
architecture was well investigated.30 
Transport and Agitation: During the process, the reaction intermediates gain 
advantages in mass and size. In fact, their mobility is becoming increasingly difficult and the 
risk of their precipitation before reaching the target compound increases as well. Therefore, 
assuring the motion required to maintain the mobility of the compound in solution is a 
challenge for chemists.17   
Another classification, proposed by Stang, is based on the nature of the interactions 
used in the self-assembling process. He suggested three main classes of supramolecular 
compounds depending on the nature of the interaction: (i) supramolecular architectures via 
hydrogen boding; (ii) supramolecular structures designed by using non-covalent interactions 
such as ion-ion, ion-dipole, π-stacking, van der Waals forces and hydrophobic interactions, 
and (iii) those employing a strong and directional metal-ligand links for assembly process.8 
 
1.1.3 Molecular Self-Assemblies via Hydrogen Bonds 
 
It is evident that the most visible example highlighting the potential of the non-
covalent interaction in making extremely complex macro-molecules in our life comes from 
Nature.31 For example, in protein folding, hydrogen bonds are responsible to maintain the 
stability. The self-assembling of the phospholipids through the hydrophobic effect gives a 
bilayer supramolecular structure.32 Similarly, the double helical structure of DNA is another 
example of Nature’s supramolecular chemistry, where different nucleotides carried by each 
DNA strands interact via hydrogen bonding.31 Inspiration for chemists from these 
aforementioned structures is not limited in mimicking the biomolecules but giving rise to a 
highly fertile ground of creativity.8, 33 The breadth of these interactions as synthetic tools has 
progressively increased due to their unique advantages. Mirkin gathered two major points: i) 
the flexibility of the self-assembling system allows free spatial conformational switches 
(changes) to the structure. ii) the specificity in the synthetic process in which the final 
compound occurs in the lowest state of energy leading to the most thermodynamically 
favorable structure.6 
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The Rebek group developed a number of supramolecular capsules by assembling two 
cavitands and four glycoluril derivatives holding via hydrogen bonding,34, 35 to overcome the 
problems of the polymerization during the process which present the main challenges in this 
area of chemistry (Scheme 1).15b, 36 
 
Scheme 1. Potential structures formed by assembling cavitands via non covalent bonds (a) discrete 
capsule and (b) polymeric species.15b 
 
Aekeroy et al. designed a new kind of cavitands and functionalized it with tetra-
acetamido groups (like a chelating group) generating a N-H···O hydrogen bonds, “a self-
complementary hydrogen-bond interaction” leading to the formation of a discrete 
supramolecular capsule C1 (Fig. 2).15b   
 
Figure 2. Molecular structure and space filling diagram of the discrete supramolecular capsule 
(C1).15b 
 
A new class of synthetic bio-nanoassembly using biomolecules like segment of protein 
or DNA precursor as main building blocks has become a challenging area.37, 38, 39 An elegant 
example of macrocycle constructed through a hydrogen bonding, using DNA precursor has 
been described by H. Sleiman et al. in the presence of ruthenium (II) complex as a template. 
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The mixture of the subunits leads spontaneously to the formation of a square structure. 
Without addition of the template (assistance), a number of systems with different shape and 
size are formed in the final mixture (Fig. 3).40 
 
Figure 3. Selective formation of self-assembling cycles using DNA precursors in the presence of the 
template synthesis (ruthenium (II) complex) (ii) A mixtures of oligomers and self-assembling cycles 
with different geometries. (Adapted from ref.40) 
 
Interesting developments have been made by chemists in the last decades to increase 
the efficiency of these kinds of interactions by using a new synthetic strategy like template 
synthesis and controlling the complementarity in the shape (chelate effect).15b,40 Despite of 
this, during the germination process of the desired structure, the scale and the degree of 
complexity increases. However the ability to control the geometry of the structure becomes 
more and more difficult, due to the lack of the directionality.38 Coordination-driven self-
assembly, which defines the third approach, is an interesting subset of self-assembly. The 
highly directional and relatively strong metal-ligand coordination bonds affords the possibility 
to design and synthetize a numerous of 2D and 3D supramolecular assemblies with well-
defined shapes, sizes and geometries.41, 42, 43 
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1.2 Coordination-Driven Self-Assembly 
 
The effectiveness of the metal directed self-assembly strategy to design and synthesize 
discrete architectures has been widely demonstrated. Based on the "bottom-up" synthetic 
strategy, a plethora of two and three dimensional structures have been produced in recent 
years.8, 44 Starting with simple structure like squares,45 polyhedrals46 and triangles,47 chemists 
have created well-defined structure such as grids48, double squares49 and helicates48, 50 with 
high precision, great efficiency and different functionalities.51 
 In addition to the basic concepts of coordination chemistry, nowadays supramolecular 
chemists are establishing the fundamental concepts of this new area of chemistry. These new 
developments can be classified into three major elements. The first focuses more on the 
characteristics of the metal-ligand bond (strength, lability and stability), which provides 
precious information about the rigidity, thermodynamic and kinetic stability of the final 
structure. The second concerns the geometrical algorithms: the prearrangement of the 
coordination angles, availability of the coordination sites together with the complementarity 
in shapes between the starting building blocks is crucial to perform the directionality to the 
target supramolecular architecture. The third is based on the thermodynamic and the kinetic 
driven formation of the final system. Based on these concepts, three major synthetic strategies 
have been established "Weak-Link", "Symmetry Interaction" and "Directional Bonding" 
approaches.6, 8  
 
1.2.1 Metal-Ligand Linkage 
 
To gain further insights about the structure, reactivity and stability of supramolecular 
assemblies produced via a coordination-driven self-assembly strategy, knowing the 
thermodynamic, kinetic and geometric aspects of the metal coordination precursors are 
essential. While the stability and the inertness are the main characteristics of organic or 
inorganic molecules produced via classical chemical covalent bonds, the lability and the 
relative stability are however crucial in the case of coordination metal compounds. These 
differences come from many factors such as bonding mode, bond strength and electronic 
structure of the final molecules.52 The covalent bonds are formed by two non-metal atoms 
sharing two electrons from both elements. The linkage generated by this electronic interaction 
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is quite robust. It varies from 250-500 kJ·mol-1 for a single bond (C−H, C−C, O−H and N−H), 
up to 500 kJ·mol-1 for a double bond (C=O, C=N) and 800 kJ·mol-1 for a triple bond (C≡C). 
The coordination bond is on the other hand formed when a ligand (Lewis base) provides an 
electron pair to a charged or neutral metal (Lewis acid). The force connecting the metal center 
with ligands depends on the energy of the atomic orbitals interacting between the two 
elements. The metal-ligand bond is a part of the large family of the weak interactions. Their 
strength (50-150 kJ·mol-1) is intermediate between the intermolecular interactions (eg. 
hydrogen bond, Van der Waals forces (<60 kJ·mol-1)) and the covalent bonds (Table 1).52, 53   
Table 1. Strength of some covalent and non-covalent forces 
Type of interaction or bonding Strength (kJ·mol-1) 
Van der Waals forces <5 
π-π 10-40 
Hydrophobic effects <50 
Cation-π 5-80 
Dipole-dipole 5-50 
Hydrogen bond 20-60 
Metal-ligand 50-150 
Covalent bond 250-800 
 
The bond strength is an energetic parameter. Even though it’s merely indicative of an 
order of magnitude, it leads to a clear classification of the chemical interactions (weak and 
strong). It clearly shows that the energetic barrier for such bond, which is usually easily 
formed and broken, is more favorable compared to the covalent bond. Despite this facility of 
the dynamic exchange, the efficiency of the weak interactions to generate systems with good 
thermodynamic stability has been well demonstrated.52 
For the coordination metal compounds, the thermodynamic stability is crucial to 
rationalize our knowledge about the behavior of metal complexes in solution. It deals with the 
stability constant (K) and the Gibbs free energy (ΔG°) in the reaction equilibrium. If the 
association constant K is very high, the energy is negative (ΔG° < 0) and the final complex is 
stable. This thermodynamic factor is directly related to the reaction environment (solvent, 
temperature, ligand and metal ion). The charge, the electronic and the geometric structure of 
the metal ion and the sterical (geometrical factor) and the chelating effect (entropic factor 
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(ΔS)) related to the ligand are the major elements affecting the stability of the final complex.                        
Another qualitative theory was developed in 1963 by Ralph G. Pearson who introduced the 
notion of the "hard, soft" acid and base or class (a) and class (b). "Hard acids bind strongly to 
hard bases and soft acids bind strongly to soft bases". This theory gives the opportunity to 
better predict the thermodynamic behavior of such metal complexes.54 
The stability and the inertness of the complexes are two different types of parameters: 
the first one related to the thermodynamic stability and the second one to the kinetic stability. 
To overcome this confusion, many examples are discussed in the literature in which 
coordination compounds are stable and labile or inert and instable. Despite their stability, the 
rates of the ligand exchange in these three complexes [Ni(CN)6]3-, [Mn(CN)6]3-, [Cr(CN)6]3-  
are different. The substitution of the CN- ligand by their labeled 14CN- in the nickel system is 
very rapid (30s) compare the last two complexes (1h and 24d, respectively). Therefore, the 
Ni-CN coordination bond in the complex [Ni(CN)6]3- is termed labile, whereas the Mn-CN 
bond in [Mn(CN)6]3- and the Cr-CN bond in [Cr(CN)6]3- are called inert.55, 56 
 
 
In acid solution the [Co(NH3)6]3+ complex with inert coordination bonds decompose 
following this pathway:  
         
  
Henry Taube (Nobel Prize in Chemistry, 1983) is a pioneer who studied the dynamic 
behavior and developed the kinetic parameters of several coordination compounds.57  He 
classified the complexes into labile and inert groups based on the reaction time and the rate of 
the metal-ligand exchange on the basis of substitution reaction and isomerization. In addition, 
labile complexes react fast, about one minute in 0.1 M solution at room temperature (25 °C) 
and those that are inert, under the same conditions react slowly (more than 2 hours). The rate 
of the metal-ligand exchange was also rationalized by Taube with the study of the 
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substitutions reactions of water molecules in different complexes. He noted that even the 
strength of the M-OH2 bond is merely in the same order of magnitude, the rate of exchange 
vary largely according to the metal ions. For example the rate of exchange for the Mg(II), 
Ni(II), Ca(II) and Na(I) is very fast (up to 109 sec–1) compared to the Pt(II), Ru(II), Os(II), 
Ir(III), Cr(III) with a slow rate of exchange (taking hours or even days) (Fig. 4). This lability 
is related to the nature of the coordinated groups, the radius, the charge and the electronic 
configuration of the complex ion.52, 57 
 
Figure 4. Schematic, logarithmic presentation of relative kinetics of aqua (H2O) ligand exchange, for 
a variety of metal ions.52 
 
The lability of the metal coordination bond is clearly demonstrated in the substitution 
reactions which proceed via two kinetic pathways, namely associative and dissociative 
process. The substitution can be easily followed if the incoming ligand is a water molecule 
(which can be labeled with the isotope oxygen-18) or by isotopic labeled molecular analogue 
of the substituted ligand.56 
Associative Process: This pathway is abundant for square planar complexes, where the 
dissociation of the substituted ligands takes place after the coordination of an incoming group 
as a fifth ligand (Fig. 5). The rate of the exchange is generally enhanced by the trans effect of 
the incoming ligands that are opposite to other certain ligands.  
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Figure 5. Metal-ligand exchange via an associative process: a) General pathway; b) Substitution of 
an ammonia ligand by a chloro ion in the complex [Pt(NH3)4]2+. 
 
Dissociative Process: The dissociation of the coordinated groups takes place before the 
association of the new ligands. For example, in octahedral coordination compounds, a five-
coordinate intermediate is generated during the process before reaching the equilibrium (Fig. 
6). 
 
Figure 6. Metal-ligand exchange via a dissociative process: a) General pathway; b) Substitution of 
water molecule by an iodide ion in the complex [Co(CN)5(H2O)]2-. 
 
The versatility of the coordination bonds, in addition to the ligands exchange are two 
major advantages provided by the coordination compounds. This dynamic behavior has been 
explored in two large areas: catalysis and biology. In the field of catalysis, this behavior is 
used to enhance the rate of the reaction and to produce original compounds inaccessible with 
conventional synthetic processes. Different catalytic processes with a collection of 
transformations and exchange mechanisms have been reported.58 
  In biology, reactivity and activity correlations give precious information about the 
mechanism and mode of action of the metallo-drugs with DNA and the bio-molecules.52, 59 
Moreover, it plays a key role in explaining and predicting the dynamic behavior and the 
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flexibility of the different blocks forming the coordination driven metalla-assemblies and an 
eventual self-organizations phenomena which presents the main topic of this work. 
 
1.2.2 Synthetic Strategies 
 
At the molecular level, it has been proven that the dynamic behavior of a single metal 
complex is related to the reversibility of the interaction between the metal ion and the ligands. 
However, the extrapolation of the same models to predict or to have deep information about 
such dynamic process at the macromolecular level may lead to false interpretations. 
A supramolecular system is an arrangement of a finite number of metal complexes and 
a collection of flexible ligands held together via a reversible and spontaneous process. In this 
pathway the initial precursors, the intermediates and the thermodynamic stable 
supramolecular assemblies are in vivacious interactions.8  The thermodynamic and the kinetic 
pathway of this course depend on the chemical properties, the geometrical affinity and the 
assembly conditions of this species.22, 60, 61 The design and the elaboration of the coordination 
driven metalla-assemblies can be understood by considering three different synthetic 
approaches. Each of these strategies possesses its specific and proper rules which dictate the 
formation of the metalla-assemblies.6, 62 
 
a- Weak-Link Approach 
 
The "Weak Link Approach" (WLA) is a simple convergent synthetic route capable of 
producing a number of flexible 2D and 3D metalla-rectangles, prisms and cylinders with 
adaptable cavity and geometry.63 The first bimetallic Rh(I) macrocycles synthesized via this 
strategy was presented by Mirkin et al. in 1998. He reacted a 1:1 stoichiometric ratio of Rh(I) 
precursor with a phosphanyl alkyl ether hemilabile ligand in the presence of silver 
tetrafluoroborate to produce the condensed structure A1, and isolated as tetrafluoroborate salt 
with high yield (<95%).64 
The phosphanyl alkyl ether ligand is an unsymmetric chelating ligand with two 
different connecting side (P,O). It interacts with the metal center through a strong (M-P) and 
weak (M-O) bonds. Addition of a small molecule such as carbone monoxide or acetonitrile 
(anscillary ligand) to the solution of the complex A1 breaks the weak bonds (M-O) and forms 
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strong (M-CO) or (M-CH3N) bonds. This self-rearrangement in the chemical forces generate 
a spontaneous spatial self-reorganization, leading to the formation of the open form structures 
A2 and A3 respectively, in which the two rings are expanded by 6 Å. In this thermodynamic 
stable structure, still the metal center is not inert. It possesses free coordination sites which 
can be used in many purposes. Mirkin et al. connected the two metalla-rectangles A2 and A3 
using ditopic ligands. For example, addition of one equivalent of 4,4`-biphenyldiisocyanide or 
4,4`-biphenyldicarbonitrile to A3 results in two elegant multifunctional cylinders C1 and C2 
respectively (Fig. 7).64    
 
Figure 7. Generation of 2D and 3D supramolecular assemblies with tailorable geometries from a 
starting condensed structure. An example highlighting the dynamic stuructural behavior of the 
coordination metalla-assemblies synthesized via the Weak-Link Approach.64 
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Later on, this work inspired chemists to successfully design a number of homo-
metallic supramolecular architectures with variable geometries and wide range of properties 
(Scheme 2).65 The major concept dictating the formation of these structures still deals with 
three major elements: simple flexible hemilabile ligands, rigid anscillary ligands and naked 
transition metal precursors.66 
 
Scheme 2. Principle of the Weak-Link Approach.67 
 
The spontaneous substitution of an anscillary ligand by another flexible donator group 
and the partial ligand dissociation of the hemilabile ligand without impacting the geometry of 
desired supramolecular structure are the major advantage of this approach. This trademark 
gives the possibility to produce a new class of supramolecular assemblies with high versatility 
and dynamic structures.68 
Even though, the major drawback resides in the low thermodynamic stability of the 
condensed structure. In fact an increasing of the temperature leads to the decomposition of the 
kinetic supramolecular system (fig. 8).6, 63a, 69   
 
Figure 8. Decomposition of the dimer structure into the thermodynamic stable monomer under 
thermodynamic control.6, 63a, 69 
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b- Symmetry Interaction Approach 
 
In this synthetic strategy, the geometry requirement to design the supramolecular structure 
is more important than in the other two strategies. Specific attention to the complementarity 
and symmetrical demands between the initial precursors is needed to overcome the wrong 
pathway leading to the formation of oligomeric mixtures.8 This specificity comes from both 
the metal ions and the ligands. In fact the acceptor groups used are generally naked metal ions 
which have a collection of binding possibilities and availability in their binding sites. The 
donor groups are rigid multibranched chelating ligands acting as bidentate ligands which are 
kinetically less labiled than monodentate analogues with respect to the coordination geometry 
of the metal ion. These kinds of ligand provide, however, a great stability in the targeted 
system due to the strong binding affinity with metal ions. This design strategy has been 
pioneered by Maverick70, 71 and developed later by Saalfrank72, Lehn73 and Raymond74. A 
plethora of highly symmetrical neutral or negatively charged supramolecular clusters based 
on the metal-ligands coordination bonds has been synthesized.75 The M4L6 tetrahedron is one 
of the most common tridimensional structures developed with this strategy.76 It consists of 
four metal ions at the vertices and six bis-bidentate ligands at the edges of the final structure 
(Fig. 9).77 
 
Figure 9. The tetrahedral M4L6 host assembled from four pseudo-octahedral metal centers and six bis-
bidentate catechol-amide ligands.77 
 
These tetrahedrons possess a cavity, whose ability to hide a guest molecules, 
especially cationic species, was intensively studied.78 The investigation of the kinetic self-
corrections and self-rearrangement phenomena under thermodynamic control has greatly 
progressed in recent years.77, The main target of these studies was to determine the main 
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elements and the pathway of the dynamic exchange of the guest from the M4L6 
supramolecular tetrahedral host. In fact two mechanism of exchange have been proposed, a 
dissociative or a non-dissociative pathway (Fig. 10).77  
 
Figure 10. Guest-exchange mechanisms involving host rupture (a) or passage through an aperture 
(b). An example of the flexibility and the dynamic behavior of the metalla-supramolecular assemblies 
synthesized via the symmetry interaction approach has been empirically proved.77 
 
The first mechanism consists of a partial disconnection of the ligand to the metal ion, 
thus opening a gate to ingress or egress the guest molecule: The tetrahedral structure being 
maintained. While in the second process a spatial self-rearrangement based on the elasticity of 
the host is needed to generate a gate for the release and catch of small molecules. In these 
studies, the results are in favor of mechanism (b) as the most plausible exchanging pathway. 
In fact, three arguments put evidences in that conclusion: i) the rapid exchange of NEt4+ by 
PEt4+ in both labile ([Ga4L6]12-) and inert hosts([Ti4L6]8- and [Ge4L6]8-) (Fig. 11); ii) the 
flexibility of the hosts to provide a gate for an eventual catch and release of a guest molecule 
through a non-dissociative pathway has been confirmed by theoretical calculations; iii) no 
exchange noted in the case of the CoCp*2+, a bulky guest molecule.77   
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Figure 11. The dynamic guest exchange of NEt4+ by PEt4+ in the [Ga4L6]12-, [Ge4L6]8-, and [Ti4L6]8- 
hosts in DMF-d7 at room temperature. (The ingress of PEt4+ within the cavity of the hosts increases 
with time, while encapsulated NEt4+ decreases).77 
 
1.2.3 Directional Bonding Approach: General Concept   
 
With a simple self-assembly synthetic pathway, a narrow geometrical design require 
high efficiency in the construction of metalla-assemblies structures, whether two or three-
dimensional. Nowadays, the directional bonding approach has become the most commonly 
used strategy. It consists of combining a stoichiometric ratio of building blocks with 
complementarity in shapes and geometries via the most suitable low-energy pathway.79 The 
form and the self-assembly properties depend on the affinity between the initial precursors 
(ligand and metal complex), their direction, angles and energies.41b  The first polygon 
obtained via this strategy, A4, was developed by Fujita et al. in 1990. It is a square metalla-
assembly, consisting of a 1:1 stoichiometric ratio of two type of building blocks, a linear 
ditopic ligand (4,4'-bipyridine) and an end capped (non-naked) metal complex (palladium (II) 
ethylene diamine, Pd (en)) (Fig. 12).45  
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Figure 12. Synthesis of the square A4 ({[(en)Pd(4,4’-bipyridine)4]8+}).43 
 
The pre-arrangement of the suitable rules favoring the formation of this coordination 
driven metalla-assembly are crucial. It can be summarized in three different aspects: 
geometrical concepts, properties of the chemical interactions and thermodynamics 
considerations.43  
While the major concepts dictating the formation of the structure described above are 
resuming the fundamental rules of the directional bonding strategy. Many pioneers in this 
field like Stang80, Severin81 and Fujita45 groups have successfully reprogrammed these three 
aspects. A large number of two and three dimensional metalla-assemblies having unique 
geometries, properties and applications were produced.51 The generalization and the 
rationalization of these rules in a general approach called (directional bonding approach) are 
very much reviewed. 
 
a- Geometrical Considerations 
 
Basically in this approach, the angles and the availability of the coordination sites of 
the metal complex are intentionally prearranged and designed. In fact, for A4, the 90° angle 
was produced and protected during the synthetic process by an inert metal-ligand bond 
forming a highly stable five membered metalla-cycle. Therefore, the rigidity is provided by 
the ethylene diamine - a chelating group occupying two available coordination sites at the 
metal ion. The complementarity in shape also favored square-planar geometry between Pd(II) 
metal complex and the bipyridine groups by replacing the two (NO3-) ligands and 
coordinating to the metal while respecting the initial molecular geometry.43   
 Chapter 1: Introduction 
19 
Even though, the use of naked metal ions (availability in the coordination sites) led to 
the formation of structures with miscellaneous shape, size and number of metals.82,41a 
Similarly in 2010, coordination of dipyridylthiophene with palladium (II) complex enabled 
the formation of spherical supramolecular structure C3 of type M24L48 containing 72 
assembly units. This giant cage was characterized by X-ray crystallographic analysis (Fig. 
13).83  
 
Figure 13. Molecular structure of rhombicuboctahedron C3 composed of dipyridylthiophene ligands 
and palladium (II).83, 84 
 
Stang is one of the pioneers in this field, who intensively developed this chemistry. He 
not only synthesized a plethora of metalla-assemblies: cubes, rectangles, squares, prisms, but 
also rationalizes the knowledge by coding the geometrical algorithm giving rise to the major 
number of the two and three dimensional structures with different shapes, size and 
geometries. 30, 84 For example, of a square-shaped supramolecular structure can be conceivable 
by various paths. One approach is to take a metal complex having coordinate angle 90 ° and 
mix it with the same proportion of a ditopic linear ligand. It is also possible to reverse the 
angles between the metal and the ligand. Finally, another alternative may be the mixing of 
ligand and complex (1:1) both having 90° angle of coordination. This approach results in 
different combinations of discrete structures as listed in (Table 2).8 
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Table 2. Library of ditopic ligands and metal complexes leading to various polygones.8 
 
 
 The development of three-dimensional systems (polyhedra) follows the same 
principle. In the case of a cube, for instance, a metal complex with tritopique angles of 90 ° is 
coordinated with a linear ditopic ligand. Different combinations of resulting polyhedron are 
listed in (Table 3).8 
Table 3. Library of ditopic and tritopic unit leading to various polyhedrons.8 
 
 
b- Metal-Ligand Coordination Bond 
 
As described in the section (1.2.1), the strength of the bonds, kinetic and 
thermodynamic properties of the metal-ligand coordination precursors is highly dependent on 
the metal center and the ligands. Their impact on the self-assembly formation of 
supramolecular entities has already been demonstrated. In addition, as reviewed by Fujita, it is 
empirically proven that [(en)Pd(NO3)2] and 4,4- bipyridine are the most successful precursor 
combinations. Many others experiments using different metals ions like (Ni, Co, Fe, Mn) and 
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combinations with different chelating ligands was never successful, except in the case of the 
platinum(II) but under high temperature 100 °C and slow reaction (several weeks).85 
Examination of the synthesis of Pt and Pd squares with cyano-ligand is another example 
(Figure 14). Under kinetic control, the palladium precursors form the targeted square. 
However a mixture of oligomers was found for the platinum analogue (Fig. 14).22, 23 
 
Figure 14. The formation of Pt oligomers versus thermodynamic product the Pd square. An example 
of the kinetic self-corrections phenomena.22, 23 
 
While the Pt corners possess similar chemical properties and spatial geometry as the 
Pd(II) complex, the reactivity and bonding strength of two metal ions with the linear ditopic 
ligand are different. The rate of the exchange of the 4,4-bipyridine with the Pt(II) complex is 
slower than the Pd(II) counterpart. Therefore, the rapid exchange between the initial building 
blocks, the reaction intermediates and the final compound is crucial during the synthetic 
process. This dynamic behavior favor the self-rearrangement and the self-correction during 
the synthetic process, transforming an eventual intermediate oligomers into a stable 
thermodynamically system.43  
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c- Thermodynamic Aspects 
 
 It is evident that targeting a single product can only be achieved if it is energetically 
favored vis a vis other systems. Therefore, the initial precursors should correctly pass through 
the right thermodynamic pathway to give quantitatively high yield. Otherwise, the reaction 
process may pass through many level and minima of thermodynamic energy, generating some 
byproducts such as oligomer mixture or closing structures (Scheme 3).43 
 
 
 
 
Scheme 3. A putative germination pathway of some supramolecular squares: 1) initial precursors; 2) 
oligomers mixture; 3) unstable closing structure; 4) thermodynamic system. 
 
If kinetic correction phenomena are not efficient, a thermodynamic equilibrium 
between triangle and rectangle is commonly encountered.86 This balance can be rationalized 
and interpreted from a thermodynamic point of view. Indeed, the enthalpy promotes squares 
to minimize the steric constraints (angle of 90° to 60°), while the entropy favors the triangle 
formation which involves fewer components and therefore generates more species from the 
same quantity of reagents. 
According to Le Chatelier principle, any variation of an external element (temperature, 
concentration, stoichiometric ratio) in the reaction environment affects this fluctuation and 
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favor one structure vis a vis another. An increase in concentration leads to the species favored 
by enthalpy (square) and a rise in temperature (and therefore the disorder) benefits the 
entropic species (triangle).20a, 84 
In the case of thermodynamic stable assemblies, exerting an external stimulus leads to 
novel self-organization phenomena.87 Severin et al. reported an example of a kinetic self-
rearrangement of an octanuclear arene ruthenium metalla-cage to a tetranuclear metalla-plate. 
The thermodynamic stability of these two structures is very sensitive to the solvent. In 
chloroform solution the system A5 is the most stable. While in the dichloromethane solution 
it decomposes into the complex A6 (Fig. 15).28  
 
Figure 15. Dynamic structural transformations of the systems A5 vs A6 under solvent control.28 
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Changing the stoichiometric balance of reacting species has been examined by Neogi 
et al..88, 89 The response of defined heteroleptic metallosupramolecular racks, rectangles, and 
trigonal prisms through the addition of pyridine ligands has been investigated. For example, 
excess of 1,2-di(pyridine-4-yl)ethyne, forces the metalla-rectangle to alter into a rack 
architecture in the solution (Fig. 16).89  
 
Figure 16. Dynamic interconversion of a thermodynamic stable closed system (A7) to an open 
structure (A8) under a stoichiometric control.89 
 
The spontaneous selection of a specific product from a collection of possibilities 
remains the main challenge in coordination-driven self-assembly. These spontaneous 
selections are related to the self-repairing, self-recognition, and self-rearrangement of the 
different species during the synthetic process, transforming an eventual intermediate 
oligomers into a stable thermodynamically system.21a  These self-organization phenomena are 
commonly encountered as theoretical argument to explain a successfully running algorithm. It 
was supported by the versatility of the coordination bonds and sometimes by such dynamic 
structural properties and thermodynamic fluctuations of some coordination-driven self-
assemblies. Indeed, examples that directly and quantitatively evidence these dynamic 
behaviors remain scarce. The kinetic and thermodynamic aspects of the assembly-
disassembly processes involved during the preparation of such supramolecular assemblies are 
the major factors of this trademark. In addition, a better understanding of these rules is 
essential for further chemical development. 
The current work focuses on the arene-ruthenium metalla-assemblies built from stable 
dinuclear arene ruthenium units and polypyridyl donor via the directional bonding approach.90  
Investigations insight into the thermodynamic and kinetics rules dictating the formation of 
these systems in solution is the main issue of this thesis. 
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1.3 Arene Ruthenium Metalla-Assemblies  
 
1.3.1 Introduction 
 
Ruthenium is a transition metal with the electronic configuration [Kr] [4d7] [5s1]. It is 
a group VIII member together with iron (Fe) and osmium (Os) and the element number 44 of 
Mendeleev’s periodic table. The oxidation states of ruthenium in organometallic chemistry 
vary from 0 to IV, the oxidation states of II and III being the most importantes.91, 92 Most of 
the ruthenium complexes possess an octahedral geometry stabilized by an 18-electron 
configuration.  Some exceptions, however, do exist. For example, the triisopropylphosphine 
ruthenium compound [CpRuCl(PPri3)] is a 16-electron complex with a square-planar 
stereochemistry.93  
In the past four decades, ruthenium became a potential alternative to its analogues in 
the family of "platinum metals" (Ru, Os; Rh, Ir; Pd, and Pt) owing to many reasons: 
i) a remarkable reactivity due to the flexibility in its oxidation states, the 
geometries, the coordination numbers, and a relative lability in the interaction 
between the metal ion and the ligands;58, 94  
ii) an important biological activity which has been interpreted as the similarity 
with iron in biological medium. Ruthenium is a nontoxic metal that can mimic 
the behavior of iron (Fe) which is from the same group VIII of Mendeleev’s 
periodic table.95, 96, 97  
In many examples, a facile oxidation of the ruthenium ion and the lack of stability has 
also been observed. Especially, the reduction of Ru(III) to Ru(II) in biological medium was 
noteworthy in many active ruthenium species.98 Therefore a better control of the electronic 
environment of the metal center along with the ligands exchange is crucial. 
The use of the arene ligand in the ruthenium complex provides many advantages: 
i) robustness and protection of the metal center, therefore the stability of the 
complex is maintained while the three remaining ligands keep a possibility of a 
"slow" exchange;52, 99  
ii) the facile functionalization of the arene ligands by biologically active 
compounds, resulting in the co-existence of hydrophobic character with the 
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hydrophilic metal center which produce an amphilic system with remarkable 
biological properties;97  
iii) the arene is an L3 ligands with hapticity (η6). It occupies three coordination 
sites, providing a predictable coordination angle and directionality to the 
incoming ligand which is crucial in supramolecular chemistry.99-100 
The reactivity of the arene ruthenium complexes, their impact in the final 
supramolecular assemblies along with the host-guest properties and the biological activities 
are the main issues of the current work. 
 
1.3.2 Half-Sandwich Arene Ruthenium Complexes: Synthetic Strategies and Reactivity 
 
a- Preparation  
 
The dinuclear benzene ruthenium chloride was the first arene ruthenium complex 
discovered in 1967 by Winkhaus and Singer. The reaction of RuCl3·nH2O with the 1,3-
cyclohexadiene derivative in ethanol solvent leads to a brown product.101 Even though, the 
identification of the correct formula and the dimeric structure of this new complex was 
confirmed only seven years later by Bennett.102 The X-ray analysis showed chloro-bridged 
dimers in which the two ruthenium metal ions were in oxidation state II and were coordinated 
to benzene (an L3 ligand with hapticity η6).103 The precise formula of this compound is [(η6-
C6H6)Ru(μ2-Cl)Cl]2. 
 
 
Later on, many dimeric arene ruthenium analogues have been designed. Many 
synthetic routes are discovered related to the arene nature.104 The most commonly used 
strategy is still the one discovered early by Winkhaus and Singer employing the electronically 
poor dienes such as α-phellandrene or 1-methyl-1,3-cyclohexadiene.102  
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Other complexes containing electronically rich arenes, such as (C6Me6) or durene 
(1,2,4,5-Me4C6H2) are however synthesized only through the arene exchange route. For 
example, the exchange of the para-cymene ligand by the hexamethylbenzene analogue at high 
temperature (around 200°C) leads to the desired hexamethylbenzene dimer.105 
 
 
In order to improve the biological properties of the arene ruthenium complexes, 
different functions are grafted to the ruthenium dimers.106 One possibility is a general and 
multi-steps approach, which consists of the functionalization of the arene ligand via  
conventional coupling reaction such as esterification reaction, followed by Birch reduction to 
generate the diene through the reduction of the aromatic ring.107 Finally, the complexation 
reaction gives rise to the targeted compound via the Winkhaus and Singer method. The 
dinuclear complex [RuCl2{C6H5(CH2)3OCO-p-C6H4-OC8H17}]2 synthesized in 2006, in our 
groups is a good example of the developed form of dimeric ruthenium complexes.108 
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The second approach was reported at first by White in 2005, in which the formation of 
the functionalized complex can be formed via one pot strategy. The mixture of the ruthenium 
tri-chloride with 1-methoxy-1,4- cyclohexadiene (commercially available diene) in ethanol, or 
1,2-ethanediol gives rise to the desired compounds. 109  The coupling reaction occurs by an 
alkoxy exchange via an acid catalyzed mechanism.99  
 
 
b- Reactivity 
 
Apart from the substitution reactions of the arene ligands occurring under harsh 
conditions, these π ligands are inert and attributed to the protection of the oxidation state of 
the metal ion and the stability of the complex.99 In general, the rich chemistry of the dimeric 
arene ruthenium complexes is based on their air stability and the reactions with a collection of 
neutral donor ligands having two electrons (phosphines, nitriles, pyridines, carbonyle and 
dimethylsulfoxide).102 These reactions lead to the decomposition of the dimeric structure 
yielding mononuclear complexes [(η6-arene)RuCl2L] via cleavage of the chloro-bridge (route 
A1). Cationic mononuclear complexes with type [(η6-arene)RuClL2]+  or [(η6-arene)RuClL2]+  
usually have been obtained by the coordination of two or three ligands L. Eventually, these 
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cationic species are favorable in polar solvents or in the presence of a halide scavenger (route 
A2, A3) (Scheme 4).102  
 
 
Scheme 4. Reactivity of the chloro-bridged arene ruthenium complexes. 
 
One of the original aspects of the reactivity of the ruthenium-arene complexes is their 
behavior in aqueous solution. In 1972, Zelonka and Baird observed aqua complexes of 
ruthenium during the hydrolysis of [(arene)RuCl2]2 in D2O.110 Few years later, Ludi isolated 
and characterized the ruthenium and the osmium aqua dicationic complexes 
([(C6H6)Ru(OH2)3]2+ and its analogue [(C6H6)Os(OH2)3]2+) as a tosylate salt.111 The X-ray 
analysis of the ruthenium species shows a mononuclear tri-aqua complex in a pseudo 
octahedral geometry at the ruthenium (II) atom. The structure is similar to a three legged 
"piano stool" in which the arene ligand presents the seat and the water molecules are the legs 
(Scheme 5). Hence then, the term "piano stool" was assigned and nowadays this kind of 
complexes are an attractive systems in many field of applications.111 
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« Piano-stool » structure of the tri-aqua arene ruthenium complex 
 
Scheme 5. Hydrolysis of the arene ruthenium chloro-bridged complexes.112 
 
In the past two decades, these chloro-bridged arene-ruthenium complexes were used as 
initial precursors to synthesize new molecular clips with different shape, size and stability. 
Indeed, the chloro-bridge was substituted by a rigid multibranched chelating ligands or thiol 
groups, increasing in a controlled manner the distance between ruthenium atoms, along with 
the rigidity of the dimeric structure.113 Some of these half-sandwich complexes showed a very 
high activity against cancer cells, especially the thiols compounds.114 Their ability to oxidase 
the glutathione facilitate the destruction of the tumor cells has already been confirmed      
(Fig. 17).115 
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Figure 17. Oxidation of the glutathione by tri-thiolato bridged arene ruthenium complex.115a 
 
Another application of these complexes is their ability to generate supramolecular 
assemblies. In fact, the two chloro ligands are labile and usually easily replaced by solvent 
molecules or others donor groups. For example, the coordination of the methanol groups in 
the oxalato clip in the presence of the silver triflate (Fig. 18).116 This reactivity of the half 
sandwich complexes is crucial to elaborate supramolecular self-assembling systems.100                                    
 
Figure 18. Synthesis and reactivity of the oxalato metalla-clips [(arene)2Ru2(μ-C2O4)Cl2].116 
 
1.3.3 Overview of Arene Ruthenium Metalla-Assemblies 
 
Arene ruthenium metal-assemblies produced via directional bonding approach are 
remarkable examples of successful coordination driven self-assembly strategy. Many two and 
three dimensional metallacycles have been reported showing great efficiency in sensing,117 
catalysis118 and drugs transportations.119  
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As building blocks of metalla-assemblies, arene ruthenium complexes offer a unique and 
controllable octahedral geometry. Blocking of three coordination sites of metal center  allows 
the three remaining coordination sites to be available for self-assemblies.90a Two main 
strategies have been employed to generate metalla-assemblies from arene ruthenium building 
blocks (Fig. 19):  
(A) by mixing tritopic ligands composed of a bidentate and a monodentate end with 
“naked” arene ruthenium corners,117  (B) by forming stable dinuclear arene ruthenium clips 
prior to the final assembly step involving various connectors.116 Both methods have 
successfully produced esthetical architectures as well as functional metalla-assemblies. 
 
 
 
 
 
 
 
 
 
 
Figure 19. Schematic representation of the two main strategies to form arene ruthenium metalla-
cycles. 
 
During the past two decades Severin120 and Fujita121 groups produced numerous tri- 
and hexanuclear metalla-cycles with spherical or circular geometries. These host systems 
show very good ability to selectively recognize many cationic species such Li+.117 The first 
metalla-cycle was synthesized in 2001 by Severin et al.. The synthetic approach consists of 
1:1 stoichiometric ratio of mononuclear complexes with three available coordination sites 
with unsymmetrical tritopic ligands. The final ruthenium metalla-cycle is a chiral and 
ionophore trimeric complex with great sensing ability.122  
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In the second strategy, the dinuclear metalla-clips are the main building blocks. The 
two ruthenium metal ions are linked by very stable bis-chelating ligands. Consequently, two 
remaining sites with an angle of 90° are available to coordinate to di, tri or tetradentate 
symmetrical ligands. Furthermore, the stereochemistry of reactional intermediates before 
reaching the final closure steps giving raise to the ruthenium metalla-assembly is still not 
clear. Indeed, the incoming ligands can take a syn or anti spatial configuration, unlike the 
platinum metalla-assemblies analogous, produced by Stang, who forced a cis-orientation of 
the ligands connected to the metal-complex precursors.123 Investigation of the stereochemical 
properties of the plausible reaction intermediates involved during the preparation of arene 
ruthenium metalla-assemblies is the main objective of this current work.  
In 1997, Süss-Fink reported the first tetracationic arene ruthenium metalla-rectangle 
formed from two [(arene)2Ru2(μ-C2O4)Cl2] complex and two 4.4’ bipyridine (bpy) units (Fig. 
20).116 This new finding offered a new possibility to overcome the thermodynamic problems 
encountered in the synthesis of metalla-rectangles.124  
 
Figure 20. Synthesis of the [(p-cymene)4Ru4(C2O4)2(bpy)2]4+ metalla-rectangle. 
 
Later on, our group and some other supramolecular chemists developed this strategy 
further. Different metalla-clips with different functionalities and size have been 
synthesized.90b The dinuclear arene ruthenium precursors with general formula [(η6-
arene)2Ru2(OO∩OO)Cl2] (OO∩OO = oxalato, 2,5-dioxydo-1,4-benzoquinonato (dobq), 5,8-
dioxydo-1,4-naphthoquinonato (donq), 2,5-dichlorido-1,4-benzoquinonato (dClobq)) are 
intensively used by our groups.100 The combination of ruthenium building blocks with 
bidentate, tridentate and tetradentate connectors generated metalla-rectangles, metalla-prisms 
and metalla-cubes with general formula [(η6-arene)nRun(L)n/2(OO∩OO)n/2]n+ {n = 4, 6, 8} 
(Scheme 6). These two- and three-dimensional assemblies are well defined and they have 
been fully characterized, and in some cases by single-crystal X-ray structure analysis.  
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Scheme 6. Tetranuclear ,hexanuclear and octanuclear arene ruthenium metalla-assemblies held form 
dinuclear arene ruthenium metlla-clips and a collection of connectors. 
 
The general synthetic approach consists of the activation of the metalla-clips by 
removal of two chloride ions by a halide scavenger followed by the separation of the di-
cationic arene ruthenium reactional intermediate. Addition of the suitable stoichiometric ratio 
of the panels leads to the desired metalla-assemblies via the self-assembly process. The final 
compounds are usually isolated as salts such as trifluoromethane sulfonate salts. 
In recent years, our groups extensively used the second strategy to prepare metalla-
assemblies with biological functions.
 
The potential of the arene-ruthenium metalla-assemblies 
as anticancer drugs has been well demonstrated. The in-vitro results of these compounds show 
higher cytotoxicity compared to the cis-platine the common metallo-drugs used in 
chemotherapy.
119a, 125
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Furthermore, the physicochemical properties of these metal-assemblies in biological 
medium have been reported recently. A notable example is the reactivity between ruthenium 
hexa-cationic prisms and biological ligands such as Arginine (Arg), Histidine (Hi), and 
Lysine (Ly) (Fig. 21). This study shows that some of these supramolecular hosts can maintain 
their stability more than 12 hours. Even after destruction of the metalla-prism structure, the 
construction of new active species is noteworthy, which presents the plausible pathway giving 
raise to the high cytotoxicity of these systems.126  
 
Figure 21. Formation of chelate complexes from the interaction between [(p-
cymene)6Ru6(tpt)2(dobq)3]6+ and some amino acids, (tpt: 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine).126 
 
The high cytotoxicity, the relative robustness, along with the existence of a 
hydrophobic cavity capable of recognizing a biological active guest molecule favored these 
systems to be an excellent drug delivery vectors.  
 
1.3.4 Arene Ruthenium Metalla-Assemblies and Host-Guest Chemistry 
 
After the success of the platinum and palladium metalla-assemblies as micro reactors 
for some catalytic reactions or an efficient drug delivery vectors,51 a remarkable interest to the 
ruthenium host systems analogues has been noted. This popularity is due to the interesting 
host-guest features of this kind of supramolecular hosts. Their ability to recognize planar 
aromatic molecules or some biologically actives species inside their cavity is one of the key 
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elements of this success.127 Furthermore, their host-guest properties in sensing and drug 
transportation have been extensively developed.128, 119b 
Severin et al., designed the first ruthenium ionophore metallacycle which selectively 
recognized cationic species in water.122 Recently, several nitroaromatic compounds such as 4-
nitrotoluene, nitrobenzene, 4-nitrophenol and trinitrotoluene (TNT) have been trapped inside 
the cavity of arene ruthenium metalla-cages, which confirms their potential ability as sensors 
for explosive compounds.128 
Furthermore, the water solubility and the high cytotoxicity of arene ruthenium 
complexes allow these systems to provide new features in the drug design: 
i) Protection of the active molecules from the harsh conditions of biological 
media such as in stomach and liver; 
ii) Facile transportation in the blood stream and accessibility into the cell 
membranes and others barriers due to the amphilic and cationic properties of 
the host-guest system;129 
iii) High intrinsic cytotoxicity;  
iv) Enhancing the selectivity due to the enhanced permeability and retention (EPR 
effect) resulting from the big molecular weight of final host-guest system.130  
The enhanced permeability and retention is a biological phenomenon which describes 
the preferential accumulation of the macromolecular system in tumour cells.130  Nowadays, 
the extrapolation of this strategy to the host-guest chemistry targeting an efficient cancer 
treatment has become popular.131 Since 2008, our group has developed this new approach by 
designing many active host guest compounds. This application revolves around two areas of 
cancer treatment, which is chemotherapy and photodynamic therapy (PDT).  
Many common commercial anti-cancer drugs have been encapsulated in the 
hydrophobic cavity of several metalla-cages and cubes. The first host-guest system was 
obtained in 2008. It consists of the encapsulation of the platinum and palladium 
acetylacetonate ([Pt(acac)2], [Pd(acac)2]), a hydrophobic anti-cancer drugs, inside the cavity 
of the [(η6-p-cym)6Ru6(tpt)2(dobq)3]6+ metalla-prism. The synthesis of this new hybrid 
supramolecular system was confirmed by X-ray analysis, revealing the encapsulation of guest 
molecule inside the hydrophobic cavity of host (Fig. 22). This supramolecular host-guest 
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system showed good water solubility allowing high intrinsic cytotoxicity as compared to the 
empty initial metalla-prism and the initial hydrophobic guest molecule.127 
 
 
Figure 22. Molecular structure of the host-guest system [Pt(acac)2⊂(η6-p-cym)6Ru6(tpt)2(dobq)3]6+.100 
 
On the other hand, the pyrene derivative, (1-(4,6-dichloro-1,3,5-triazin-2-yl) pyrene) 
which possesses good fluorescent properties was used as guest-molecule to confirm the 
efficiency of this host system to deliver drugs into cancer cells (Fig. 23). Therefore, 
fluorescence-captured images from tumor cells, show high fluorescent intensity for the host-
guest system as compared to the guest molecule alone. This result confirms the release of the 
guest-molecule, and reflects the improvement of the uptake of the active species, which is a 
crucial element to improve the efficiency of the cancer treatments.132  
Pyrene, which is a flat hydrophobic molecule, shows very good accessibility to ingress 
and egress within the cavity of the metalla-prisms. Many factors contribute to stabilize it 
inside such as the hydrophobic and the π-π stacking interactions. In addition, several 
biological active functions such as floxuridine (2'-deoxy-5-fluorouridine) were attached to this 
polyaromatic hydrocarbon molecule (Fig. 23). The new derivatives have been transported 
preferentially by the vectors into the cancer cells allowing high anti-cancer activity.133  
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Figure 23. Pyrene derivatives encapsulated in [(η6-p-cym)6Ru6(tpt)2(dobq)3]6+ metalla-prism. 
 
Interestingly, when these planar aromatic molecules get trapped inside the cavity of 
metlla-cages, they lose their fluorescent properties. The spectroscopic analysis confirmed the 
quenching of the fluorescence light emitted by these guest molecules gradually after the 
addition of the host complex. The degradation of the intensity was proportional to the host, 
guest ratio, probably due to the electronic interactions between the two systems. Two putative 
approaches could explain this behavior. One possibility is that the host complex behaves like 
an umbrella limiting the penetration of the excitation light into the guest, like a greenhouse 
which absorbs the fluorescence response of the molecules.134  
Recently, the investigation of this new finding was extended to the hydrophobic 
photosensitizers, targeting a safety photodynamic therapy (PDT) treatment. Indeed, protecting 
the photo-active guest molecules from undesirable light excitation, potentially avoid the skin 
photosensitivity, the main side effect in (PDT).135  Several arene ruthenium metalla-prisms 
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and cubes with different portal size were found to be excellent nano-carriers to deliver 
photosensitizers (eg. porphin) into cancer cells (Fig. 24).136  
 
 
Figure 24. Synthesis of the host-guest system [porphi⊂(η6-p-cym)8Ru8(tpvb)2(dhnq)4]8+, (tpvb: 1,3,5-
tris{2-(4- pyridyl)vinyl}benzene).137 
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1.4 Aims of this Work  
 
Ruthenium – the latest transition metal to be discovered and used in organometallic 
chemistry has an increasing number of papers making it one of the most studied elements. 
Introduction of ruthenium as key element in the coordination driven self-assembling 
supramolecular systems dates back to the pioneering work by Süss-Fink in 1997, resulting in 
the discovery of first arene ruthenium metalla-rectangle. This work allowed the discovery of 
new series of tetranuclear, hexanuclear and octanuclear metalla-assemblies, their anticancer 
activities and drug delivery abilities to treat cancers, making it an interdisciplinary field 
gathering chemistry and biology. However, little is known about the dynamic behavior  of 
these systems in solution.    
  
The aim of this thesis was to rationalize the thermodynamic and kinetic rules directing 
the formation of this family of metalla-assemblies. In the first part of the work the dynamic 
ligand exchange behavior of cationic arene ruthenium metalla-rectangles of the type [(p-
cymene)4Ru4(OO∩OO)2(N∩N)2]4+ (OO∩OO = oxalato, 2,5-dioxydo-1,4-benzoquinonato, 
5,8-dioxydo-1,4-naphthoquinonato; N∩N = 4,4'-bipyridine-H8, 4,4'-bipyridine-D8) have been 
explored in solution using 1H/2D isotope labeling of the 4,4'-bipyridine connectors. In addition 
to the formation mechanism of this type of metalla-cycles, which have been investigated by 
NMR spectroscopy. 
 
The second part, a series of new tetracationic metalla-rectangles and hexacationic 
metalla-prisms were prepared and characterized. Their biological activities as anticancer 
drugs and drug delivery vectors have been developed. Some were found to show remarkable 
selectivity to cancer cells and high efficiency in PDT treatment. 
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2          
Insight into the Dynamic Ligand 
Exchange Process Involved in 
Bipyridyl-Linked Arene         
Ruthenium Metalla-         
Rectangles 
 
 
 
 
 
As mentioned in sections 1.3.1 and 1.3.2, arene ruthenium metalla-assemblies built 
from stable dinuclear metalla-clips and polypyridyl donor ligands have attracted a great deal 
of attention due to their intriguing structure and potential applications. While most 
investigations have largely focused on the synthetic routes and the structural features of these 
supramolecular assemblies, there are no reports dealing with the dynamic characteristics of 
such structures. Isotope labeling is an appropriate tool for characterizing dynamic exchange in 
metalla-supramolecular assemblies.138 With this technique, the dynamic ligand exchange 
processes in arene ruthenium metalla rectangles as well as the subsequent equilibrium under 
thermodynamic control were successfully studied. Moreover, on the basis of quantitative 
mass-spectroscopic results, the kinetics of the exchange process are discussed. 
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2.1 Approaches to Directly and Quantitatively Evidence the Dynamic Behavior 
of Coordination-Driven Metalla-Assemblies 
 
As mentioned in section 1.2, a fundamental facet of coordination-driven self-
assemblies is the possible dynamic exchange process of the different building blocks 
involved.87a, 139 Self-repairing, self-recognition, and self-rearrangement are frequently 
encountered in metalla-assemblies, and these dynamic behaviors have been used to explain 
experimental results, even in many occasions without supporting experimental data. Indeed, 
examples that directly and quantitatively evidence the dynamic behavior of coordination-
driven metalla-assemblies remain scarce.140  
This limited number of studies is partially due to the difficulty of finding an 
appropriate method of characterization. Among these methods, isotope labeling is potentially 
the easiest one to utilize; being compatible with NMR spectroscopy and mass spectrometry. 
However, the preparation of isotope-labeled compounds is not always trivial and can be 
expensive. Zheng and Stang employed 1H/2D 4,4'-bipyridine ligands (bpy-H8 and bpy-D8) to 
study the dynamic ligand exchange behavior of platinum-based supramolecular metalla-
cycles.138 A mixture of the homo-isotopic tetranuclear complexes [(1,8-bis(trans-
Pt(PEt3)2)anthracene)2(bpy-H8)2]4+ and [(1,8-bis(trans-Pt(PEt3)2)anthracene)2(bpy-D8)2]4+ was 
heated to 64°C and the dynamic ligand exchange process was monitored by ESI mass 
spectrometry for a prolonged period. After several days, the reaction has reached equilibrium 
and a final 1:2:1 ratio between the homo-H16:hetero-H8/D8:homo-D16 metalla-rectangles was 
observed (Fig. 25). The dynamic exchange behavior of the Pt-N bonding assemblies was 
established, confirming the self-assembled nature of this system and the effectiveness of the 
1H/2D isotope labeling methodology. 
 
 Chapter 2: Dynamic Ligand Exchange Process in Arene Ruthenium Metalla-Rectangles 
43 
 
 
Figure 25. Homo- and hetero-metalla-rectangles of the general formula [(1,8-bis(trans-
Pt(PEt3)2)anthracene)2(bpy)2]4+ obtained after mixing equimolar amounts of the homo-H16 and homo-
D16 metalla-rectangles, adapted from reference.138 
 
Another approach to study dynamic ligand exchange processes consists of adding to a 
well-defined metalla-assembly a competing ligand or competing metal ion, and after 
reorganization and equilibrium, to analyze the new species formed.141 Recently, Neogi and 
co-workers studied the response of defined heteroleptic metalla-supramolecular racks, 
rectangles, and trigonal prisms through the addition of pyridyl-based donor ligands. For 
example, excess of 1,2-di(pyridine-4-yl)ethyne forces a metalla-rectangle to alter into a rack 
architecture in solution.89 Dynamic exchange processes can also be initiated by adding a 
competing metal ion as elegantly demonstrated by Hiraoka and Shionoya.142 This kind of 
studies not only allows a better understanding of the dynamic behavior of these metalla-
assemblies in solution but also a perspective of new synthetic routes to construct varying 
structural motifs.  
In this chapter, a combination of these two methods, addition of competing ligands 
and isotope labeling, has been used to study the dynamic ligand exchange behaviors of arene 
ruthenium metalla-rectangles containing bipyridyl linkers. Moreover, on the basis of 
quantitative mass spectral measurements and NMR spectroscopy, the kinetics of the stimuli-
triggered ligand exchange process have been investigated. 
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2.2 Synthesis and Characterization of the Arene Ruthenium Metalla-
Rectangles 
 
Six isotopical (isolated and purified) and three heteroisotopic (not isolated) arene 
ruthenium metalla-rectangles (see Fig. 26) of the general formula [(p-
cymene)4Ru4(OO∩OO)2(N∩N)2]4+ (OO∩OO = oxalato, 2,5-dioxydo-1,4-benzoquinonato, 
5,8-dioxydo-1,4-naphthoquinonato; N∩N = 4,4'-bipyridine-H8, 4,4'-bipyridine-D8) have been 
synthesized using the 1H/2D isotope-labeled 4,4'-bipyridine linkers. ESI-MS and 1H NMR are 
used to observe and characterize the dynamic ligand exchange process operating in these 
cationic arene ruthenium metalla-assemblies. 
 
 
Figure 26. Molecular structures of the cationic arene ruthenium metalla-rectangles. 
 
The synthesis of the isotopical metalla-rectangles, [(p-cymene)4Ru4(OO∩OO)2(bpy-
H8)2]4+ and [(p-cymene)4Ru4(OO∩OO)2(bpy-D8)2]4+, has been performed following published 
methods using the corresponding dinuclear clips and bpy-H8 or bpy-D8, respectively.113a, 116, 
143  
On the other hand, two equivalents of the arene ruthenium metalla-clips {(p-
cymene)2Ru2(OO∩OO)}2+ react with a mixture of one equivalent of 4,4'-bipyridine-H8 (bpy-
H8) and one equivalent of 4,4'-bipyridine-D8 (bpy-D8) to form a combination of the homo- 
and hetero-metalla-rectangles. The resulting mixture of each metalla-rectangle represents a 
statistical product distribution (theoretical value 1:2:1, homo-H16, hetero-H8/D8, homo-D8) 
(Fig. 27). In the case of the oxalato derivative, we were unable to confirm the formation of the 
hetero-H8/D8 metalla-rectangle; no peak corresponding to the intact arene ruthenium metalla-
rectangles being observed by ESI-MS. Nevertheless, considering the behavior of the other 
two metalla-rectangles, a mixture of [(p-cymene)4Ru4(oxalato)2(bpy-H8)2]4+, [(p-
cymene)4Ru4(oxalato)2(bpy-D8)2]4+ and [(p-cymene)4Ru4(oxalato)2(bpy-H8)(bpy-D8)]4+ is 
certainly obtained. 
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Figure 27. Resulting statistical mixture of the homo- and hetero-metalla-rectangles (OO∩OO = 
oxalato, 2,5-dioxydo-1,4-benzoquinonato, 5,8-dioxydo-1,4-naphthoquinonato). 
 
2.3 Characterization of the Dynamic Ligand Exchange 
 
2.3.1 Dynamic Ligand Exchange between Homo- and Hetero-Metalla-Rectangles 
 
In order to observe a possible dynamic ligand exchange process between the homo-H16 
and homo-D16 metalla-rectangles, as previously performed by Zheng and Stang with the 
metalla-rectangle [(1,8-bis(trans-Pt(PEt3)2)anthracene)2(bpy)2]4+ (Fig. 25),138 we first mixed in 
methanol-d4 the protonated metalla-rectangles and and their corresponding deuterated 
analogues in a 1:1 ratio. The evolution of the mixtures was then followed for 14 days by 1H 
NMR and ESI-MS (methanol-d4, 40°C). From the 1H NMR spectrum we can notice in all 
cases the absence of signals associated to uncoordinated 4,4'-bipyridine-H8 ligands. For 
metalla-rectangles [(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy)2]4+ and [(p-
cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy)2]4+, ESI-MS confirms that both 
protonated and deuterated metalla-rectangles are intact with no peak corresponding to the 
hetero-H8/D8 metalla-rectangles, thus suggesting no exchange of the 4,4'-bipyridine ligands. 
Selected peaks from the ESI-MS spectrum of [(p-cymene)4Ru4(2,5-dioxydo-1,4-
benzoquinonato)2(bpy)2]4+ and [(p-cymene)4Ru4(5,8-dioxydo-1,4-
naphthoquinonato)2(bpy)2]4+, at the beginning, after 14 days, and from the mixed metalla-
rectangles synthesized in a statistical 1:2:1 ratio, are presented in Figure 28. (Calculated ESI-
MS peaks are presented in Fig. 29). The absence of the peaks corresponding to the hetero-
derivatives [M(H8/D8) - 2 CF3SO3]2+ at m/z = 918 and 968, respectively, is clearly evidenced 
from these ESI-MS measurements (Fig. 28) 
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Figure 28. ESI-MS spectra of [(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy)2]4+ (top) and 
[(p-cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy)2]4+ (bottom), at the beginning after mixing 
the two homo-rectangles (left), after 14 days in solution at 40°C (middle), and from the mixed metalla-
rectangles synthesized in a 1:2:1 ratio (right). 
 
 
Figure 29. Calculated (up) and experimental (down) ESI-MS spectra of mixed metalla-rectangles 
synthesized in a 1:2:1 ratio: [(p-cymene)4Ru4(oxalato)2(bpy)2]4+ (left), [(p-cymene)4Ru4(2,5-dioxydo-
1,4-benzoquinonato)2(bpy)2]4+ (middle) and [(p-cymene)4Ru4(5,8-dioxydo-1,4-
naphthoquinonato)2(bpy)2]4+ (right). 
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We also tried to initiate the exchange process by exposing the mixtures of the homo-
metalla-rectangles under UV light and heating. After 24 hours in methanol-d4 under UV 
irradiation (λ = 375 nm), we did not observe any exchange (1H NMR and ESI-MS), only the 
apparition of free p-cymene molecules by 1H NMR spectroscopy, suggesting decomposition 
of the arene ruthenium units. Similarly, after 48 hours at 65°C in methanol-d4, no evidence for 
the formation of the hetero-derivatives was observed, only slow decomposition of the metalla-
rectangles. 
 
2.3.2 Dynamic Ligand Exchange in the Presence of Competing Ligand 
 
The absence of spontaneous ligand exchange process by simply mixing two isotopical 
metalla-rectangles forced us to modify our strategy. We decided to add to the homo-metalla-
rectangles one equivalent of the free 4,4'-bipyridine ligand of the opposite labeling. First, we 
added one equivalent of 4,4'-bipyridine-H8 to the smallest deuterated metalla-rectangle [(p-
cymene)4Ru4(oxalato)2(bpy-D8)2]4+ in methanol-d4. Instantly, signals corresponding to 
coordinated bpy-H8 appear (H′α and H′β) in the 1H NMR spectrum (Fig. 30). 
 
 
Figure 30. Representative 1H NMR spectra following the ligand exchange process with metalla-
rectangle [(p-cymene)4Ru4(oxalato)2(bpy-D8)2]4+ in methanol-d4 (23 °C) upon addition of bpy-H8. 
 
In parallel, a decrease in the intensity of the signals (Hα and Hβ) of the free bpy-H8 was 
observed. After 24 hours, the mixture had reached equilibrium and no more changes were 
observed in the 1H NMR spectrum. The opposite experiment, addition of one equivalent of 
4,4'-bipyridine-D8 to the metalla-rectangle [(p-cymene)4Ru4(oxalato)2(bpy-H8)2]4+ in 
methanol-d4, shows exactly the opposite behavior, which is in this case an increase of free 
bpy-H8 signals and a decrease of the signals associated to the coordinated bpy-H8 protons. 
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The presence of free bpy-H8 and a larger complex with coordinated bpy-H8 ligand was 
confirmed by diffusion-ordered NMR spectroscopy (DOSY). The DOSY spectrum of the 
mixture obtained after addition of bpy-H8 to [(p-cymene)4Ru4(oxalato)2(bpy-D8)2]4+ in 
methanol-d4 shows two species (Fig. 31), with a larger coefficient for the newly formed 
species, confirming the coordination of bpy-H8 to ruthenium.  
 
Figure 31. 1H NMR and DOSY spectra (methanol-d4, 23°C) after addition of bpy-H8 to [(p-
cymene)4Ru4(oxalato)2(bpy-D8)2]4+ showing the resonances of the free bpy-H8 (highlighted with red 
ovals) and the protons of the coordinated bpy-H8 (blue ovals). 
 
To identify the nature of these new species, the two mixtures obtained after 24 hours 
were studied by ESI-MS. In both cases, the ESI mass spectra show two distinctive fragments 
incorporating both bpy ligands in their core (bpy-H8 or bpy-D8), a di-cationic fragment with 
peaks at m/z = 786 and 790, and a mono-cationic fragment with peaks at m/z = 864 and 872 
(Fig. 32).  
 
Figure 32. ESI-MS peaks corresponding to the species [(p-cymene)4Ru4(oxalato)2(bpy) + 2 CF3SO3]2+ 
and [(p-cymene)2Ru2(oxalato)(bpy) + CF3SO3]+
 
(right). 
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Despite similar behaviors, the kinetics of the ligand exchange processes before 
reaching equilibrium are different in these two experiments. The exchange process has been 
followed by 1H NMR spectroscopy for 6 hours (Fig. 33), the rate of increase in the intensity 
of the coordinated bpy-H8 signals in the first experiment is slower as compared to the rate of 
increase in intensity of the signals of free bpy-H8 in the second experiment (Fig. 33a). This is 
due to the fact that in the first case, to exchange a Ru-N(bpy-D8) bond with a Ru-N(bpy-H8) 
bond, the disassembly of the metalla-rectangle [(p-cymene)4Ru4(oxalato)2(bpy-D8)2]4+ has to 
take place first. In other words, two kinetic constants, a dissociative (kd) and an associative 
(ka) one, are operating. In the second case (Fig. 33b), the appearance of free bpy-H8 signals is 
due to the disassembly of the metalla-rectangle [(p-cymene)4Ru4(oxalato)2(bpy-H8)2]4+, thus 
involving only a dissociative process. 
 
 
 
 
Figure 33. Representative 1H NMR spectra (6 hours) following the kinetic exchange between [(p-
cymene)4Ru4(oxalato)2(bpy)2]4+ (▄) and 4,4'-bipyridine (*) (methanol-d4, 23 °C); a) [(p-
cymene)4Ru4(oxalato)2(bpy-D8)2]4+ + bpy-H8; b) [(p-cymene)4Ru4(oxalato)2(bpy-H8)2]4+ + bpy-D8 (# = 
free p-cymene). 
 
In the case of the [(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy)2]4+ 
metalla-rectangle, a different behavior has been observed. In fact, when one equivalent of 
bpy-H8 is added to [(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy-D8)2]4+ in 
methanol-d4 (Fig. 34a), the intensity of the signals corresponding to the protons of the free 
bpy-H8 (*) decreases, accompanied by the apparition of a signal at δ = 7.1 ppm associated to 
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free p-cymene (#). However, no formation of [(p-cymene)4Ru4(2,5-dioxydo-1,4-
benzoquinonato)2(bpy-H8)2]4+ or other {(p-cymene)Ru(bpy-H8)} species is observed. It is 
worth mentioning here that upon addition of 4,4'-bipyridine to all metalla-rectangles, 
apparition of free p-cymene was observed by 1H NMR spectroscopy. On the other hand, the 
opposite experiment, addition of bpy-D8 to [(p-cymene)4Ru4(2,5-dioxydo-1,4-
benzoquinonato)2(bpy-H8)2]4+, shows that the intensity of the signals corresponding to the 
protons of free bpy-H8 increases and the intensity of the signals associated to coordinated 
bpy-H8 decreases as expected (Fig. 34b). In terms of kinetics, the same behavior has been 
observed, a faster appearance of the signals associated to free bpy-H8 after disassembly of the 
proteomic metalla-rectangle. 
 
 
 
Figure 34. Representative 1H NMR spectra (6 hours) following the kinetic exchange between [(p-
cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy)2]4+ (▄) and 4,4'-bipyridine (*) (methanol-d4, 23 
°C); a) [(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy-D8)2]4+ + bpy-H8; b) [(p-
cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy-H8)2]4+ + bpy-D8 (# = free p-cymene). 
 
In the case of [(p-cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy)2]4+, the 
dynamic ligand exchange process in methanol-d4 upon addition of bpy is similar to that 
observed with the oxalato metalla-rectangles: A rapid exchange of the bpy ligands in solution 
after disassembly of the metalla-rectangle (Fig. 35). On the other hand, as opposed to the 
oxalato and 2,5-dioxydo-1,4-benzoquinonato derivatives, the presence of free p-cymene 
molecules is not detected in solution, thus suggesting a more robust metalla-assembly. On the 
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1H NMR spectrum, the protons associated to the 5,8-dioxydo-1,4-naphthoquinonato bridging 
ligand are observed as a singlet at δ = 7.24 ppm.  
 
 
 
Figure 35. Representative 1H NMR spectra (6 hours) following the kinetic exchange between [(p-
cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy)2]4+ (▄) and 4,4'-bipyridine (*) (methanol-d4, 
23 °C); a) [(p-cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy-D8)2]4+ + bpy-H8; b) [(p-
cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy-H8)2]4+ + bpy-D8. 
 
Interestingly, the ESI mass spectra of the solutions isolated after 6 hours reaction time 
show peaks corresponding to all metalla-rectangles at m/z = 964, 968 and 972, [M(H16) - 2 
CF3SO3]2+, [M(H8/D8) - 2 CF3SO3]2+ and [M(D16) - 2 CF3SO3]2+, respectively. The intensity 
of the peak corresponding to the mixed metalla-rectangle is nonetheless very low. Otherwise, 
peaks corresponding to fragments incorporating a bpy ligand in their core (bpy-H8 or bpy-D8) 
and {(p-cymene)2Ru2(5,8-dioxydo-1,4-naphthoquinonato)}2+ units are also observed; a di-
cationic fragment with peaks at m/z = 886 and 890, and a mono-cationic fragment with peaks 
at m/z = 964 and 972. These fragments have been attributed to the two species [(p-
cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy) + 2 CF3SO3]2+ and [(p-
cymene)2Ru2(5,8-dioxydo-1,4-naphthoquinonato)(bpy) + CF3SO3]+, respectively (Fig. 36). 
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Figure 36. Molecular structure of the two fragments [(p-cymene)4Ru4(5,8-dioxydo-1,4-
naphthoquinonato)2(bpy) + 2 CF3SO3]2+ and [(p-cymene)2Ru2(5,8-dioxydo-1,4-
naphthoquinonato)(bpy) + CF3SO3]+ 
 
2.4 Determination of the Initial Rate of the Exchange  
 
As previously observed by NMR and mass spectrometry, addition of bpy to the metalla-
rectangles produces several intermediates, thus obscuring the kinetics of the assembly-
disassembly processes of the metalla-rectangles. Therefore, we chose to determine the initial 
rate of the reaction, when the initial concentrations of the metalla-rectangle and bpy are 
known and when the exchange processes follow a linear response (Fig. 37). 
 
Figure 37. Initial rates of the exchange processes between the homo oxalato-metalla-rectangles and 
the free 4,4'-bipyridine of the opposite labeling, {homo-D16 + bpy-H8: (a) 1:1 ratio (23 °C); (b) 1:10 
ratio (23 °C),(c) 1:1 ratio (40 °C),  homo-H16 + bpy-D8: 1:10 ratio (23 °C)}. 
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These initial rates values of the exchange processes at room temperature with a 1:1 
and 1:10 ratio (metalla-rectangle:bpy) and at 40°C with a 1:1 ratio are given in Table 4. 
 
Table 4. Initial rates of the exchange processes between the homo-metalla-rectangles and the free 
4,4'-bipyridine of the opposite labeling, (homo-D16 + bpy-H8 = V0', homo-H16 + bpy-D8 = V0''). 
metalla-rectangle 
[(p-
cymene)4Ru4(OO∩OO)2(bpy)2]4+ 
 initial rate  10-5 
V0' (mol·L-1·min-1) 
  initial rate  10-5 
 V0'' (mol·L-1·min-1) 
 
 
OO∩OO = 
1 
eq 
10 eq 1 eq 
(40°C) 
1 
eq 
10 eq 1 eq 
(40°C) 
oxalato 5.8 14.1 20.4 3.8 7.2 14.8 
2,5-dioxydo-1,4-benzoquinonato - - 1.9 - - - 
5,8-dioxydo-1,4-naphthoquinonato 4.7 8.2 7.1 4.4 9.6 17.4 
 
For the 2,5-dioxydo-1,4-benzoquinonato metalla-rectangle, the initial rate of the 
exchange process was only determined upon addition of bpy-H8 to [(p-cymene)4Ru4(2,5-
dioxydo-1,4-benzoquinonato)2(bpy-D8)2]4+ at 40°C. The coordination of bpy-H8 to the 
ruthenium atom is quite slow at this temperature and suggests a good stability of the metalla-
rectangle. On the other hand, the initial rates of the exchange processes involving the other 
metalla-rectangles are faster and follow a similar trend. In both cases, the exchange process is 
more rapid when a 10 fold excess of bpy is added and when the temperature of the reaction is 
raised to 40°C. 
Finally, when the addition of one equivalent of the free 4,4'-bipyridine ligand to the six 
homo-metalla-rectangles is performed at -20°C in methanol-d4, no exchange occurs: All 1H 
NMR spectra remaining identical for several hours, confirming the relative stability of these 
arene ruthenium metalla-rectangles in solution. 
 
2.5 Conclusions 
 
The dynamic ligand exchange behavior of cationic arene ruthenium metalla-rectangles 
of the type [(p-cymene)4Ru4(OO∩OO)2(N∩N)2]4+ (OO∩OO = oxalato, 2,5-dioxydo-1,4-
benzoquinonato, 5,8-dioxydo-1,4-naphthoquinonato; N∩N = 4,4'-bipyridine-H8, 4,4'-
bipyridine-D8) has been studied in solution. The robustness of the rectangular architecture has 
been evidenced by NMR and ESI mass spectrometry. Thermodynamic and kinetic aspects of 
the ligand exchange process have been explored using 1H/2D isotope labeling of the 4,4'-
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bipyridine connectors. This study shows that ligand exchange does not proceed spontaneously 
for these metalla-assemblies, even at high temperature, unless an external stimulus is applied. 
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3           
Investigating the Formation 
Mechanism of Arene     
Ruthenium Metalla-         
Cycles by NMR         
Spectroscopy 
 
 
 
 
 
As demonstrated previously, the arene ruthenium metalla-rectangles built with 4,4'-
bipyridine linkers and the OO∩OO bridging units are robust and inert to ligand exchange 
unless an external stimulus is applied. However, one question remains: These structures 
constructed via a self-assembling process, are they kinetic or thermodynamic products? 
In this chapter, the synthesis and characterization of twelve dinuclear arene ruthenium 
complexes as models of the intermediate species formed during the supramolecular assembly 
of arene ruthenium metalla-cycles have been reported. The kinetic and thermodynamic 
aspects dictating the formation of these dinuclear complexes, in addition to their 
stereochemical properties have been studied in solution using NMR spectroscopy. Several 
experiments, including an intramolecular [2+2] photochemical cycloaddition, gave valuable 
answers regarding the probable mechanism leading to the formation of arene ruthenium 
metalla-cycles and concerning the nature of the intermediate species. 
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3.1 Preparation of Dimetallic Arene Ruthenium Complexes 
 
A series of dinuclear arene ruthenium complexes has been synthesized in methanol 
(RT, 24 h) by mixing in the presence of AgCF3SO3 (Scheme 7) one equivalent of a metalla-
clip [(p-cymene)2Ru2(OO∩OO)Cl2] (OO∩OO = oxalato; 2,5-dioxydo-1,4-benzoquinonato 
(dobq); 5,8-dioxydo-1,4-naphthoquinonato (donq)) with two equivalents of a monodentate N-
ligand (Ln) (L1 = 4-phenylpyridine; L2 = 4-styrylpyridine, L3 = 4-methylpyridine, L4 = 4-
tbutylpyridine). Consequently, twelve dinuclear arene ruthenium complexes of the general 
formula [(p-cymene)2Ru2(OO∩OO)(Ln)2]2+ were obtained in good yields (OO∩OO = donq, 
Ln = L1, [1]2+; OO∩OO = donq, Ln = L2, [2]2+; OO∩OO = donq, Ln = L3, [3]2+; OO∩OO = 
donq, Ln = L4, [4]2+; OO∩OO = dobq, Ln = L1, [5]2+; OO∩OO = dobq, Ln = L2, [6]2+; 
OO∩OO = dobq, Ln = L3, [7]2+; OO∩OO = dobq, Ln = L4, [8]2+; OO∩OO = oxalato, Ln = L1, 
[9]2+; OO∩OO = oxalato, Ln = L2, [10]2+; OO∩OO = oxalato, Ln = L3, [11]2+; OO∩OO = 
oxalato, Ln = L4, [12]2+). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. Synthesis of the dinuclear arene ruthenium complexes [1]2+[12]2+. 
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All complexes were isolated as their triflate salts and as mixtures of cis and trans 
isomers (Scheme 7). The presence of cis and trans isomers can be expected and was not 
surprising, however, only the cis isomer is consistent with the formation of discrete metalla-
assemblies. 
The choice of 4-phenylpyridine (L1), 4-styrylpyridine (L2) and 4-tbutylpyridine (L4) as 
monodentate N-ligand was not accidental. The L1 and L2 derivatives are closely related to 
respectively 4,4'-bipyridyne and 1,2-bis(pyridine-4-yl)ethylene, two linkers commonly used 
to prepare metalla-rectangles,144 while the tbutyl derivative adds steric repulsions and 
accordingly should favor the formation of trans isomers. 
 
3.2 X-ray Analysis Characterization 
 
Despite having mixtures of the cis and trans isomers for all complexes, two trans 
derivatives have been isolated by crystallization of their triflate salts. These two crystalline 
structures allowed confirmation of the proposed complexes and subsequently allowed 
assignment to the corresponding isomers (cis and trans) for the two sets of signals observed in 
the 1H NMR spectra. The molecular structures of [trans-4]2+ and [trans-7]2+ are presented in 
Figures 38 and 39, respectively. 
In both structures, the ruthenium atoms adopted the typical three-legged piano-stool 
geometry with a metal···metal separation of 8.3958(6) and 8.4132(6) Å in [trans-4]2+ and 
7.9389(4) Å in [trans-7]2+. Despite the presence of two crystallographically independent 
dinuclear complexes in the crystal packing of [trans-4](CF3SO3)2 2 (CH3)2CO, the two 
dicationic complexes were found to be geometrically identical. Moreover, the geometrical 
parameters observed in [trans-4]2+ and [trans-7]2+ were comparable to those observed in the 
related complexes [(p-cymene)2Ru2(donq)(OH2)2]2+,145 and [(p-cymene)4Ru4(dobq)2(4,4'-
bipyridyne)2]4+.146 
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Figure 38. ORTEP drawing of the cation [trans-4]2+ at the 50% probability level ellipsoids, with 
hydrogen atoms, triflate anions and acetone molecules omitted for clarity. Selected bond lengths (Å) 
and angles (°): Ru1-N1 2.115(2), Ru1-O1 2.052(2), Ru1-O2 2.048(2), O1-C2 1.284(3), O2-C4 
1.285(3); O1-Ru1-O2 86.84(6), O1-Ru1-N1 84.02(7), O2-Ru1-N1 84.42(7). 
 
In both structures, the angle observed between the plane defined by the OO∩OO 
bridging ligand and the plane formed by the adjacent pyridyl ring was < 90°. This deviation 
from 90° was more pronounced in [trans-7]2+ with an angle of 79.54(6)°, while in [trans-4]2+ 
these angles were found at 86.08(6) and 87.50(6)°, respectively. 
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Figure 39. ORTEP drawing of the cation [trans-7]2+ at the 50% probability level ellipsoids, with 
hydrogen atoms and triflate anions omitted for clarity. Selected bond lengths (Å) and angles (°): Ru1-
N1 2.111(2), Ru1-O1 2.094(1), Ru1-O2 2.077(1), O1-C11 1.274(2), O2-C12 1.283(2); O1-Ru1-O2 
77.16(5), O1-Ru1-N1 84.14(6), O2-Ru1-N1 84.32(6). 
 
3.3 Investigation of the Stereochemical Properties of the Dinuclear Complexes 
in Solution Using NMR Spectroscopy 
 
ROESY measurements have clearly confirmed the existence of two isomers in 
solution (Fig. 40).  Furthermore, the assignment of the 1H and 13C NMR spectroscopy signals 
to the corresponding cis and trans isomers was based on the X-ray structures of [trans-
4](CF3SO3)2 and [trans-7](CF3SO3)2, and similar behavior was assumed for [1]2+ to [8]2+; 
NOE experiments were used for the oxalato derivatives [9]2+ to [12]2+. 
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Figure 40. ROESY NMR spectrum of the complex [9]2+ in CD3OD (cis , trans *, 23°C). The exchange 
cross peaks observed between the cis and trans conformers are highlighted by rectangles. 
 
In all complexes, the 1H NMR spectra show the signals of the aromatic protons 
associated to the p-cymene moieties and to the pyridyl groups of the Ln ligands to be more 
downfield shifted  for the trans isomer as compared to the corresponding signals of the cis 
isomer. For the donq and dobq derivatives the shift (Δδ) is around 0.15 ppm. As an example, 
HSQC spectra of the complex [4]2+ is presented in Figure 41. 
 
Figure 41. 1H NMR, 13C NMR – HSQC spectra of the complex [4]2+ in CD3OD (pyridyl region; cis , 
trans *, 23°C). 
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This difference between the 1H signals of the cis and trans isomers is more 
pronounced for the oxalato derivatives, in which a Δδ of roughly 0.5 ppm is observed 
between the two sets of signals (Fig. 42). 
 
Figure 42. 1H NMR, 13C NMR – HSQC spectra of the complex [11]2+ in CD3OD (pyridyl region; cis , 
trans *, 23°C). 
 
 
Interestingly, for the cations [cis-10]2+ and [cis-12]2+, several 1H NMR signals show 
diastereotopic behavior, this suggests that the cis conformer has a lower symmetry. Indeed, 
the presence of two tert-butyl or two styryl groups in relatively close proximity forces the two 
adjacent pyridyl ligands to adopt a staggered conformation (Fig. 44), which reduces the 
symmetry of the dinuclear complexes. Consequently, the pyridyl and p-cymene aromatic 
protons appear as two sets of four doublets, as emphasized in the inset of Figure 43. However, 
in [cis-12]2+, the methyl groups of the tert-butyl groups and the methyl group of the p-cymene 
ligands are also nonequivalent, which suggests the loss of the C2 symmetry. This can be 
rationalized from a steric perspective, as the tert-butyl groups are not free to rotate (Fig. 44). 
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Figure 43. 1H NMR spectrum of the cation [12]2+ in CD3OD (cis , trans *, 23°C). 
 
 
 
 
 
 
 
 
 
Figure 44. Schematic representation of the cation [cis-12]2+ showing the staggered conformation and 
the steric hindrance of the 4-tertbutylpyridine ligands (side and top views). 
 
The cis-trans ratio was generally close to 50:50 with slightly more of the trans isomers 
for the donq and dobq dinuclear complexes [1]2+[8]2+, whereas the cis isomers dominated for 
the oxalato derivatives [9]2+ and [11]2+, and the trans isomer prevailed in [10]2+ and [12]2+ 
(Table 5).  
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Table 5. Cis-trans isomer ratio in a CD3OD solution (23°C, determined by 1H NMR) for cations 
[1]2+[12]2+ after 1 hour and after 1 week. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This isomer distribution was rationalized from the shorter Ru···Ru separation found in 
the oxalato derivatives (ca. 5.5 Å),147 which resulted in additional π-π stacking interactions 
between the adjacent N-ligands in [cis-9]2+ and [cis-11]2+, whereas steric hindrance of the Ln 
ligands favored the formation of [trans-10]2+ and [trans-12]2+.  
 
3.4 Thermodynamic and Kinetics Aspects Dictating the Formation of the 
Dinuclear Complexes 
 
The cis-trans ratios determined from the 1H NMR spectroscopic data were used to 
estimate the standard free energy change (ΔG°) of the cis and trans conformers (ΔG° = -RT · 
ln K). The higher concentration of the cis isomer in the oxalato derivatives [9]2+ and [11]2+ 
was attributed to a π-π stacking contribution. This contribution was estimated by comparing 
the ΔG° of the donq derivatives [1]2+ and [3]2+, for which no π-π interactions are possible 
owing to the longer Ru···Ru separation (> 8.3 Å),134a than those of the oxalato derivatives. As 
expected, the stabilization was higher for 4-phenylpyridine (0.9 kcal · mol–1) than for 4-
 
1 hours (CD3OD) 1 week (CD3OD) 
cis trans cis trans 
[1]2+ 46 54 45 55 
[2]2+ 41 59 40 60 
[3]2+ 47 53 46 54 
[4]2+ 42 58 41 59 
[5]2+ 39 61 37 63 
[6]2+ 38 62 39 61 
[7]2+ 38 62 38 62 
[8]2+ 32 68 31 69 
[9]2+ 78 22 80 20 
[10]2+ 20 80 20 80 
[11]2+ 70 30 69 31 
[12]2+ 24 76 38 62 
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methylpyridine (0.6 kcal · mol–1; Table 6). These values are consistent with the planar 
aromatic surface of the respective pyridyl ligands. 
Table 6. Estimated π-π stacking contribution in cations [9]2+ and [11]2+, favoring the cis isomers. 
 
  
 
 
 
The kinetics of the cis-trans interconversion for the oxalato derivatives were also 
studied in solution by 1H NMR spectroscopy. The results showed that the cis-trans ratio 
remained almost unchanged for days, except for [12]2+ for which an increase of the cis isomer 
ratio was observed over a 1 week period (Table 5), thus suggesting a longer period to reach 
equilibrium for this system. 
The presence of the tbutyl group kinetically favors the formation of the trans isomer. 
However, the concentration of the cis isomer increased over time, and after reaching a 
dynamic equilibrium (CD3OD, 23°C), the steric contribution of the tbutyl group was 
estimated (Table 7). The difference in the ΔG° between the 4-methylpyridine derivative [11]2+ 
and the 4-tbutylpyridine derivative [12]2+ was 0.8 kcal · mol-1. 
 
Table 7. Estimated steric hindrance contribution in [12]2+, favoring the trans isomer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1]2+ [9]2+ [3]2+ [11]2+ 
cis-trans ratio 45 / 55 80 / 20 46 / 54 69 / 31 
ΔG° ( kcal · mol–1) 0.1 -0.8 0.1 -0.5 
π - π stacking contribution in  
kcal · mol–1, calculated from the 
Δ(ΔG°) 
-0.9 -0.6 
[12]2+ [11]2+ 
cis-trans ratio 38 / 62 69 / 31 
ΔG° ( kcal · mol–1) 0.3 -0.5 
steric contribution in kcal · mol–1,     
calculated from the Δ(ΔG°) -0.8 
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3.5 Plausible Mechanism of the Cis–Trans Conversion 
 
ROESY experiments confirmed the dynamic exchange between the cis and trans 
isomers. Indeed, for all complexes, exchange cross peaks between the pyridyl protons of the 
terminal N-ligands of the cis and of the trans isomer were observed. As an example, the 
ROESY spectrum of [12]2+ is presented in Figure 45. Additionally, weak signals associated 
with free N-ligands, also exchanging with the two isomers, were noticed in the 1H NMR 
spectra, supporting the dynamic nature of the Ru-N bond in these dinuclear arene ruthenium 
complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. ROESY NMR spectrum of the cation [12]2+ in CD3OD (23°C). The exchange cross peaks 
observed between the pyridyl protons of the cis () and trans (*) conformers and between the trans 
and free 4-tbutylpyridine (#) are highlighted by black and green rectangles, respectively. 
 
The presence of weak signals assigned to non-coordinated N-ligands in the 1H NMR 
spectra of [1]2+ to [12]2+, together with the clear correlation between the pyridyl-protons of 
the free N-ligand, the cis and the trans isomers in the ROESY experiments, suggest a cis-
trans conversion involving decomplexation of a N-ligand followed by racemization at the 
metal center, and re-coordination of the N-ligand to generate the opposite conformer. 
Therefore, in analogy to a SN1 type reaction, a mechanism for the cis-trans conversion was 
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proposed, see Figure 46. As previously studied by Ward and Hofmann,148 the energy 
associated to an inversion of configuration for a two-legged piano stool intermediate (16e 
species) is estimated to be lower than 15 kcal · mol-1. Such 16 valence electron species have 
been occasionally isolated and characterized.149 
 
 
 
 
 
 
 
 
 
Figure 46. Proposed mechanism of the cis-trans conversion involving a 16e intermediate. 
 
3.6 Dinuclear Arene Ruthenium Complexes as Template for [2+2] 
Cycloaddition  
 
The presence of two parallel 4-styrylpyridine ligands in the oxalato derivative [cis-
10]2+ implied that a [2+2] cycloaddition reaction might occur between, as previously observed 
with the oxalato-bridged metalla-rectangle [(p-cymene)4Ru4(oxalato)2(4,4'-
bipyridylethylene)2]4+.150 Accordingly, when a methanol solution of [10]2+ was irradiated with 
a UV lamp (exc = 365 nm), a photochemical [2+2] cycloaddition reaction was observed, 
forming quantitatively the dicationic cyclobutane derivative [13]2+ (Scheme 8). The complete 
conversion of [10]2+ to [13]2+ was observed after 60 hours and confirm the dynamic nature of 
the Ru-N bond and the cis-trans interconversion in solution. During the photochemical [2+2] 
cycloaddition reaction in methanol, the initial orange solution of [10]2+ has turned dark red 
upon formation of [13]2+ (see insert in Scheme 8). 
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Scheme 8. Synthesis of the [2+2] cycloaddition product [13]2+ from [10]2+. 
 
However, in the solid state, only partial conversion of the orange powder of [10]2+ was 
observed (up to 30%), even after a prolonged UV-irradiation (3 days). This result is not 
surprising as the cis-trans conversion was only expected to occur in solution. The formation 
of [13]2+ was further confirmed by multiple one-dimensional and two-dimensional NMR 
experiments (1H, HSQC) (Fig. 47, 48) and by ESI mass spectrometry (Fig. 49). 
The [2+2] cycloaddition reaction of the olefinic bonds was followed by 1H NMR 
spectroscopy. The appearance of two doublets at δ = 4.78 and 4.65 ppm assigned to the 
cyclobutane protons, and the disappearance of the two doublets of the olefinic protons of the 
cis isomer at δ = 7.45 and 6.89 ppm together with the disappearance of the four doublets of 
the trans isomer at δ = 7.77, 7.64, 7.35 and 7.25 ppm confirmed the formation of [13]2+ (Fig. 
47).  
 
These observations are consistent with the previously reported [2+2] cycloaddition of 
4-styrylpyridine in di-silver complexes.151 The 13C NMR spectrum of complex [13]2+ also 
showed two signals corresponding to the cyclobutane carbon atoms at δ 48.94 ppm and δ 
45.14 ppm, respectively (Fig. 48).  
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Figure 47. 1H NMR spectra of cations [10]2+ and [13]2+ in CD3OD (aromatic region, 23°C). 
 
 
Figure 48. HSQC NMR spectrum of the complex [13]2+ in CD3OD 
 
The presence of only two 13C signals for the cyclobutane ring suggests the formation 
of a single cyclobutane-isomer: The cis coordination of the two 4-styrylpyridine precursors 
controlling the stereo-chemistry of the [2+2] cycloaddition product. It is noteworthy to 
a) 
b) 
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mention from the infrared spectra, that the band corresponding to the stretching vibration of 
the ethylene groups (CH=CH), centered at 1595(s) cm-1 in the free 4-styrylpyridine,152 which is 
also observed in [10]2+, disappeared during the formation of [13]2+. 
ESI mass spectrometry was employed to further confirm the cycloaddition process in 
[cis-10]2+. In fact, the mass spectrum of the compound [10](CF3SO3)2 before the 
cycloaddition had two major peaks at m/z = 708 (#) and 890 (•) attributed to the fragments 
[(p-cymene)2Ru2(oxalato) + CF3SO3]+ (#) and [(p-cymene)2Ru2(oxalato)(4-styrylpyridine) + 
CF3SO3]+ (•), respectively (Fig. 8), with no sign of the intact complex [10]2+. After 24 h of 
UV-irradiation (365 nm), we observed the appearance of a new peak at m/z = 1071 (*) 
corresponding to the fragment [(p-cymene)2Ru2(oxalato){di(4-styrylpyridine)cyclobutane} + 
CF3SO3]+ coupled with the decrease of the other two peaks. 
However, as the time increased to 60 h, we observed the disappearance of the peaks 
corresponding to [(p-cymene)2Ru2(oxalato)(4-styrylpyridine) + CF3SO3]+ (•) and [(p-
cymene)2Ru2(oxalato) + CF3SO3]+ (#) with a clean mass spectrum containing only a major 
peak at m/z = 1071 corresponding to [(p-cymene)2Ru2(oxalato){di(4-
styrylpyridyl)cyclobutane} + CF3SO3]+ (*), which further supports the formation of the [2+2] 
cycloaddition complex [13]2+. 
 
 
 
 
 
 
 
 
 
Figure 49. ESI-MS of complex [10]2+ before irradiation (left), after 48 hours (middle) of UV-
irradiation (365 nm) and after 60 hours of UV-irradiation (right). 
The [2+2] cycloaddition adduct [13]2+ mimics the final step during the formation of 
metalla-rectangles, namely the closure of the metalla-assembly. Overall, the stability of 
metalla-cycle [13]2+ was found to be extremely high, as already indicated by ESI mass 
spectrometry. All attempts to isolate the di(4-styrylpyridyl)cyclobutane molecule have failed 
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in our hands, such as refluxing complex [13]2+ in acetonitrile or dmso, even in the presence of 
triphenylphosphine, a strong coordinating agent.  
The stability of [13]2+ is in agreement with our recent finding that arene ruthenium 
metalla-rectangles build with 4,4'-bipyridine linkers and the same OO∩OO bridging units are 
inert to ligand exchange unless an external stimulus is applied.153 Obviously, the formation of 
a metalla-cycle in [13]2+ has introduced an additional stability to the system, similar to the 
stability obtained when forming metalla-cycles. 
 
3.7 Conclusions 
 
The stereochemical properties of twelve dinuclear arene ruthenium complexes have 
been studied in solution. The dinuclear complexes of the general formula [(p-cymene)2- 
Ru2(OOOO)(Ln)2](CF3SO3)2 (OOOO = oxalato, 2,5-dioxido-1,4-benzoquinonato, 5,8-
dioxido-1,4-naphthoquinonato; Ln = 4-phenylpyridine, 4-styrylpyridine, 4-methylpyridine, 4- 
tert-butylpyridine) have been isolated as mixtures of the cis and trans isomers. All of the 
complexes showed a noticeable lability of the pyridyl-based ligands (Ln) in solution and rapid 
exchange between the cis and trans isomers. The equilibrium between the cis and trans 
isomers was confirmed by 1H NMR spectroscopy, and the intermediate species were 
identified and, thus, provided valuable insights into the formation mechanism of arene 
ruthenium metalla-assemblies. 
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4          
Strategy to Optimize the 
Biological Activity of Arene 
Ruthenium Metalla-Assemblies 
 
 
 
 
 
 
Modification of the structural integrity of an active parent agent by functionalization 
or grafting hydrophilic groups or lipophilic motifs is an efficient approach usually used to 
enhance the biological activity of such compounds.106, 154  
In this chapter, three new dinuclear arene ruthenium metalla-clips of the general 
formula [(p-cymene)2Ru2Cl2(μ-L)], which have been prepared by Arion group in the 
university of Vienna, from [(p-cymene)2Ru2Cl2(μ-Cl)2] and H2L organic linkers (H2La = 
diethyl-1,2-diazenedicarboxylate, H2Lb = N,N′-bis(2-hydroxyethyl)oxamide, H2Lc = N,N′-
bis{2-(2- hydroxyethoxy)ethyl}ethanediamide) are described. The bis-chelating bridging-
linkers possess two functional groups that can be synthetically modified for physico-chemical 
optimizations. Reaction of these three dinuclear metalla-clips with 4,4′-bipyridine, 1,2-bis(4-
pyridyl)ethylene, and 4,4′-azopyridine affords, in the presence of AgCF3SO3, nine 
tetracationic tetranuclear metalla-rectangles. Similarly, the tridentate ligands 2,4,6-tris(4-
pyridyl)-1,3,5-triazine and 1,3,5-tris{2-(4-pyridyl)vinyl}benzene were used to generate six 
hexacationic hexanuclear metallaprisms. All metalla-assemblies and the dinuclear complexes 
were evaluated by the Dyson group in the  Ecole Polytechnique Fédérale de Lausanne as 
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anticancer agents against cancerous (A2780) and noncancerous (HEK293) cell lines, showing 
an excellent selectivity for cancer cells.  
 
4.1 Ruthenium Complexes as Anticancer Drugs 
 
Cancer is one of the most common causes of death in the modern world.155 In cancer, 
an estrange tissue is formed from a single defected cell (germ) due to genetic mutation. This 
genetic problem, manifested by rapid DNA replication, gives rise to cellular multiplication 
process resulting a big tumor tissue. This dangerous tissue ultimately leads toward metastases, 
i.e. its rapid widespread in the body. The type of treatment usually depends on the size and the 
region effected. In early stages, it is removed by surgery, followed by radiotherapy or/and 
chemotherapy to eliminate the remaining traces of tumor. The second treatment plays a 
significant to inhibit the re-germination of cancer from an eventual remaining affected cell. 
The radiotherapy implies the ionizing light to destroy the tumor cells but kills the surrounding 
normal tissues as well. Chemotherapy is considered as viable alternative to inhibit the 
proliferation of the cancer cells by apoptosis in second stage. 
The active molecules in chemotherapy come from organic frameworks type 
background. They are either extracted from plants or designed / synthesized in laboratories. 
Some metal-based drugs also manifest good therapeutic activities such as Salvarsan and its 
arsenical derivatives developed in the early 20th century by Paul Ehrlich.156  Cis-
diamminedichloroplatinium (II) (cisplatin), a planar square platinium complex, discovered by 
Rosenberg in 1967 was the first metalo-drug approved for clinical use.157 This drug showed 
good efficiency to treat ovarian, head-and-neck, bladder and testicular cancers by inhibiting 
the DNA replication, thus uncontrolled growth of cells.158 However, the treatments with 
cisplatin suffer many shortcomings such as the side effects due to the lack of selectivity, and 
the resistance from some cancer types due to the specificity problems.159 
Other transition metal-based drug analogues such as copper, palladium, gold, iridium, 
and rhodium have also been developed to kill cancer cells.160 Among these active compounds, 
ruthenium complexes proved their ability to compete the commercial drugs by providing a 
new kind of actions vs tumor cells.161 The first ruthenium complexes having good biological 
activities were neutral. Their design mimicked the structure of cisplatin. For example, the 
(cis-Ru(NH3)3Cl3) developed by Durig162 in 1976 or the (cis-Ru(NH3)4Cl2) discovered by 
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Clark163 in 1980. However, the solubility related issues in these complexes limited their 
further use.164  
Recently two compounds containing ionic Ru(III) complexes, NAMI-A and KP 10 19, 
successfully passed through the second clinical phase. NAMI-A is highly effective against 
lung metastasis but low activity against primary tumors (Fig. 50).165 KP 10 19, is, however, 
very active against colon carcinomas but is not anti-metastatic.166 Recent studies suggest that 
the anticancer activities of these complexes are based on the redox behavior of ruthenium in 
biological medium. Indeed, the Ru(III) inorganic compounds become active only after their 
reduction to Ru (II) species.161 
 
Figure 50. NAMI-A and KP1019, two ruthenium compounds in phase (II) of clinical trials.167, 168 
 
In order to exploit this finding, a collection of highly cytotoxic arene ruthenium (II) 
complexes of type [(η6-arene)Ru(η2-N,N-L)Cl]+ (e.g.; L= ethylendiamine) and [(η6-
arene)Ru(pta)X2] (pta= 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane, X= Cl, Br, I) have been 
developed by Sadler169 and Dyson106, 170, respectively. Among these, RM175 and RAPTA-C 
are the most promising arene ruthenium compounds for anticancer chemotherapy (Fig. 51).171, 
172 
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Figure 51. Molecular structure of [(η6-biphenyl)Ru(μ-ethylendiamine)Cl][PF6] (RM175)171 and [(η6-
arene)Ru(pta)Cl2] (RAPTA-C)172 arene ruthenium complexes. 
 
Stimulated by the promising anticancer activity of arene ruthenium complexes,160, 173 
related studies of arene ruthenium metalla-assemblies have become a flourishing area.90b, 174 A 
great majority of these metalla-assemblies are derived from dinuclear arene ruthenium clips 
and poly-pyridyl connectors. The dinuclear metalla-clips are generally composed of two arene 
ruthenium units bridged by bis-chelating OO∩OO ligands, such as oxalato, 2,5-dioxido-1,4-
benzoquinonato, 5,8-dioxido-1,4-naphthoquinonato, or 6,11-dioxido-5,12-
naphthacenedionato 
ligands.116, 175 
However, a few arene ruthenium metalla-clips have also been prepared using 
NN∩NN,176 and NO∩NO177 bis-chelating bridging-linkers. These bis-chelating bridging-
linkers provide the dinuclear metalla-clips with robustness and inertness153 and play a 
structural role in the successful synthesis of arene ruthenium metalla-assemblies by 
introducing a directional-bonding feature. In addition, they can also add functionality to the 
supramolecular systems, and accordingly, they can enhance the biological activity of the 
metalla-assemblies by modifying their physical and/or chemical properties.  
 
Recently, we have demonstrated that embelin can be used as a bis-chelating OO∩OO 
linker to generate, in combination with 2,4,6-tris(4-pyridyl)-1,3,5-triazine (tpt), metalla-
prisms with three lipophilic arms (Fig. 52).131a 
Embelin (H2L) is a quinonoid natural product with a C11 alkyl chain.178 It was also 
shown that the pentamethylcyclopentadienyl (Cp*) rhodium analogue [(Cp*)6Rh6(μ-tpt)2(μ-
L)3]6+, possesses interesting in vitro and in vivo activity,129 implying that these linkers can 
enhance the biological properties of half-sandwich metalla-assemblies.  
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Figure 52. A metalla-prism assembled from embelin linkers, arene ruthenium corners, and 2,4,6-
tris(4-pyridyl)-1,3,5-triazine panels.131a 
 
Herein, we present a series of arene ruthenium metalla-clips incorporating a new 
family of ON∩NO bis-chelating bridging-linkers. The physico-chemical property of the 
metalla-assemblies can be easily modified by the introduction on these linkers of various 
functional groups. Therefore, from the three p-cymene ruthenium metalla-clips, nine 
tetracationic metalla-rectangles and six hexacationic metalla-prisms were prepared and 
characterized. All 18 compounds were evaluated for their cytotoxicity against cancerous 
(human ovarian cancer cells A2780) and noncancerous (kidney embryonic cells HEK293) 
cells, and some were found to show remarkable selectivity for the former. 
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4.2 Synthesis and Characterization of the Dinuclear Arene Ruthenium 
Metalla-Clips 
 
Dinuclear arene ruthenium metalla-clips (14a−14c) of the general formula [(p-
cymene)2Ru2Cl2(μ-L)] (Fig. 53) were obtained in methanol by reacting diethyl-1,2-
diazenedicarboxylate (H2L
a
), N,N′-bis(2-hydroxyethyl)oxamide (H2L
b
), or N,N′-bis{2-(2-
hydroxyethoxy)ethyl}ethanediamide (H2L
c
) with [(p-cymene)2Ru2Cl2(μ-Cl)2] in the presence 
of triethylamine.  
 
Figure 53. Molecular structures of the dinuclear arene ruthenium metalla-clips 14a−14c. 
 
The coordination of the ON∩NO bis-chelating bridging-linker between the two arene 
ruthenium units was confirmed by 
1
H NMR spectroscopy and mass spectrometry (see the 
Experimental Section).  
Furthermore, the molecular structure of complexes 14a and 14c was established by 
single-crystal X-ray structure analysis. Crystals of 14a and 14c were grown in chloroform. 
Despite the presence of two stereogenic centers in 14a−14c, the dinuclear complexes are not 
chiral, with only the meso isomer being formed, as confirmed by single-crystal structure 
analyses. The inversion center was perfectly positioned halfway between the two metals. The 
molecular structures of 14a and 14c are shown in Figures 54 and 55, respectively, together 
with selected geometrical parameters. In 14a, the Ru···Ru distance is 4.9411(5) Å, whereas, 
in 14c, the same Ru···Ru distance is slightly longer, 5.5716(3) Å. The Ru−N and Ru−O bond 
lengths are identical in both structures and are comparable to those found in 
pentamethylcyclopentadienyl rhodium and iridium oxamidato derivatives.
179
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Figure 54. ORTEP drawing of 14a at 50% probability level ellipsoids. Selected bond distances (Å) 
and angles (deg): Ru1−N1i = 2.090(2), Ru1−O1 = 2.110(2), Ru1−Cl1 = 2.4301(8), N1−N1i = 
1.422(5), Ru1−C4 = 2.209(3), Ru1−C5 = 2.200(3), Ru1−C6 = 2.165(3), Ru1−C7 = 2.177(3), 
Ru1−C8 = 2.147(3), Ru1−C9 = 2.175(3); O1−Ru1−N1i = 75.58(9), (i = 1 − x, 1 − y, 1 − z). 
 
 
 
Figure 55. ORTEP drawing of 14c at 50% probability level ellipsoids. Selected bond distances (Å) 
and angles (deg): Ru1−N1 = 2.0901(15), Ru1−O1i = 2.1094(13), Ru1−Cl1 = 2.4220(5), C1−O1 = 
1.279(2), C1−N1 = 1.307(2), Ru1−C6 = 2.193(2), Ru1−C7 = 2.205(2), Ru1−C8 = 2.200(2), Ru1−C9 
= 2.187(2), Ru1−C10 = 2.158(2), Ru1−C11= 2.174(2); N1−Ru1−O1i = 77.86(5), (i = 1 − x, 1 − y, 
−z). 
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In 14a, the N1−N1i bond distance is 1.422(5) Å, which corresponds to a N−N single 
bond. Similarly, in 14c, the central C1−C1i bond length is 1.493(3) Å, consistent with a C−C 
single bond. However, in both cases, the bond lengths in the bridging ON∩NO ligands were 
found to be somewhere between single and double bonds, suggesting electronic delocalization 
along the two N−C−O units. 
 
4.3 Synthesis and Characterization of a Series of Tetranuclear Arene 
Ruthenium Metalla-Rectangles 
 
The dinuclear arene ruthenium metalla-clips 14a−14c were reacted with 4,4′-
bipyridine (bpy), 1,2-bis(4-pyridyl)ethylene (bpe), or 4,4′-azopyridine (bpa) in the presence of 
AgCF3SO3 to afford the corresponding tetracationic metalla-rectangles,  [(p-cymene)4Ru4(μ-
bpy)2(μ-L)2]4+ ([15a]4+−[15c]4+), [(p-cymene)4-Ru4(μ-bpe)2(μ-L)2]4+ ([16a]4+−[16c]4+), and 
[(p-cymene)4Ru4(μ-bpa)2- (μ-L)2]4+ ([17a]4+−[17c]4+) in good yield. The structures of these 
cationic tetranuclear arene ruthenium metalla-rectangles are presented in Figure 56.  
 
Figure 56. Structures of the arene ruthenium metalla-rectangles [15a]4+−[17c]4+. 
 
All complexes were isolated and characterized as their triflate salts. The presence of 
two ON∩NO bis-chelating bridging-linkers within the metalla-rectangles [15a]4+−[17c]4+ 
gave rise to different isomers: the dinuclear arene ruthenium units being either of the same or 
of the opposite configurations. As previously mentioned, the metalla-clips [14a]4+−[14c]4+ 
were isolated as the meso form, the chloride atoms being trans from each other. However, 
upon formation of discrete metalla-assemblies, a cis orientation of the N-based connecting-
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ligands is necessary, thus adding chirality to these systems. Indeed, three isomers were 
observed for each metalla-rectangle, a pair of enantiomers and a meso form (Fig. 57).  
The 1H NMR data of all metalla-rectangles showed two sets of signals, in agreement 
with the expected isomers. In all cases, the ratio between the racemic and the meso isomer 
was essentially 50:50, in accordance with a statistical distribution. Unfortunately, we were 
unable to associate a set of signals with a specific isomer. The chemical shifts of the different 
protons are listed in the Experimental Section.  
 
 
 
Figure 57. Schematic representations of the different isomers observed in metalla-rectangles 
([15a]4+−[17c]4+). 
 
All 1H NMR spectra were recorded in CD3OD or CD2Cl2 at 23 °C, and as previously 
mentioned, two sets of signals were observed for these metalla-rectangles (Experimental 
sections), with noticeable overlap for the signals of the peripheral protons. In metalla-
rectangle [17b]4+, eight doublets were observed between 5.4 and 6.2 ppm for the 
diastereotopic protons of the p-cymene rings (Fig. 58), which were associated with eight 13C 
signals (Fig. 59). 
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Figure 58.  1H NMR spectrum (CD2Cl2, 23°C) of the complex [17b](CF3SO3)4. 
 
 
 
Figure 59.  1H NMR, 13C NMR – HSQC spectra (CD2Cl2, 23°C) of the complex [17b](CF3SO3)4 (p- 
cymen region). 
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4.4 Synthesis and Characterization of a Series of Hexanuclear Arene 
Ruthenium Metalla-Prisms 
 
The dinuclear arene ruthenium metalla-clips 14a−14c were also reacted with 2,4,6-
tris(4-pyridyl)-1,3,5-triazine (tpt) or 1,3,5- tris{2-(4-pyridyl)vinyl}benzene (tpv) in the 
presence of AgCF3SO3 to afford in good yield the corresponding hexacationic hexanuclear 
metalla prisms, [(p-cymene)6Ru6(μ-tpt)2(μ-L)3]6+ ([18a]6+−[18c]6+) and [(p-cymene)6Ru6(μ-
tpv)2(μ-L)3]6+ ([19a]6+−[19c]6+). All complexes were isolated and characterized as their 
triflate salts. The proposed structures of these cationic arene ruthenium metalla-prisms are 
presented in Figure 60. 
 
Figure 60. Structures of the arene ruthenium metalla-prisms [18a]6+−[19c]6+. 
 
By analogy with the metalla-rectangles [15a]4+−[17c]4, the 1H NMR spectra of the 
metalla-prisms [18a]6+−[19c]6+ showed several sets of signals. As an example, the1H NMR 
spectrum of [18a]6+ is presented in Figure 61.  
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Figure 61. 1H NMR spectrum (CD2Cl2, 23°C) of the complex [18a](CF3SO3)6. 
 
The fixed R,R or S,S configuration of the dinuclear arene ruthenium units should, in 
principle, give rise to only two pairs of enantiomers for these metalla-prisms: the homochiral 
R,R−R,R−R,R and S,S−S,S−S,S enantiomers as well as the mixed enantiomers R,R−R,R−S,S 
and S,S−S,S−R,R. However, four sets of signals were observed for the metalla-prisms 
[18a]6+−[19c]6+, thus suggesting an additional element of chirality. In these metalla-prisms, 
the side arms of the ON∩NO bis-chelating ligands are certainly forcing the tridentate panels 
to adopt a staggered conformation, thus adding helical chirality to these systems: helical 
chirality being commonly observed in arene ruthenium metalla-prisms180 and other metalla-
assemblies.131b, 181 As shown in Figure 62, the four isomers were clearly observed in the NMR 
spectra of metalla-prism [18a]6+, in which 16 doublets associated with 16 individual carbons 
were observed for the aromatic CH groups of the p-cymene ligands. 
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Figure 62. 1H NMR and 13C NMR−HSQC spectra (CD2Cl2, 23 °C) of [18a](CF3SO3)6 (p-cymene 
region). 
 
4.5 Antiproliferative Activity Studies of the Arene Ruthenium Metalla-
Assemblies 
 
The antiproliferative activity of all the complexes was evaluated against human 
ovarian (A2780) carcinoma cells and nontumorigenic human embryonic (HEK293) kidney 
cells using the MTT assay.182 The IC50 values after 72 h of exposure to the compounds are 
listed in Table 8, and for comparison, the biological activity of cisplatin is also reported. All 
tetracationic metalla-rectangles [15a]4+−[17c]4+and metalla-prisms [18a]6+−[19c]6+, except for 
metalla-rectangles [16a]4+ and [17b]4+, exhibit IC50 values in the submicromolar range against 
the A2780 human ovarian cancer cells, and their activities are comparable to those of 
previously describedhexacationic thiolato-bridged ruthenium complexes (IC50 from 0.2−0.6 
μM).125 Interestingly, the hexacationic metalla-prisms [19a]4+−[19c]4+were less active and the 
neutral dinuclear metalla-clips 14a−14c were essentially inactive. 
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Table 8.  IC50 values (μM) of the complexes after 72 h exposure on human ovarian (A2780) carcinoma 
cells and noncancerous human embryonic kidney (HEK293) cells.  
 
Compound HEK293 
cells 
A2780 cells SCa 
14a >100 >100  
14b >100 >100  
14c >100 >100  
[15a](CF3SO3)4 4.7 ± 1.2 0.7 ± 0.1 6.6 
[15b](CF3SO3)4 7.2 ± 1.2 0.8 ± 0.3 8.5 
[15c](CF3SO3)4 4.5 ± 0.3 0.4 ± 0.1 13 
[16a](CF3SO3)4 25.3 ± 0.7 3.1 ± 0.6 8.2 
[16b](CF3SO3)4 7.0 ± 0.2 0.8 ± 0.2 8.5 
[16c](CF3SO3)4 2.4 ± 0.1 0.5 ± 0.1 5 
[17a](CF3SO3)4 2.9 ± 0.4 0.8 ± 0.1 3.5 
[17b](CF3SO3)4 7.3 ± 0.7 2.0 ± 0.2 3.6 
[17c](CF3SO3)4 4.9 ± 0.2 0.9 ± 0.1 5.3 
[18a](CF3SO3)6 7.2 ± 0.1 0.6 ± 0.1 11.1 
[18b](CF3SO3)6 1.6 ± 0.3 0.3 ± 0.1 5.4 
[18c](CF3SO3)6 2.4 ± 0.2 0.3 ± 0.1 7.3 
[19a](CF3SO3)6 16.7 ± 0.2 7.3 ± 0.3 2.3 
[19b](CF3SO3)6 6.4 ± 0.5 >20 0.3 
[19c](CF3SO3)6 11.6 ± 1.5 4.59 ± 0.2 2.5 
Cisplatin 8.4 ± 1.2 1.4 ± 0.2 6 
 
aSC = selectivity coefficient = IC50 HEK293/IC50 A2780. 
 
The selectivity coefficients (SC = IC50 on HEK293/IC50 on A2780) of the tetracationic 
metalla-rectangles [15a]4+−[17c]4+and of the hexacationic metalla-prisms [18a]6+−[18c]6+are 
good; i.e., these complexes are ca. 1 order of magnitude more cytotoxic toward cancer cells 
than the noncancerous cells studied. In contrast, the hexanuclear metalla-prisms 
[19a]6+−[19c]6+ bridged by the tpv panels show higher IC50 values and less favorable 
selectivity coefficients, in accordance to previously reported hexacationic metalla-assemblies 
bearing benzoquinonato (IC50 ≈ 25 μM) and naphtoquinonato bridges (IC50 ≈ 5 μM).133  
The nature of the substituent of the ON∩NO bridging-linker strongly influences the 
cytotoxicity of the complexes. A trend can be observed for metalla-assemblies with the N-(2- 
ethoxy)ethanol side arms ([15c]4+−[19c]6+), which generally exhibited lower IC50 values 
compared to other metalla-assemblies of the same series. In addition, as control experiments, 
the antiproliferative activity of the dinuclear arene ruthenium metalla-clips 14a−14c was 
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evaluated, and all three compounds show IC50 values > 100 μM, 2 orders of magnitude higher 
than their corresponding metalla-assemblies. These observations are in agreement with 
previous reports describing a series of neutral and cationic dithiolato and cationic trithiolato-
bridged arene ruthenium complexes.125, 113b A plausible reason for the higher cytotoxicity of 
the cationic species may be the better uptake of positively charged molecules into cells 
compared to their neutral counterparts.183 
 
4.6 Conclusions 
 
A new family of ON∩NO bis-chelating linkers has been used to generate dinuclear, 
tetranuclear, and hexanuclear arene ruthenium complexes incorporating functional groups. 
The neutral dinuclear complexes show no antiproliferative activity, while the cationic metalla-
assemblies are all cytotoxic with IC50 values in the lower μM range. Interestingly, the cationic 
metalla-assemblies with the N-(2-ethoxy) ethanol functional groups on the ON∩NO linkers 
possess excellent selectivity for cancerous over noncancerous cells, suggesting that 
functionalization at the bridging-linkers offers great potential for the biological optimization 
of metalla-assemblies. 
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5        
Arene Ruthenium Metalla-
Prisms as Photosensitizer 
Delivery Vehicles into      
Cancer Cells 
 
 
 
 
 
Porphyrins and phthalocyanines are the common photosensitizers usually employed in 
photodynamic therapy (PDT). These photo-active agents, in general, have poorly water-
solubility and limited selectivity thus affecting overall photosensitivity.184 Functionalization, 
substitution with hydrophilic groups of the parent agent or hiding inside a nano-carrier to be 
deliver into their target, are the promising strategies developed, in recent years, to enhance the 
biological activity of these PDT drugs.185  
Among these nano-transporters, water-soluble metalla-cages developed in our group 
since 2008, have been found excellent nano-vectors for the delivery of guest molecules into 
cancer cells.127 In addition to the transport and the selective delivery, shielding of the photo-
activity in the presence of light is a new opportunity offered by these metalla-assemblies thus 
resulting in limited skin photosensitivity – a major drawbacks encountered in PDT.137 
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As a continuation of the investigation in our group, herein we report the synthesis and 
characterization of three arene ruthenium metalla-prisms with different portal size of the 
general formula [(p-cymene)6Ru6(μ-tpt)2(μ-L)3]6+ (2,5-dihydroxy-3-phenyl-1,4-benzoquinone 
(H2Ld) (d), 2,5-dihydroxy-3,6-diphenyl-1,4-benzoquinone (H2Le) (e) and 2,5-dihydroxy-3,6-
dimesityl-1,4-benzoquinone (H2Lf) (f)). The encapsulation of the porphin guest-molecule 
inside the cavities of these host systems have been confirmed using different analytical 
measurements. The photodynamic activities of two host-guest systems have been evaluated in 
the group of Prof. Vincent Sol at Université de Limoges on the human colon cancer cell line 
HT-29. An excellent photo-toxicity was noteworthy with a potential of intracellular release of 
photosensitizers by these nano-organometallic cages. 
 
5.1 Arene Ruthenium Metalla-Prisms: A New Approach in Photodynamic 
Therapy (PDT) 
 
Photodynamic therapy (PDT) is a novel method with proven ability to treat the 
prostate, skin, lung, head and neck cancers. It can be employed as an alternative strategy to 
compete with conventional clinical treatment of cancers.186 Since the hematoporphyrin 
derivative (Photofrin) became the first PTD agent approved for clinical use (1995) to treat 
bladder cancer in Canada,187 many new photosensitizer formulations have made entry to the 
clinical prescription e.g. Verteporfin – a benzoporphyrin derivative (trade name Visudyne) in 
the US, metatetrahydroxyphenyl chlorin (trade name Foscan) in Europe (Fig. 63).188 
 
Figure 63. Typically photosensitizers clinically used in PDT.189 
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  Photodynamic therapy (PDT) involves the administering of a non-toxic, light sensitive 
compound in the tumor cells. This photoactive compound, when exposed selectively to visible 
light irradiation, becomes toxic to malignant cancerous tissues via generation of singlet 
oxygen and other reactive oxygen species (Fig. 64).190 Accumulation of the photosensitizer 
(PS) in nonspecific targets are considered to be less toxic for the healthy tissues, compared to 
the anticancer drugs being used in chemotherapy which have proven track record to be 
aggressive and invasive for the human body. Another advantage of this technique is the use of 
activating light which has inert nature vis-à-vis the ionizing light in radiotherapy with 
destructive effects.191 
 
Figure 64. An overview of the photodynamic therapy treatment.191 
 
To enhance the efficiency of PDT treatment, many improvements are sought by 
different research groups, which can be classified in two main strategies: 
 The first strategy involves the development of a combination therapy by using a 
second modality or increasing the susceptibility of the tumor prior to PDT.192  
 The second approach focuses more on the specificity and the selectivity of the 
photosensitizer targeting. There are three basic approaches to improve these two factors; the 
first one consists of using an inactive PS prodrug which is inactive in the normal cells but it 
can be regained after linkage with a specific cancerous cellular function (such as enzymes) 
(Fig. 65).193  
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Figure 65. The photosensitizer prodrugs are distributed in both normal and affected cells, but it’s 
activated only in the cancer cells in the presence of specific enzymes. Irradiation by a specific light 
destroys the target cells.193  
 
The other approaches being employed involve the modification of structural integrity 
of the active parent agent by attaching a hydrophilic group or a lipophilic motif like cell-
penetrating peptide194 and monoclonal antibodies,195 thereby improving the specificity of the 
final pro-agents into cancer cells (just like a pro-drug strategy), or by enhancing the 
selectivity through the development of photosensitizer delivery vehicles such as gold 
nanoparticles,196 liposome,197 and even viruses185a that can internalize the selectively for a 
target tissue. 
However, the missing link in both strategies is the photoprotection of photosensitizer 
molecules since their unexpected activation produce undesired skin lesions – the main side 
effect of PDT. Recently, our group observed that hiding planar aromatic molecules with good 
fluorescent properties inside a tetra-cationic arene ruthenium metallarectangles leads to the 
quenching of the fluorescence light emitted by these guest molecules.198 We extended the 
study to large organometallic cages, and it is demonstrated that the photoactivity of the 
hydrophobic photosensitizers is inhibited by their encapsulation in these metalla-cages, thus 
potentially avoiding the side effect of skin photosensitivity. As mentioned in the section 1.3.4, 
several arene ruthenim metalla-prisms and cubes with different portal size were found to be 
excellent nano-carriers for the delivery of photosensitizers (porhyrins and phthalocyanines) 
into cancer cells (Fig. 24). These studies show an important correlation between the host 
portal size and the release of the guest molecules.137, 199 
In this chapter, three arene ruthenium metalla-clips incorporating a new family of 
benzo-quinonato derivatives used as bis-chelating bridging linkers are described. These 
metalla-clips are used to synthesize three new metalla cages with different portal size. The 
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PDT activities of the porphin molecule trapped inside the cavity of theses host systems have 
been reported. 
5.2 Synthesis and Characterization of the Arene Ruthenium Metalla-Clips 
 
The design of the three hydroxybenzo-quinonato derivatives is based on the synthetic 
strategy reported by Grée which involves Suzuki–Miyaura coupling reactions, the key step to 
efficiently introduce all the desired functionalized aromatic substituents. Compounds d and e 
are known, but compound f is new (Fig. 66) (more details in experimental sections).200 
 
Figure 66. Synthesis of  the hydroxybenzo-quinonato derivatives (e−f).200 
 
The dinuclear  arene ruthenium metalla-clips 20d−20f with the general formula [(p-
cymene)2Ru2Cl2(μ-L)] (Fig. 67) have been obtained by reacting the corresponding 
benzoquinone derivatives,  2,5-dihydroxy-3-phenyl-1,4-benzoquinone (H2Ld) (d), 2,5-
dihydroxy-3,6-diphenyl-1,4-benzoquinone (H2Le) (e) and 2,5-dihydroxy-3,6-dimesityl-1,4-
benzoquinone (H2Lf) (f) with [(p-cymene)2Ru2Cl2(μ-Cl)2] in methanol at room temperature 
for 24 hours.  
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Figure 67. Molecular structure of the dinuclear arene ruthenium metalla-clips 20d−20f. 
 
The coordination of the quinonato bis-chelating bridging-linkers between the two 
arene ruthenium units was confirmed by NMR spectroscopy, mass spectrometry and 
elemental analysis (see Experimental Section). Furthermore, the molecular structure of 
complex 20e was established by single-crystal X-ray structure analysis. The three complexes 
show good solubility in halogenated solvents such as chloroform and dichloromethane, but a 
limited solubility in methanol and ethanol. 
The 1H NMR spectra of the complexes 20d−20f, realized in CD2Cl2 and CDCl3, 
shows different signals at the interval [7.60 – 6.90 (ppm)] corresponds to the phenyl protons, 
along with the signals of the p-cymene groups; four doublets at  {(5.66 ppm), (5.39 ppm); 
(5.68 ppm), (5.37 ppm)} associated to the complexes 20d and 20e respectively, and two 
multiplets at [(5.68 – 5.64 ppm), (5.36 – 5.32 ppm)] for the complex 20f. Interestingly the 
benzo-quinonato proton (Hdobq) in the complex 20d show two singlets at 5.79 ppm and 5.81 
ppm with intensity 8:2 confirming the existence of two isomers with different proportions 
(Fig. 68).  
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Figure 68. Excerpt of 1H NMR spectrum of the complex 20d. 
 
Despite the presence of two isomers in solution, only one crystallizes as confirmed by 
the single-crystal structure analysis (Fig. 69). 
 
Figure 69. ORTEP drawing of 20d at 50% probability level ellipsoids. 
 
The existence of three mono-cationic fragments [M – Cl]+ in the ESI-MS spectra at 
m/z = 723.3, 796.2, 852.5 respectively for the complex 20d-20f, put forward the formation of 
metalla-clips.  
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5.3 Synthesis and Characterization of the Hexanuclear Arene Ruthenium 
Metalla-Prisms  
 
The synthesis of the arene ruthenium metalla-assemblies followed a one-pot strategy 
in which the dinuclear arene ruthenium metalla-clips 20d−20f reacted with 2,4,6-tris(4-
pyridyl)-1,3,5-triazine (tpt) ligand in the presence of silver trifluoromethanesulfonate  
(AgCF3SO3) to afford the corresponding hexacationic metalla-prisms, [(p-cymene)6Ru6(μ-
tpt)2(μ-L)3]6+ ([21d]6+−[21f]6+) in good yield. All complexes were isolated and characterized 
as their triflate salts. The formation of theses metalla-assemblies was confirmed by means of 
NMR spectroscopy, mass spectrometry and elemental analysis (see the Experimental 
Section). Furthermore, the proposed molecular structures of these cationic arene ruthenium 
metalla-prisms are presented in Figure 70. 
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Figure 70. Synthesis of the hexa-cationic metalla-prisms [21d]6+−[21f]6+. 
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The addition of 1 equiv. of porphin during the synthesis of the three hexacationic 
metalla-prisms leads to the encapsulation of this photosensitizer inside the cavity of the host 
complexes (Fig. 71).  The formation of the host-guest systems was single out and 
characterized by means of infrared, UV-visible, fluorescence and NMR spectroscopies as well 
as mass spectrometry. Moreover, the host-guest systems [22d]6+−[22f]6+ are alternatively 
accessible by reaction of the empty cages [21d]6+−[21f]6+ and one equivalent of porphine in 
methanol solution, as confirmed by NMR spectroscopy. 
Ru
Ru
O
O O
O
N
N
N
N
NN
3
2
Cl
Cl
- 6 AgCl
+ 6 AgCF3SO3
[22d]6+, [22e]6+, [22f]6+
+
Ru
Ru
Ru
O
O O
O
6+
Ru
O
O O
O
Ru
Ru
O
O O
O
N
N
N
N
N N
N
N
N
N
N N
R1 R2
R2
R R2
R1
R1
R2
N
NH N
HN
N
NH N
HN
 
Figure 71. Synthesis of the hexa-cationic host-guest systems ([porphin⊂cage]6+) [22d]6+−[22f]6+. 
 
The Infra-red spectra of the complexes show a high absorption signal at around 1260 
cm-1 associated to the trifluoromethanesulfonates anions (CF3SO3−) together with absorptions 
at around 1600 cm-1 characteristics of the quinone functions (C=O) of the bis-chelating 
bridging linkers. 
The UV-Visible absorption spectra of the metalla-prisms [21d]6+−[22f]6+ are 
characterized by an intense high-energy band centered at around 295 nm, which is assigned to 
a ligand-localized or  intraligand π → π* transition as well as broad low-energy bands related 
to metal-to-ligand charge transfer (MLCT) transitions. Furthermore, the formation of the host-
guest systems ([porphin⊂cage]6+) [22d]6+−[22f]6+ was further confirmed by the presence of 
an additional band absorption characteristic to porphin at around 395 nm (Fig. 72).184 
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Figure 72. UV−visible spectra of porphin and complexes [21d]6+−[22f]6+ (1.0 × 10-5 M in CH2Cl2). 
 
The ability of the metalla-prisms to protect porphin from light was tested, based on 
fluorescence spectroscopy measurements. In dichloromethane solution, the fluorescence 
emission of the porphin trapped inside the cages upon excitation at 405 nm is relatively 
quenched. However, the spectral features of the three host-guest systems are different. While 
for [22d]6+ the fluorescence spectrum show a bathochromic shift as compared to porphin 
alone, no "shift" was observed for the two other systems. Moreover, the hypochromic effect 
was more important in these two complexes compared to the complex [22d]6+ (Fig. 73). 
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Figure 73. Corrected emission spectra of [22d]6+−[22f]6+ and porphin (CH2Cl2, 25 °C, 10-6 M, λexc 
405 nm). 
 
Evidence for host-guest systems was also established by the 1H NMR spectroscopy 
results. For all the three systems [22d]6+−[22f]6+, the signals associated to the pyridyl protons 
of the 2,4,6-tris(4-pyridyl)-1,3,5-triazine (Hα and Hβ) panels and the amine protons of the 
porphin (NHpo) are shifted upfield (ΔδHα ≈ 0.5 ppm; ΔδHβ ≈ 2.1 ppm; ΔδNHpo ≈ 2.5 ppm) in 
comparison to the protons of the empty host complexes. Signals of the aromatic ring in 
quinone derivatives shifted downfield (ΔδHar ≈ 0.6 ppm) for the three systems (Fig. 74). On 
the other hand, the two methyl groups on the phenyl ring in the system [22f]6+ are 
consequently shifted downfield (ΔδCH3-ar ≈ 0.5 ppm) compared to the complex [21f]6+. The 
signals corresponding to the p-cymene ligands are not affected by the presence of a guest 
molecule in the cavity due to their localization in the periphery of the metalla-assemblies as 
reported elsewhere.184 
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Figure 74. 1H NMR spectra of the porphin molecule (down), the complexes [22e]6+ (middle) and 
[21e]6+ (up) in (CD2Cl2, 23°C). 
 
Interestingly, upon formation of the metalla-prisms [21d]6+ and [22d]6+, the signal 
assigned to the aromatic proton of the quinonato derivative bridging units was divided into 3 
signals with intensity 1:2:1 (for [21d]6+), while in the host-guest system [22d]6+, 4 signals 
were observed with intensity 1:1:1:1 (Fig. 75, 76). The splitting of this signal is associated to 
the presence of two isomers. Indeed, the presence of the phenyl group on the benzo-quinonato 
bridging linker decrease the symmetry in the metalla-prisms and  give rise to symmetrical 
isomer and an unsymmetrical isomer in which the phenyl groups share the same quadrant 
(Fig. 75, 76).131a  
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Figure 75. Molecular structure of the two isomers of the metalla-prism [21d]6+. 
 
 
Figure 76. Excerpts of 1H NMR spectra of the complexes 20d (down), [21d]6+ (middle) and [22d]6+ 
(up), in (CD2Cl2, 23°C). 
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In order to further confirm the formation of the host–guest systems, a series of 
diffusion-ordered NMR (DOSY) spectra were recorded. These experiments show that the 
proton resonances of the host and the guest molecules possess the same diffusion coefficient 
(D ≈ -9.25 log (m2/s)) for [porphin⊂cage]6+ complexes, thus indicating the presence of only 
one associated specie in solution (Fig. 77). The diffusion coefficients of the three host–guest 
system ([porphin⊂cage]6+)  in CD2Cl2 are comparable to those found for similar analogues 
and consistent with the respective molecular sizes of the different species.137, 184 
 
Figure 77. 1H NMR and DOSY spectra (CD3OD, 23°C) of the complex [22e]6+, showing the 
resonances of the encapsulated porphin (highlighted with red ovals). 
 
In these large systems, ROESY experiments perform an excellent technique for 
determining the host-guest interactions. In addition, these 2D spectra clearly show a strong 
nuclear Overhauser effect of the aromatic porphin protons (Hpo) with the pyridyl protons (Hα 
and Hβ) of the tpt panels. On the other hand, since no interaction between porphin and the p-
cymene ligands is observed, we can conclude that the photosensitizer guest molecule is 
successfully encapsulated inside the cavity of the host complexes [21d]6+−[21f]6+ (Fig. 78).184  
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Figure 78. 2D ROESY NMR spectra of the host-guest systems [22d]6+ (left) and [22f]6+ (right) in 
(CD2Cl2, 23°C). The ROEs cross peaks observed between the hosts and the guest are highlighted by 
green rectangles. 
 
The formation of the host–guest systems was further confirmed by electrospray 
ionization mass spectrometry (ESI-MS). All spectra showed different signals at m/z = 1146.1, 
1221.2, 1329.5 corresponding respectively to the tri-cationic fragments [22d + 3 CF3SO3]3+, 
[22e + 3 CF3SO3]3+and [22f + 2CH3OH + 3 CF3SO3]3+ (Fig. 79). 
 
Figure 79. Excerpts of the ESI-MS spectra corresponding to [22d + 3 CF3SO3]3+ (left), [22e + 3 
CF3SO3]3+ (middle) and [22f + 2CH3OH + 3 CF3SO3]3+ (right). 
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5.4 Application in Photodynamic Therapy 
 
 The photodynamic activity of the four compounds [21e]6+, [21f]6+, [22e]6+ and [22f]6+ 
were evaluated on human colorectal cancer cells (HT-29) with the concentration varying from 
1 to 1000 nM at a fixed light dose of 20 J/cm2. In the absence of porphin, the empty cages 
exposed to light show no photo-activity. However, the [porphin⊂cage]6+ host-guest systems 
([22e]6+, [22f]6+) exhibit an excellent photo-toxicity, hence proving the release of porphin in 
the illuminated cells. Moreover, a 10 nM concentration of the compound [22f]6+ was 
sufficient to inhibit 50% of cells viability. Thus, the complex [22f]6+ is ten times more active 
than the complex [22e]6+ (Fig. 80). This difference may be related to the photosensitizer’s 
release rate and the portal size of the two hosts. 
 
Figure 80. Phototoxicity on human colorectal cancer cells (HT-29) from compounds [21e]6+ and 
[21f]6+ (top), [22e]6+, and [22f]6+ (bottom), at different concentrations (10 to 1000 nM), and after 
exposure to light (20 J/cm2). 
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5.5 Conclusions 
 
A series of OO∩OO hydroxybenzo-quinonato bis-chelating bridging ligands have 
been used to generate dinuclear and hexanuclear arene ruthenium complexes incorporating 
either one or two phenyl groups. Despite the similarity in the dynamic host-guest behavior in 
NMR time scale, the fluorescence emissions of porphin and the photo-activity in the host-
guest compounds are quite different. The metalla-prisms with relatively small portal size 
show an excellent photo-toxicity with half maximal inhibitory concentrations in the nM 
range. 
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6        
General Conclusions and 
Perspectives 
 
 
 
 
 
The thermodynamic and kinetic rules driving the formation of arene ruthenium 
metalla-assemblies constructed by a prearranged self-assembling process, in addition to the 
exploration of their anticancer activities as potential drugs and drugs delivery vectors are 
described in the present thesis.  
 
6.1 Insight into the Thermodynamic and the Kinetic Aspects Dictating the 
Formation of Arene Ruthenium Metalla-Assemblies 
 
The synthetic routes and empirical parameters allowing an efficient formation of arene 
ruthenium metalla-assemblies are now well established. However, the dynamic behavior of 
these structures and the exact thermodynamic and/or kinetic pathways were not known. The 
studies and results presented in this thesis have given some answers to these issues and have 
contributed to rationalizing the thermodynamic and kinetic aspects in coordination driven 
metalla-assemblies. 
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The first part of this work deals with the dynamic ligand exchange                        
behavior of the arene ruthenium metalla-rectangles having the general formula                        
[(p-cymene)Ru4(OO∩OO)2(N∩N)2]4+ (OO∩OO = oxalato, 2,5-dioxydo-1,4-benzoquinonato, 
5,8-dioxydo-1,4-naphthoquinonato; N∩N = 4,4’-bipyridine-H8, 4,4’-bipyridine-D8). The 
1H/2D isotope labeling study of the 4,4’-bipyridine connectors shows that the ligand 
exchanges does not proceed spontaneously, even at high temperature. This exchange occurs 
only when an external stimulus is present (Scheme 9). This finding demonstrates the 
robustness of the matalla-cyclic architectures. This extra strength of metalla-assemblies favors 
their application in cancer treatment, where the stability is a crucial factor for drug delivery 
vectors. 
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Scheme 9. Description of the dynamic ligand exchange of the arene ruthenium metalla-rectangles; 
absence of spontaneous ligand exchange process between two isotopical metalla-rectangles with the 
opposite labeling (up), putative dynamic ligand exchange behavior in the presence of 4,4’-bipyridine 
as competing ligand (down). 
 
In the second part, the intermediary species leading to the formation of stable arene 
ruthenium metalla-assemblies built from OO∩OO bridging ligands and bi-pyridyl linkers are 
identified. The dynamic nature of the Ru-N bond in the solution before the closure of metalla-
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cycle is confirmed by NMR experiments. This helped us to propose the formation mechanism 
of arene ruthenium metalla-assemblies (Scheme 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. Plausible self-assembling pathway leading to the formation of arene ruthenium 
metalla-cycles. 
 
However, one question remains unanswered for arene ruthenium metalla-cycles linked 
with bi-pyridyl linkers: Does the final step involve two half-rectangles (Scheme 11A), or a 
fully occupied cis dinuclear metalla-clip with a naked metalla-clip (Scheme 11B), or a 
contribution of both? Hopefully, further studies will give the answer to this remaining 
question. 
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Scheme 11. Hypothetical steps leading to the formation of arene ruthenium metalla-cycles. 
 
6.2 Arene Ruthenium Metalla-Prisms as Anticancer Drugs and Drug Delivery 
Vectors 
 
Since the discovery of the "Enhanced permeability and retention" (EPR) effect in the 
1980s by Maeda, structural factors, especially the influence of size and shapes have been 
examined in view of enhancing the biological activity of the chemotherapeutic agents. Among 
macromolecular compounds, water-soluble arene ruthenium metalla-prisms developed in our 
group since 2008, showed excellent antiproliferative activities against human ovarian cancer 
cells as well as great ability to deliver active species into tumor tissues. In order to improve 
these two main benefits, two new strategies have been developed and tested in this present 
work. 
In addition, a new family of ON∩NO bis-chelating linkers has been used to generate a 
new family of dinuclear, tetranuclear, and hexanuclear arene ruthenium complexes 
incorporating different functional groups. The neutral dinuclear complexes have shown no 
antiproliferative activity, while the cationic metalla-assemblies were all cytotoxic with IC50 
values in the lower μM range. Interestingly, the cationic metalla-assemblies with the N-(2-
ethoxy)ethanol functional groups on the ON∩NO linkers possessed excellent selectivity for 
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cancerous over noncancerous cells, suggesting that functionalization at the bridging-linkers 
offers great potential for the biological optimization of metalla-assemblies (Fig. 81, Table 9). 
 
 
 
 
                                               
 
 
 
Figure 81. Molecular structures of the arene ruthenium metalla-assemblies [15c]4+ and [18c]6+ 
incorporating N-(2-ethoxy)ethanol functional groups, possessing an excellent selectivity for 
cancerous over noncancerous cells. 
 
 Table 9.  IC50 values (μM) of the complexes [15c]4+, [18c]6+  and cisplatin after 72 h exposure on 
human ovarian (A2780) carcinoma cells and noncancerous human embryonic kidney (HEK293) cells. 
Compound HEK293 
cells 
A2780 cells SCa 
[15c](CF3SO3)4  4.5 ± 0.3  0.4 ± 0.1  13 
[18c](CF3SO3)6  2.4 ± 0.2  0.3 ± 0.1  7.3 
cisplatin  8.4 ± 1.2  1.4 ± 0.2  6 
 
aSC = selectivity coefficient = IC50 HEK293/IC50 A2780. 
 
The second part deals with the applications of the arene ruthenium metalla-prisms as 
vehicles for intracellular delivery of photosensitizers. Consequently, a series of OO∩OO 
hydroxybenzo-quinonato bis-chelating bridging ligands are used to build three hexanuclear 
arene ruthenium metalla-prisms with different portal sizes. The metalla-prism with relatively 
smaller portal size [22f]6+ show good photo-protection ability of the porphin molecule, and an 
excellent photo-toxicity with half maximal inhibitory concentrations in nM range. This 
difference would be more highlighted in vivo, where the stability of the complex encapsulated 
[15c]4+
                                                                                                             
[18c]6+
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within the nano-transporter is crucial to inhibit the undesirable premature release of the guest 
molecule before reaching the target. 
 
6.3 Perspectives 
 
Arene ruthenium metalla-assemblies incorporating functional groups in their bis-
chelating bridging ligands have been developed in this thesis. These assemblies demonstrated 
selective and efficient anticancer activities, thus opening a new area of research in our group. 
Consequently, one possible new feature would be the incorporation of hydrophilic 
functions to the arene ligands to allow a better stability towards the final metalla-assemblies 
structures, along with a simple administration in the blood. On the other hand, segments of 
peptides or proteins such as transferrin can be attached to the bis-chelating linker’s functional 
groups, providing better accessibility to the biological barriers and cells membranes.  
Moreover, the Dyson group recently showed that a fluoroalkychain attached to 
mononuclear arene ruthenium complexes results in an excellent thermo-activity to these 
systems. Under mild hyperthermia, an excellent cytotoxicity and selectivity for cancerous 
over noncancerous cells was note-worthy for these compounds.201 Extrapolation of this 
strategy to the tetranuclear, hexanuclear and octanuclear arene ruthenium metalla-assemblies 
by attaching the fluoroalkychain to the hydroxybenzo-quinonato bis-chelating bridging ligand 
is a possible perspective (Fig. 82).  
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Figure 82. Structures of the targeted arene ruthenium metalla-prisms incorporating fluoroalkychain. 
 
The arene ruthenium metalla-prisms synthesized in the present work are able to 
encapsulate a collection of different guest molecules. Among these active species, cisplatin 
prodrugs are very promising candidates (Fig. 83). In addition, their intracellular transportation 
by the metalla-cages could be a good strategy in order to mitigate the premature aquation and 
undesirable interactions, which are plausible limitations of the cisplatin.202 Another possibility 
is the encapsulation of new highly efficient and photostable photosensitizers e.g. the ones 
based on BODIPY Chromophore for further two photon excitation PDT treatment purposes 
(Fig. 83). 
 
Figure 83. New cisplatin derived prodrug synthesized by the group of Dr. Wee Han Ang (National 
University of Singapore)(left), and 4,4-difluoro-2,6-diiodo-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-
indacene (2I-BDP) photosensitizer.203 
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7        
Experimental Section 
 
 
 
 
 
7.1 General Remarks 
 
7.1.1 Solvents, Lamp and Products 
 
Solvents of analytical grade purchased from commercial sources (Acros organic, 
Honeywell solvents and VWR international) degassed and saturated with nitrogen prior to 
use, were employed for the synthesis of the starting organic compounds; they were used as 
received unless specified otherwise for the organometallic complexes. The photoreactions 
with UV light were performed with an UV reactor (Luzchem Research, photoreactor,  = 365 
nm). 4,4′-bipyridine-D8 (bpy-D8) (purity 98 atom % D), 4,4′-bipyridine (bpy), 1,2-bis(4-
pyridyl)ethylene (bpe), 4,4′-azopyridine (bpa), 4-phenylpyridine (L1), 4-styrylpyridine (L2), 4-
methylpyridine (L3), 4-tert-butylpyridine (L4) were purchased from Sigma-Aldrich, while the 
tridentate spacers 2,4,6-tris(4-pyridyl)-1,3,5-triazine (tpt)204 and 1,3,5-tris{2-(4-
pyridyl)vinyl}benzene (tpv)205 were prepared according to published methods. Porphin is 
commercially available from Frontier Scientific. All other reagents were purchased from Alfa 
Aesar, Acros organics, TCI-Europe or Aldrich and used as received unless specified 
otherwise. 
The arene ruthenium complexes [(p-cymene)2Ru2Cl2(μ-Cl)2],206 [(p-
cymene)2Ru2(OO∩OO)Cl2] (OO∩OO = oxalato,116 2,5-dioxido-1,4-benzoquinonato,127 5,8-
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dioxido-1,4-naphthoquinonato207), along with, the arene ruthenium metalla-rectangle [(p-
cymene)Ru4(OO∩OO)2(bpy-H8)2](CF3SO3)4 (OO∩OO = oxalato, 2,5-dioxydo-1,4-
benzoquinonato, 5,8-dioxydo-1,4-naphthoquinonato) were prepared according to published 
methods.11 
 
7.1.2 NMR Experiments 
 
The 1H, 13C{1H}, COSY, HSQC, HMBC, ROESY and DOSY NMR spectra were 
recorded with Bruker Avance II 400 spectrometers, and the residual protonated solvent was 
used as an internal standard. The 2D ROESY experiments were recorded with 8 or 16 scans 
for each of the 400 t1 increments. The duration of the spin-lock time was 0.3 s, and the spin 
lock was performed with a train of 180 (x) – 180 (–x) pulses to reduce the TOCSY 
magnetization transfer.208 The data were multiplied with a squared cosine window function in 
both dimensions before Fourier transformation and zero-filled to 2048 and 1024 points in ω2 
and ω1 dimensions, respectively. 
 
7.1.3 Analytical Instruments 
 
Infrared spectra were recorded as KBr pellets on a Perkin-Elmer FTIR 1720 X 
spectrometer. UV/Visible absorption spectra were recorded with a Perkin–Elmer UV/Visible 
spectrophotometer Lambda 24 using precision cells made of quartz (1 cm). Fluorescence 
spectra were recorded on a Perkin-Elmer-LS50B luminescence spectrometer. Electrospray 
and nanoelectrospray mass spectra were recorded in the positive-ion mode with LCQ ion trap 
(Thermo Finnigan) and LTQ Orbitrap XL mass spectrometers (Thermo Scientific), 
respectively, and with a Bruker FTMS 4.7 T BioAPEX II mass spectrometer. The elemental 
analyses of 14a–14c were performed at the Microanalytical Laboratory of the University of 
Vienna (Austria), while, for the other complexes [(1–13), (15a–22f)], the elemental analyses 
were carried out by the Mikroelementaranalytisches Laboratorium, ETH Zürich 
(Switzerland). 
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7.1.4 X-ray Crystallographic Details  
 
X-ray diffraction measurements of 14a and 14c were performed on an X8 APEXII 
CCD diffractometer. Single crystals were positioned at 35 and 40 mm from the detector, and 
2488 and 2098 frames were measured, each for 30 s over a 1° scan width, respectively. The 
data were processed using the SAINT software. X-Ray Crystallography. Crystals of [trans-
4](CF3SO3)2 · 2 (CH3)2CO and [trans-7](CF3SO3)2 were mounted on a Stoe Image Plate 
Diffraction system equipped with a   circle goniometer, using Mo-Kα graphite 
monochromatic radiation (λ = 0.71073 Å) with  range 0-200º. The structures were solved by 
direct methods using the program SHELXS-97, while the refinement and all further 
calculations were carried out using SHELXL-97.209 The H atoms were included in calculated 
positions and treated as riding atoms using the SHELXL default parameters. The non-H atoms 
were refined anisotropically, using weighted full-matrix least-squares on F2.  
 
7.1.5 Biological Studies  
 
Cytotoxicity Test (MTT assay) (performed by the group of Professor Dyson (EPFL)) 
 
Cell lines, Cell Culture, and Cell Viability Test; HEK293 human embryonic kidney 
cells (ATCC CRL-1573) were obtained from ATCC (Middlesex, U.K.), and the A2780 
human ovarian carcinoma cell line was obtained from the European Collection of Cell 
Cultures (calatogue number 93112519, Salisbury, U.K.). All cell culture media were 
purchased from Life Technologies (Zug, Switzerland). A2780 cells were cultured in RPMI-
1640 medium (Gibco, GlutaMax), while HEK293 cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM, Gibco, GlutaMax) supplemented with 10% fetal bovine serum (FBS, 
Sigma-Aldrich, Buchs, Switzerland) and 1% penicillin/streptomycin (Life Technologies, Zug, 
Switzerland). Cells were incubated in a CO2 incubator with 5% CO2 and 100% relative 
humidity at 37 °C. MTT (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide) was purchased from Calbiochem (Zug, Switzerland). The cell viability was 
determined by the MTT assay. The absorption was read using a SpectraMax M52 microplate 
reader (Molecular Devices, Sunnyvale, CA, USA). Cells were seeded in 96-well plates as 
monolayers with 100 μL of cell suspension (approximately 5000 cells) per well and 
preincubated for 24 h in medium supplemented with 10% FBS. All compounds were 
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dissolved in DMSO. The stock solutions were serially diluted in the culture medium to the 
appropriate concentration to give a final DMSO concentration of not higher than 0.5%. A 100 
μL aliquot of the compound solution was added to each well, and the plates were incubated 
for another 72 h. Subsequently, MTT (5 mg/mL solution) was added to the cells, and the 
plates were incubated for a further 2 h. The culture medium was aspirated, and the purple 
formazan crystals, formed by the mitochondrial dehydrogenase activity of vital cells, were 
dissolved in DMSO. The optical density, directly proportional to the number of surviving 
cells, was quantified at 590 nm using a multiwell plate reader, and the fraction of surviving 
cells was calculated from the absorbance of untreated control cells. The evaluation was based 
on means from at least two independent experiments, each comprising triplicates per 
concentration level. 
 
In vitro Phototoxicity Studies (MTT assay) (performed by the group of Prof. Vincent Sol at 
the Université de Limoges) 
 
The cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) staining method. 100 μL per well of cell suspension at 0.5 × 105 
cells per mL were cultured in microplates (96 wells) in complete DMEM GlutamaxTM. After 
cells had grown for 24 h, the supernatant was removed and cells were incubated in the dark 
with different concentrations of compounds [21e][CF3SO3]6, [21f][CF3SO3]6, [22e][CF3SO3]6 
and [22f][CF3SO3]6 ranging from 10 to 1000 nM for 24 h. Phototoxicity (with irradiation at a 
fluence of 20 J/cm2) of the compounds was evaluated using the MTT assay, and control 
experiments were as follow: no treatment with light exposure and assays combining treatment 
and light. 15 μL of MTT (5 g MTT/L in H2O) were added and cells incubated for 3 h. One 
hundred μl of DMSO were added to each well and mixed to dissolve the reduced MTT 
crystals and the absorbance read at 595 nm using a microplate spectrophotometer (Triad 
Serlabo Technologies). Each experiment was realized in triplicate and repeated four times. 
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7.2 Syntheses and Characterizations 
 
7.2.1 Synthesis and Characterization of the Isotopic and Heteroisotopic Arene 
Ruthenium Metalla-Rectangles 
 
General Synthetic Method for the Isotopic Metalla-Rectangles of the General Formula [(p-
cymene)Ru4(OO∩OO)2(bpy-D8)2]4+.  
A mixture of the dinuclear clip [(p-cymene)2Ru2(OO∩OO)Cl2] (OO∩OO = oxalato, 2,5-
dioxydo-1,4-benzoquinonato, 5,8-dioxydo-1,4-naphthoquinonato) (0.16 mmol) and 2 equiv of 
AgCF3SO3 (0.32 mmol) in methanol (20 mL) was stirred at room temperature for 2 h and the 
solution was filtered to remove AgCl. To the filtrate, the corresponding 4,4′-bipyridine-D8 
(bpy-D8) (0.16 mmol) was added. The mixture was stirred at room temperature for 24 h, and 
the solvent removed under vacuum. The residue was dissolved in dichloromethane (20 mL), 
the extract filtered and concentrated (3 mL), and diethyl ether was slowly added to initiate 
precipitation of the product as a dark orange or red solid. 
 
[(p-cymene)4Ru4(oxalato)2(bpy-D8)2](CF3SO3)4 (R-ox-homo-D16). Orange solid, Yield: 0.052 
mmol (65%). 1H NMR (400 MHz, MeOD): δ (ppm) , 5.96(d, 8H, 3JH-H = 6.2    Hz, CHp-cym), 
5.78 (d, 8H, 3JH-H = 6.2 Hz, CHp-cym), 2.95 (sept, 4H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.23 (s, 12H, 
CH3), 1.39 (d, 24H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, MeOD): δ (ppm) 
172.5 (C=O), 149.27 (Cbpy), 142.12 (Cbpy), 125.6 (Cbpy), 103.97 (Cp-cym), 99.13 (Cp-cym), 83.61 
(CHp-cym), 82.99 (CHp-cym), 32.48 (CH(CH3)2), 22.47 (CH(CH3)2), 18.02 (CH3). IR (cm-1): 
3077 (w, CHp-cym), 1634(s, C=O), 1578 (s, C=Cbpy), 1259 (s, CF3). UV-visible: (1.0 × 10-5 M, 
CH2Cl2, 298 K): λmax 241 nm (ε = 29 371 M-1 · cm-1), 311 nm (ε = 25 684 M-1 · cm-1). ESI-
MS: 790 [M - bpy - 2 CF3SO3]2+, 872 [1/2 M - CF3SO3]1+, 708 [1/2 M – bpy – CF3SO3]1+. 
[(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy-D8)2](CF3SO3)4 (R-dobq-homo-
D16). Red solid, Yield: 0.053 mmol (66%). 1H NMR (400 MHz, MeOD): δ (ppm) , 6.02 (d, 
8H, 3JH-H =6.4 Hz, CHp-cym), 5.80 (d, 8H, 3JH-H = 6.4 Hz, CHp-cym), 5.77 (s, 8 H, CHdhbq), 2.87 
(sep, 4H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.17 (s, 12H, CH3), 1.35 (d, 24H, 3JH-H = 6.9 Hz, 
CH(CH3)2). 13C{1H} NMR (100 MHz, MeOD): δ (ppm) 185.7 (C=O), 146.7 (Cbpy), 144.7 
(Cbpy), 123.6 (Cbpy), 105.56 (Cp-cym), 103.00 (CHdhbq), 100.35 (Cp-cym), 85.07 (CHp-cym), 83.55 
(CHp-cym), 32.73 (CH(CH3)2), 22.68 (CH(CH3)2), 18.28 (CH3). IR (cm-1): 3066 (w, CHp-cym), 
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1580 (s, C=Cbpy), 1527 (s, C=O), 1258 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): 
λmax 308 nm (ε = 45 981 M-1 · cm-1), 491 nm (ε = 30 945 M-1 · cm-1). ESI-MS: 922 [M – 2 
CF3SO3]2+.  
 
[(p-cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy-D8)2](CF3SO3)4 (R-donq-homo-
D16). Dark green solid, Yield: 0.053 mmol (66%). 1H NMR (400 MHz, MeOD): δ (ppm) , 
7.24 (s, 8 H, CHdhnq), 5.86 (d, 8H, 3JH-H=6.4 Hz, CHp-cym), 5.63 (d, 8H, 3JH-H= 6.4 Hz, CHp-
cym), 2.83 (sep, 4H, 3JH-H= 7 Hz, CH(CH3)2), 2.17 (s, 12H, CH3), 1.35 (d, 24H, 3JH-H= 7 Hz, 
CH(CH3)2). 13C{1H} NMR (100 MHz, MeOD): δ (ppm) 172.26 (C=O), 153.49 (Cbpy), 
138.62 (Cbpy), 124.15 (Cbpy), 112.58 (Cp-cym), 105.04 (CHdhnq), 101.24 (Cp-cym), 85.96 (CHp-
cym), 84.03 (CHp-cym), 31.98 (CH(CH3)2), 22.46 (CH(CH3)2), 17.31 (CH3). IR (cm-1): 3066 (w, 
CHp-cym), 1578 (s, C=Cbpy), 1536 (s, C=O), 1259 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 
298 K): λmax 317 nm (ε = 33 470 M-1 · cm-1), 433 nm (ε = 17 300 M-1 · cm-1), 642 nm (ε = 
1300 M-1 · cm-1), 695 nm (ε = 2863 M-1 · cm-1). ESI-MS: 972 [M – CF3SO3]2+. 
 
General Synthetic Method for the Heteroisotopic Metalla-Rectangles of the General Formula 
[(p-cymene)Ru4(OO∩OO)2(bpy-H8)(bpy-D8)]4+.  
A mixture of the dinuclear clip [(p-cymene)2Ru2(OO∩OO)Cl2] (OO∩OO = oxalato, 2,5-
dioxydo-1,4-benzoquinonato, 5,8-dioxydo-1,4-naphthoquinonato) (0.16 mmol) and 2 equiv of 
AgCF3SO3 (0.32 mmol) in methanol (20 mL) was stirred at room temperature for 2 h and the 
solution was filtered to remove AgCl. To the filtrate, a mixture of bpy-H8 and bpy-D8 (0.08 
mmol + 0.08 mmol) was added. The mixture was stirred at room temperature for 24 h, and the 
solvent removed under vacuum. Then the residue was dissolved in dichloromethane (20 mL), 
the extract filtered and concentrated (3 mL), and diethyl ether was slowly added to initiate 
precipitation of the product as a dark orange or red solids, the average yield of the obtained 
metalla-rectangle mixtures being 63%.  
 
All NMR data are consistent with the formation of the mixed metalla-rectangles (Figure 27), 
however, no chemical shifts of the protons between the 1H/2D species are observed, only the 
integration being consistent with the expected mixtures between the homo- and hetero-
metalla-rectangles. 
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[(p-cymene)4Ru4(oxalato)2(bpy-H8)(bpy-D8)](CF3SO3)4 (R-ox-hetero H8-D8). Orange solid. 
ESI-MS: 786 [M(D8/H8) – (bpy-D8) – 2 CF3SO3]2+, 790 [M(D8/H8) – (bpy-H8) – 2 CF3SO3]2+, 
864 [1/2 M(D8/H8) – CF3SO3]1+, 872 [1/2 M(D8/H8) – CF3SO3]1+. 
[(p-cymene)4Ru4(2,5-dioxydo-1,4-benzoquinonato)2(bpy-H8)(bpy-D8)](CF3SO3)4 (R-dobq-
hetero H8-D8). Red solid. ESI-MS: 836 [M(D8/H8) – (bpy-D8) – 2 CF3SO3]2+, 840 [M(D8/H8) 
– (bpy-H8) – 2 CF3SO3]2+, 918 [M(D8/H8) – 2 CF3SO3]2+.   
[(p-cymene)4Ru4(5,8-dioxydo-1,4-naphthoquinonato)2(bpy-H8)(bpy-D8)](CF3SO3)4 (R-dobq-
hetero H8-D8). Dark green solid. ESI-MS: 886 [M(D8/H8) – (bpy-D8) – 2 CF3SO3]2+, 890 
[M(D8/H8) – (bpy-H8) – 2 CF3SO3]2+, 968 [M(D8/H8) – 2 CF3SO3]2+. 
 
7.2.2 Preparation of the Arene Ruthenium Dimetallic Complexes 
 
General Synthetic Method for the Dinuclear Arene Ruthenium Complexes of the General 
Formula [(p-cymene)2Ru2(OO∩OO)(Ln)2]2+ [1]2+[12]2+.  
A mixture of the dinuclear complex [(p-cymene)2Ru2(OO∩OO)Cl2] (OO∩OO = oxalato, 2,5-
dioxydo-1,4-benzoquinonato and 5,8-dioxydo-1,4-naphthoquinonato) (0.16 mmol) and 2 eq. 
of AgCF3SO3 (0.32 mmol) in methanol (20 mL) was stirred at room temperature for 2 h and 
the solution was filtered to remove AgCl. To the filtrate, the corresponding 4-phenylpyridine, 
4-styrylpyridine, 4-methylpyridine and 4-tbutylpyridine (0.32 mmol) was added. The mixture 
was stirred at room temperature for 24 h, and the solvent removed under vacuum. The residue 
was dissolved in dichloromethane (20 mL), the extract filtered and concentrated (3 mL), and 
diethyl ether with pentane were slowly added to initiate precipitation of the product as an 
orange, green or red solid. 
[1][CF3SO3]2: Dark green solid, Yield: 0.09 mmol (56%). IR (cm-1): 3066 (w, CHp-cym), 1612 
(s, C=CL), 1534 (s, C=O), 1275 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 554 
nm (ε = 12 183 M-1 · cm-1), 546 nm (ε = 12 129 M-1 · cm-1), 237 nm (ε = 70545 M-1 · cm-1), 
695 nm (ε = 2863 M-1 · cm-1). ESI-MS: 963 [M – L1 – CF3SO3]+, 807 [M – 2 L1 – CF3SO3]1+. 
Calcd for C54H52F6N2O10Ru2S2 · CH2Cl2 · 2H2O: C, 47.59; H, 4.07; N, 2.02. Found: C, 47.54; 
H, 3.72; N, 1.99.  
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[cis-1][CF3SO3]2 (46%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.41 (d, 4H, 3JH-H = 6.8 Hz, 
CHα), 7.59 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.53 (m, 4H, CHar), 7.35 (m, 4H, CHar), 7.26 (s, 4H, 
CHdonq), 5.87 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.60 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.79 
(sept, 2H, 3JH-H = 7.0 Hz, CH(CH3)2), 2.14 (s, 6H, CH3), 1.28 (d, 12H, 3JH-H = 7.0 Hz, 
CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 172.36 (C=O), 153.18 (CL), 138.61 
(CL), 131.42 (CHar), 130.37 (CHar), 128.09 (CHar), 124.52 (CL), 104.81 (CHdonq), 100.91 (Cp-
cym), 85.78 (CHp-cym), 83.97 (CHp-cym), 32.02 (CH(CH3)2), 22.42 (CH(CH3)2), 17.35 (CH3). 
[trans-1][CF3SO3]2 (54%): 1H NMR (400 MHz, CD3OD): δ (ppm) 8.56 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.83 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.79 (m, 4H, CHar), 7.55 (m, 6H, CHar), 7.23 (s, 
4H, CHdonq), 5.81 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.60 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.86 
(sept, 2H, 3JH-H = 7.0 Hz, CH(CH3)2), 2.12 (s, 6H, CH3), 1.36 (d, 12H, 3JH-H = 7.0 Hz, 
CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 172.64 (C=O), 153.48 (CL), 138.57 
(CL), 131.67 (CHar), 130.56 (CHar), 128.29 (CHar), 124.58 (CL), 104.86 (CHdonq), 100.78 (Cp-
cym), 85.56 (CHp-cym), 83.90 (CHp-cym), 31.97 (CH(CH3)2), 22.48 (CH(CH3)2), 17.38 (CH3).  
[2][CF3SO3]2:  Dark green solid, Yield: 0.09 mmol (60%). IR (cm-1): 3063 (w, CHp-cym), 1609 
(s, C=CL), 1533 (s, C=O), 1274 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 306 
nm (ε = 61 955 M-1 · cm-1), 228 nm (ε = 76 676 M-1 · cm-1). ESI-MS: 989 [M – L2 –CF3SO3]+, 
807 [M – 2 L2  – CF3SO3]+. Calcd for C58H54F6N2O10Ru2S2 · CH2Cl2: C, 50.46; H, 4.02; N, 
1.99. Found: C, 50.07; H, 3.95; N, 1.86.  
[cis-2][CF3SO3]2 (41%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.28 (d, 4H, 3JH-H = 6.8 Hz, 
CHα), 7.43 (m, 4H, CHβ), 7.41 (m, 4H, CHar), 7.22 (m, 6H, CHar), 7.36 (d, 2H, 3JH-H = 16.4 
Hz, CH=CH), 6.92 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 7.26 (s, 4H, CHdonq), 5.85 (d, 4H, 3JH-H 
= 6.4 Hz, CHp-cym), 5.61 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.84 (sept, 2H, 3JH-H = 7.0 Hz, 
CH(CH3)2), 2.12 (s, 6H, CH3), 1.35 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 172.36 (C=O), 153.18 (CL), 138.61 (CL), 131.42 (CHar), 130.37 
(CHar), 128.09 (CHar), 124.52 (CL), 104.81 (CHdonq), 100.91 (Cp-cym), 85.78 (CHp-cym), 83.97 
(CHp-cym), 32.02 (CH(CH3)2), 22.42 (CH(CH3)2), 17.35 (CH3).  
[trans-2][CF3SO3]2 (59%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.42 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.66 (m, 4H, CHβ), 7.62 (m, 4H, CHar), 7.60 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 
7.42 (m, 6H, CHar), 7.21 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 7.25 (s, 4H, CHdonq), 5.80 (d, 4H, 
3JH-H = 6.4 Hz, CHp-cym), 5.58 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.78 (sept, 2H, 3JH-H = 7.0 Hz, 
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CH(CH3)2), 2.11 (s, 6H, CH3), 1.27 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 172.64 (C=O), 153.48 (CL), 138.57 (CL), 131.67 (CHar), 130.56 
(CHar), 128.29 (CHar), 124.58 (CL), 104.86 (CHdonq), 100.78 (Cp-cym), 85.56 (CHp-cym), 83.90 
(CHp-cym), 31.97 (CH(CH3)2), 22.48 (CH(CH3)2), 17.38 (CH3).  
[3][CF3SO3]2: Dark green solid, Yield: 0.11 mmol (68%). IR (cm-1): 3070 (w, CHp-cym), 1624 
(s, C=CL), 1532 (s, C=O), 1270 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 439 
nm (ε = 2 357 M-1 · cm-1), 318 nm (ε = 3 313 M-1 · cm-1), 229 nm (ε = 12 472 M-1 · cm-1), ESI-
MS: 901 [M – L3 – CF3SO3]+, 807 [M – 2 L3 – CF3SO3]+. Calcd for C44H46F6N2O10Ru2S2: C, 
46.23; H, 4.06; N, 2.45. Found: C, 45.65; H, 4.01; N, 2.36.  
[cis-3][CF3SO3]2 (47%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.23 (d, 4H, 3JH-H = 6.6 Hz, 
CHα), 7.22 (d, 4H, 3JH-H = 6.6 Hz, CHβ), 7.18 (s, 4H, CHdonq), 5.80 (d, 4H, 3JH-H = 6.3 Hz, 
CHp-cym), 5.57 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 2.77 (m, 2H, CH(CH3)2), 2.32 (s, 6H, 
CHβCCH3), 2.07 (s, 6H, CH3), 1.31 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 172.28 (C=O), 152.36 (CL), 138.49 (CHdonq), 128.09 (CL), 85.76 
(CHp-cym), 83.78 (CHp-cym), 32.01 (CH(CH3)2), 22.46 (CH(CH3)2), 20.89 (CHβCCH3), 17.36 
(CH3). 
[trans-3][CF3SO3]2 (53%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.33 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.34 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.15 (s, 4H, CHdonq), 5.76 (d, 4H, 3JH-H = 6.3 Hz, 
CHp-cym), 5.54 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 2.77 (m, 2H, CH(CH3)2), 2.43 (s, 6H, 
CHβCCH3), 2.07 (s, 6H, CH3), 1.26 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 172.55 (C=O), 152.57 (CL), 138.49 (CHdonq), 128.16 (CL), 85.49 
(CHp-cym), 83.83 (CHp-cym), 31.97 (CH(CH3)2), 22.42 (CH(CH3)2), 20.92 (CHβCCH3), 17.32 
(CH3). 
[4][CF3SO3]2: Dark green solid, Yield: 0.10 mmol (62%). IR (cm-1): 3065 (w, CHp-cym), 1637 
(s, C=CL), 1537 (s, C=O), 1275 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 554 
nm (ε = 12 183 M-1 · cm-1), 546 nm (ε = 12 129 M-1 · cm-1), 237 nm (ε = 70545 M-1 · cm-1), 
695 nm (ε = 2863 M-1 · cm-1). ESI-MS: 943 [M – L4 – CF3SO3]+, 807 [M – 2 L4 – CF3SO3]+. 
Calcd for C50H58F6N2O10Ru2S2: C, 48.93; H, 4.76; N, 2.28. Found: C, 48.71; H, 4.74; N, 2.18.  
[cis-4][CF3SO3]2 (42%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.32 (d, 4H, 3JH-H = 6.8 Hz, 
CHα), 7.45 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.20 (s, 4 H, CHdonq), 5.78 (d, 4H, 3JH-H = 6.4 Hz, 
CHp-cym), 5.57 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.83 (sept, 2H, 3JH-H = 7.0 Hz, CH(CH3)2), 
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2.11 (s, 6H, CH3), 1.34 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.22 (s, 18H, C(CH3)3). 13C{1H} 
NMR (100 MHz, CD3OD): δ (ppm) 172.35 (C=O), 165.57 (C=O), 152.58 (CL), 138.54 
(CHdonq), 124.52 (CL), 104.74 (Cp-cym), 100.71 (Cp-cym), 85.66 (CHp-cym), 83.95 (CHp-cym), 
36.02 (C(CH3)3), 31.99 (CH(CH3)2), 30.41 (C(CH3)3), 22.45 (CH(CH3)2), 17.31 (CH3).  
[trans-4][CF3SO3]2 (58%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.42 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.58 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.22 (s, 4H, CHdonq), 5.83 (d, 4H, 3JH-H = 6.4 Hz, 
CHp-cym), 5.60 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.79 (sept, 2H, 3JH-H = 7.0 Hz, CH(CH3)2), 
2.10 (s, 6H, CH3), 1.35 (s, 18H, C(CH3)3), 1.29 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} 
NMR (100 MHz, CD3OD): δ (ppm) 172.57 (C=O), 165.81 (C=O), 152.76 (CL), 138.51 
(CHdonq), 124.58 (CL), 104.77 (Cp-cym), 100.57 (Cp-cym), 85.40 (CHp-cym), 83.99 (CHp-cym), 
36.15 (C(CH3)3), 31.95 (CH(CH3)2), 30.52 (C(CH3)3), 22.42 (CH(CH3)2), 17.27 (CH3).  
[5][CF3SO3]2: Red solid, Yield: 0.09 mmol (56%). IR (cm-1): 3064 (w, CHp-cym), 1613 (s, 
C=CL), 1523 (s, C=O), 1258 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 237 
nm (ε = 46 681 M-1 · cm-1), 418 nm (ε = 11 262 M-1 · cm-1), 484 nm (ε = 11 088 M-1 · cm-1). 
ESI-MS: 922 [M – 2 CF3SO3]+, 758 [M – 2 L1 – CF3SO3]+. Calcd for C50H48F6N2O10Ru2S2: 
C, 49.34; H, 3.97; N, 2.30. Found: C, 49.48; H, 3.99; N, 2.21.  
[cis-5][CF3SO3]2 (39%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.25 (d, 4H, 3JH-H = 6.8 Hz, 
CHα), 7.64 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.53 (m, 4H, CHar), 7.40 (m, 6H, CHar), 7.42 (m, 2H, 
CHar), 6.04 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 5.84 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 5.83 (s, 2H, 
CHdobq), 2.91 (sept, 2H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.23 (s, 6H, CH3), 1.39 (d, 12H, 3JH-H = 
6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 185.42 (C=O), 154.03 (CL), 
152.78 (CL), 131.80 (CHar), 130.49 (CHar), 128.10 (CHar), 124.68 (CL), 105.01 (Cp-cym), 
102.75 (CHdobq), 99.96 (Cp-cym), 84.81 (CHp-cym), 83.29 (CHp-cym), 32.73 (CH(CH3)2), 22.53 
(CH(CH3)2), 18.20 (CH3).  
[trans-5][CF3SO3]2 (61%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.38 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.89 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.83 (m, 4H, CHar), 7.58 (m, 6H, CHar), 7.36 (m, 
2H, CHar), 5.98 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 5.79 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 5.78 (s, 
2H, CHdobq), 2.86 (sept, 2H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.24 (s, 6H, CH3), 1.32 (d, 12H, 3JH-H 
= 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 185.5 (C=O), 154.31 
(CL), 152.98 (CL), 131.99 (CHar), 130.72 (CHar), 128.39 (CHar), 124.85 (CL), 105.19 (Cp-cym), 
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102.62 (CHdobq), 99.84 (Cp-cym), 84.71 (CHp-cym), 83.49 (CHp-cym), 32.73 (CH(CH3)2), 22.53 
(CH(CH3)2), 18.20 (CH3).  
[6][CF3SO3]2: Red solid, Yield: 0.1 mmol (62%). IR (cm-1): 3066 (w, CHp-cym), 1611 (s, 
C=CL), 1520 (s, C=O), 1256 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 319 
nm (ε = 94 518 M-1 · cm-1). ESI-MS: 1120 [M – CF3SO3]+, 939 [M – L2 – CF3SO3]+, 758 [M 
– 2 L2 – CF3SO3]+. Calcd for C54H52F6N2O10Ru2S2: C, 51.10; H, 4.13; N, 2.21. Found: C, 
51.36; H, 3.97; N, 2.43.  
[cis-6][CF3SO3]2 (38%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.10 (d, 4H, 3JH-H = 6.8 Hz, 
CHα), 7.65 (m, 4H, CHar), 7.44 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.40 (m, 6H, CHar), 7.36 (d, 2H, 
3JH-H = 16.4 Hz, CH=CH), 6.87 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 6.03 (d, 4H, 3JH-H = 6.3 Hz, 
CHp-cym), 5.84 (s, 2H, CHdobq), 5.80 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 2.90 (sept, 2H, 3JH-H = 
6.9 Hz, CH(CH3)2), 2.20 (s, 6H, CH3), 1.38 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} 
NMR (100 MHz, CD3OD): δ(ppm) 185.44 (C=O), 153.61 (CL), 149.89 (CL), 130.56 (CHar), 
129.90 (CHar), 128.61 (CHar), 124.58 (CL), 105.13 (Cp-cym), 102.66 (CHdobq), 100.01 (Cp-cym), 
84.85 (CHp-cym), 83.16 (CHp-cym), 32.62 (CH(CH3)2), 22.56 (CH(CH3)2), 18.20 (CH3).  
[trans-6][CF3SO3]2 (62%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.24 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.71 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.65 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 7.38 (m, 
4H, CHar), 7.20 (m, 6H, CHar), 7.25 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 5.97 (d, 4H, 3JH-H = 6.3 
Hz, CHp-cym), 5.77 (d, 4H, 3JH-H = 6.3 Hz, CHp-cym), 5.76 (s, 2H, CHdobq), 2.84 (sept, 2H, 3JH-H 
= 6.9 Hz, CH(CH3)2), 2.22 (s, 6H, CH3), 1.32 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} 
NMR (100 MHz, CD3OD): δ (ppm) 185.44 (C=O), 153.96 (CL), 150.19 (CL), 130.83 (CHar), 
130.05 (CHar), 128.78 (CHar), 124.78 (CL), 104.92 (Cp-cym), 102.54 (CHdobq), 99.91 (Cp-cym), 
84.75 (CHp-cym), 83.16 (CHp-cym), 32.57 (CH(CH3)2), 22.53 (CH(CH3)2), 18.20 (CH3).  
[7][CF3SO3]2: Red solid, Yield: 0.11 mmol (68%). IR (cm-1): 3070 (w, CHp-cym), 1616 (s, 
C=CL), 1521 (s, C=O), 1259 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 237 
nm (ε = 46 681 M-1 · cm-1), 418 nm (ε = 11 262 M-1 · cm-1), 484 nm (ε = 11 088 M-1 · cm-1). 
ESI-MS: 944 [M – CF3SO3]+, 851 [M – L3 – CF3SO3]+. Calcd for C40H44F6N2O10Ru2S2 · H2O: 
C, 43.24; H, 4.17; N, 2.52. Found: C, 43.04; H, 3.97; N, 2.79.  
[cis-7][CF3SO3]2 (38%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.07 (d, 4H, 3JH-H = 6.6 Hz, 
CHα), 7.26 (d, 4H, 3JH-H = 6.6 Hz, CHβ), 5.99 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.76 (s, 2H, 
CHdobq), 5.73 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.80 (m, 2H, CH(CH3)2), 2.36 (s, 6H, 
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CHβCCH3), 2.16 (s, 6H, CH3), 1.38 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 185.31 (C=O), 153.88 (CL), 153.23 (CL), 128.47 (CL), 105.03 (Cp-
cym), 102.53 (CHdobq), 99.94 (Cp-cym), 84.75 (CHp-cym), 83.05 (CHp-cym), 32.57 (CH(CH3)2), 
22.52 (CH(CH3)2), 21.00 (CHβCCH3), 18.13 (CH3).  
[trans-7][CF3SO3]2 (62%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.15 (d, 4H, 3JH-H = 6.6 
Hz, CHα), 7.41 (d, 4H, 3JH-H = 6.6 Hz, CHβ), 5.93 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.76 (d, 
4H, 3JH-H = 6.4 Hz, CHp-cym), 5.69 (s, 2H, CHdobq), 2.80 (m, 2H, CH(CH3)2), 2.47 (s, 6H, 
CHβCCH3), 2.18 (s, 6H, CH3), 1.30 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 185.38 (C=O), 154.07 (CL), 153.42 (CL), 128.37 (CL), 104.84 (Cp-
cym), 102.44 (CHdobq), 99.78 (Cp-cym), 84.61 (CHp-cym), 83.35 (CHp-cym), 32.54 (CH(CH3)2), 
22.50 (CH(CH3)2), 21.02 (CHβCCH3), 18.14 (CH3).  
[8][CF3SO3]2: Red solid, Yield: 0.09 mmol (56%). IR (cm-1): 3066 (w, CHp-cym), 1622 (s, 
C=CL), 1515 (s, C=O), 1263 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 228 
nm (ε = 9 889 M-1 · cm-1), 307 nm (ε = 4 947 M-1 · cm-1), 501 nm (ε = 4 101 M-1 · cm-1). ESI-
MS: 1028 [M – CF3SO3]+, 893 [M – L4 – CF3SO3]+. Calcd for C46H56F6N2O10Ru2S2: C, 46.93; 
H, 4.79; N, 2.38. Found: C, 46.54; H, 4.87; N, 2.26.  
[cis-8][CF3SO3]2 (32%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.15 (d, 4H, 3JH-H = 6.9 Hz, 
CHα), 7.47 (d, 4H, 3JH-H = 6.9 Hz, CHβ), 5.98 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.78 (d, 4H, 
3JH-H = 6.4 Hz, CHp-cym), 5.77 (s, 2H, CHdobq), 2.83 (m, 2H, CH(CH3)2), 2.16 (s, 6H, CH3), 
1.34 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2) 1.22 (s, 18H, C(CH3)3). 13C{1H} NMR (100 MHz, 
CD3OD): δ (ppm) 185.45 (C=O), 153.49(CL), 124.76 (CL), 105.05 (Cp-cym), 102.63 (CHdobq), 
99.78 (Cp-cym), 84.71 (CHp-cym), 83.28 (CHp-cym), 36.30 (C(CH3)3), 32.55 (CH(CH3)2), 30.48 
(C(CH3)3), 22.51 (CH(CH3)2), 18.12 (CH3).  
[trans-8][CF3SO3]2 (68%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.22 (d, 4H, 3JH-H = 6.9 
Hz, CHα), 7.61 (d, 4H, 3JH-H = 6.9 Hz, CHβ), 5.92 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.73 (d, 
4H, 3JH-H = 6.4 Hz, CHp-cym), 5.72 (s, 2H, CHdobq), 2.83 (m, 2H, CH(CH3)2), 2.19 (s, 6H, 
CH3), 1.35 (s, 18H, C(CH3)3), 1.30 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 185.47 (C=O), 153.66 (CL), 124.89 (CL), 104.83 (Cp-cym), 102.48 
(CHdobq), 99.64 (Cp-cym), 84.61 (CHp-cym), 83.51 (CHp-cym), 36.17 (C(CH3)3), 32.59 
(CH(CH3)2), 30.41 (C(CH3)3), 22.51 (CH(CH3)2), 18.14 (CH3). 
 Experimental Section 
125 
[9][CF3SO3]2: Orange solid, Yield: 0.12 mmol (75%). IR (cm-1): 3068 (w, CHp-cym), 1630 (s, 
C=CL), 1540 (s, C=O), 1264 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 241 
nm (ε = 29 371 M-1 · cm-1), 311 nm (ε = 25 684 M-1 · cm-1). ESI-MS: 863 [M – L1 – 
CF3SO3]+, 708 [M – 2 L1 – CF3SO3]+. Calcd for C46H46F6N2O10Ru2S2 · H2O: C, 46.62; H, 
4.08; N, 2.36. Found: C, 46.64; H, 3.84; N, 2.30.  
[cis-9][CF3SO3]2 (78%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.03 (d, 4H, 3JH-H = 6.8 Hz, 
CHα), 7.52 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.36 (m, 4H, CHar), 7.29 (m, 2H, CHar), 7.19 (m, 4H, 
CHar), 5.93 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.76 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.84 (sept, 
2H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.22 (s, 6H, CH3), 1.37 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 
13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 172.25 (C=O), 153.67 (CL), 152.56 (CL), 131.92 
(CHar), 130.50 (CHar), 127.85 (CHar), 124.31 (CL), 98.69 (Car), 83.58 (CHp-cym), 83.03 (CHp-
cym), 32.33 (CH(CH3)2), 22.51 (CH(CH3)2), 18.08 (CH3).  
[trans-9][CF3SO3]2 (22%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.52 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 8.03 (m, 4H, CHβ), 7.92 (d, 4H, 3JH-H = 7.9 Hz, CHar), 7.61 (m, 6H, CHar), 5.90 (d, 
4H, 3JH-H = 6.4 Hz, CHp-cym), 5.67 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.56 (sept, 2H, 3JH-H = 6.9 
Hz, CH(CH3)2), 1.97 (s, 6H, CH3), 0.97 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR 
(100 MHz, CD3OD): δ (ppm) 172.25 (C=O), 154.38 (CL), 151.56 (CL), 132.18 (CHar), 130.85 
(CHar), 128.46 (CHar), 125.30 (CL), 99.28 (Car), 83.98 (CHp-cym), 81.08 (CHp-cym), 32.56 
(CH(CH3) 2), 22.13 (CH(CH3)2), 17.96 (CH3). 
[10][CF3SO3]2: Orange solid, Yield: 0.11 mmol (68%). IR (cm-1): 3067 (w, CHp-cym), 1632 (s, 
C=CL), 1618 (s, CH=CH), 1259 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 320 
nm (ε = 83 197 M-1 · cm-1). ESI-MS: 889 [M – L2 – CF3SO3]+, 708 [M – 2 L2 – CF3SO3]+.  
Calcd for C50H50F6N2O10Ru2S2: C, 49.26; H, 4.13; N, 2.30. Found: C, 49.21; H, 4.11; N, 2.19. 
[cis-10][CF3SO3]2 (20%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.41 (d, 2H, 3JH-H = 6.5 Hz, 
CHα), 8.39 (d, 2H, 3JH-H = 6.5 Hz, CHα), 7.86 (d, 2H, 3JH-H = 6.5 Hz, CHβ), 7.77 (d, 1H, 3JH-H 
= 16.4 Hz, CH=CH), 7.70 (m, 4H, CHar), 7.69 (d, 2H, 3JH-H = 6.5 Hz, CHβ), 7.65 (m, 2H, 
CHar),  7.64 (d, 1H, 3JH-H = 16.4 Hz, CH=CH), 7.44 (m, 2H, CHar), 7.40 (m, 2H, CHar), 7.35 
(d, 1H, 3JH-H = 16.4 Hz, CH=CH), 7.25 (d, 1H, 3JH-H = 16.4 Hz, CH=CH), 5.88 (d, 2H, 3JH-H = 
6.8 Hz, CHp-cym), 5.84 (d, 2H, 3JH-H = 6.8 Hz, CHp-cym), 5.65 (d, 2H, 3JH-H = 6.8 Hz, CHp-cym), 
5.61 (d, 2H, 3JH-H = 6.8 Hz, CHp-cym), 2.55 (sept, 2H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.15 (s, 3H, 
CH3), 1.96 (s, 3H, CH3),1.31 (d, 6H, 3JH-H = 6.9 Hz, CH(CH3)2), 1.01 (d, 6H, 3JH-H = 6.9 Hz, 
 Experimental Section 
126 
CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 172.32 (C=O), 153.78 (CL), 153.68 
(CL), 138.01 (CH=CH), 129.80 (CHar), 128.40 (CHar), 124.71 (CH=CH), 124.51 (CH=CH), 
124.42 (CL), 123.92 (CL),  98.91 (Car), 83.54 (CHp-cym), 82.83 (CHp-cym), 32.47 (CH(CH3)2), 
22.46 (CH(CH3)2), 18.06 (CH3).  
[trans-10][CF3SO3]2 (80%). 1H NMR (400 MHz, CD3OD): δ (ppm) 7.89 (d, 4H, 3JH-H = 6.7 
Hz, CHα), 7.45 (d, 2H, 3JH-H = 16.4 Hz, CH=CH), 7.40 (d, 4H, 3JH-H = 6.7 Hz, CHβ), 7.31 (m, 
4H, CHar),7.22 (m, 2H, CHar), 7.14 (d, 4H, 3JH-H = 6.8 Hz, CHar), 6.89 (d, 2H, 3JH-H = 16.4 Hz, 
CH=CH), 5.91 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.73 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 2.82 
(sept, 2H, 3JH-H = 6.9 Hz, CH(CH3)2), 2.19 (s, 6H, CH3), 1.36 (d, 12H, 3JH-H = 6.9 Hz, 
CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 172.32 (C=O), 153.29 (CL), 150.11 
(CL), 139.12 (CH=CH), 130.72 (CHar), 130.04 (CHar), 128.71 (CHar), 124.35 (CH=CH),  
123.97 (CL), 98.91 (Car), 83.54 (CHp-cym), 82.83 (CHp-cym), 32.47 (CH(CH3)2), 22.46 
(CH(CH3)2), 18.06 (CH3).  
[11][CF3SO3]2: Orange solid, Yield: 0.13 mmol (81%). IR (cm-1): 3069 (w, CHp-cym), 1627 (s, 
C=CL), 1537 (s, C=O), 1267 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 254 
nm (ε = 2 180 M-1 · cm-1), 307 nm (ε = 4 947 M-1 · cm-1), 501 (ε = 4 101 M-1 · cm-1). ESI-MS: 
801 [M – L3 – CF3SO3]+, 708 [M – 2 L3 – CF3SO3]+. Calcd for C36H42F6N2O10Ru2S2: C, 
41.46; H, 4.06; N, 2.69. Found: C, 41.24; H, 4.05; N, 2.61.  
[cis-11][CF3SO3]2 (70%). 1H NMR (400 MHz, CD3OD): δ (ppm) 7.84 (d, 4H, 3JH-H = 6.6 Hz, 
CHα), 7.15 (m, 4H, CHβ), 5.89 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.72 (d, 4H, 3JH-H = 6.4 Hz, 
CHp-cym), 2.80 (m, 2H, CH(CH3)2), 2.40 (s, 6H, CHβCCH3), 2.18 (s, 6H, CH3), 1.34 (d, 12H, 
3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 172.10 (C=O), 
153.63 (CL), 152.85 (CL), 103.45 (CL), 99.68 (CHp-cym), 83.53 (CHp-cym), 82.82 (CHp-cym), 
32.45 (CH(CH3)2), 22.47 (CH(CH3)2), 21.30 (CHβCCH3), 18.02 (CH3). 
[trans-11][CF3SO3]2 (30%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.32 (d, 4H, 3JH-H = 6.6 
Hz, CHα), 7.56 (m, 4H, CHβ), 5.86 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.62 (d, 4H, 3JH-H = 6.4 
Hz, CHp-cym), 2.80 (m, 2H, CH(CH3)2), 2.56 (s, 6H, CHβCCH3), 1.92 (s, 6H, CH3), 0.99 (d, 
12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 171.68 (C=O), 
154.52 (CL), 153.45 (CL), 104.96 (CL), 99.17 (CHp-cym), 83.85 (CHp-cym), 80.98 (CHp-cym), 
32.23 (CH(CH3)2), 22.12 (CH(CH3)2), 21.13 (CHβCCH3), 17.87 (CH3). 
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[12][CF3SO3]2: Orange solid, Yield: 0.12 mmol (75%). IR (cm-1): 3069 (w, CHp-cym), 1630 (s, 
C=CL), 1538 (s, C=O), 1274 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 227 
nm (ε = 4 589 M-1 · cm-1), 259 nm (ε = 3 429 M-1 · cm-1). ESI-MS: 843 [M – L4 – CF3SO3]+, 
708 [M – 2 L4 – CF3SO3]+. Calcd for C42H54F6N2O10Ru2S2: C, 44.76; H, 4.83; N, 2.49. Found: 
C, 44.86; H, 4.81; N, 2.46.  
[cis-12][CF3SO3]2 (38%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.40 (d, 2H, 3JH-H = 6.8 Hz, 
CHα), 8.08 (d, 2H, 3JH-H = 6.8 Hz, CHβ), 7.59 (d, 2H, 3JH-H = 6.8 Hz, CHα), 7.42 (d, 2H, 3JH-H 
= 6.8 Hz, CHβ), 5.95 (d, 2H, 3JH-H = 6.4 Hz, CHp-cym), 5.79 (d, 2H, 3JH-H = 6.4 Hz, CHp-cym), 
5.76 (d, 2H, 3JH-H = 6.4 Hz, CHp-cym), 5.57 (d, 2H, 3JH-H = 6.4 Hz, CHp-cym), 2.85 (m, 2H, 
CH(CH3)2), 2.21 (s, 3H, CH3), 2.13 (s, 3H, CH3), 1.37 (d, 6H, 3JH-H = 6.9 Hz, CH(CH3)2), 
1.34 (d, 6H, 3JH-H = 6.9 Hz, CH(CH3)2), 1.33 (s, 12H, C(CH3)3), 1.23 (s, 6H, C(CH3)3). 
13C{1H} NMR (100 MHz, CD3OD): δ (ppm) 171.68 (C=O), 153.69 (CL), 125.39 (CL), 98.90 
(CHp-cym), 83.74 (CHp-cym), 82.02 (CHp-cym), 36.43 (C(CH3)3), 32.48 (CH(CH3)2), 32.32 
(CH(CH3)2), 30.51 (C(CH3)3), 22.62 (C(CH3)3), 22.45 (CH(CH3)), 17.88 (CH3). 
[trans-12][CF3SO3]2 (62%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.39 (d, 4H, 3JH-H = 6.8 
Hz, CHα), 7.76 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 5.85 (d, 4H, 3JH-H = 6.4 Hz, CHp-cym), 5.52 (d, 
4H, 3JH-H = 6.4 Hz, CHp-cym), 2.57 (m, 2H, CH(CH3)2), 1.91 (s, 6H, CH3), 1.42 (s, 18H, 
C(CH3)3), 0.99 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD3OD): δ 
(ppm) 171.68 (C=O), 153.17 (CL), 124.42 (CL), 98.90 (CHp-cym), 83.60 (CHp-cym), 81.30 
(CHp-cym), 36.43 (C(CH3)3), 32.22 (CH(CH3)2), 30.57 (C(CH3)3), 22.19 (CH(CH3)), 17.84 
(CH3).  
[13][CF3SO3]2: A CD3OD solution (10 mL) of [10][CF3SO3]2 (50 mg, 0.04 mmol) was 
placed in a UV reactor (Luzchem Research, photoreactor,  = 365 nm) for 60 hours. Then the 
solvent was removed under vacuum to isolate [13][CF3SO3]2 as a red solid, yield: 0.04 mmol 
(98%). 1H NMR (400 MHz, CD3OD): δ (ppm) 8.05 (d, 2H, 3JH-H = 6.1 Hz, CHα), 7.90 (d, 2H, 
3JH-H = 6.0 Hz, CHα), 7.50 (d, 2H, 3JH-H = 6.1 Hz, CHβ), 7.18 (m, 10H, CHar), 7.11 (m, 2H, 
CHβ), 5.99 (d, 4H, 3JH-H = 6.1 Hz, CHp-cym), 5.81 (d, 4H, 3JH-H = 6.1 Hz, CHp-cym), 4.81 (d, 2H, 
3JH-H = 6.6 Hz, CHCH), 4.68 (d, 2H, 3JH-H = 6.6 Hz, CHCH), 2.87 (sept, 2H, 3JH-H = 6.9 Hz, 
CH(CH3)2), 2.24 (s, 6H, CH3), 1.40 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD3OD): δ (ppm) 172.32 (C=O), 154.02 (CL), 152.68 (CL), 129.26 (CHar), 129.19 
(CHar), 128.98 (CHar), 127.63 (CL), 125.55 (CL), 123.97 (CL), 83.14 (CHp-cym), 82.85 (CHp-
cym), 48.94 (CHCH), 45.14(CHCH), 32.55 (CH(CH3)2), 22.46 (CH(CH3)2), 18.06 (CH3). IR 
 Experimental Section 
128 
(cm-1): 3067 (w, CHp-cym), 1632 (s, C=CL), 1259 (s, CF3). UV-visible: (1.0 × 10-5 M, CH2Cl2, 
298 K): λmax 310 nm (ε = 17 266 M-1 · cm-1). ESI-MS: 1070 [M – CF3SO3]+, 708 [M – 
C26H22N2 – CF3SO3]+. Calcd for C50H50F6N2O10Ru2S2 · CH2Cl2: C, 46.97; H, 4.02; N, 2.15. 
Found: C, 47.51; H, 4.00; N, 2.79. 
 
7.2.4   Synthesis and Characterisation of the ON∩NO bis-chelating Organic Linkers and 
the Dinuclear, Tetranuclear, and Hexanuclear Arene Ruthenium Complexes 
 
Synthesis of N,N′-Bis{2-(2-hydroxyethoxy)ethyl}ethanediamide (H2Lc). To a cooled solution 
of 2-aminoethoxyethanol (−10 °C, 10 mL, 0.1 mol) and triethylamine (13.85 mL, 0.1 mol) in 
methylene chloride (120 mL) under an inert atmosphere was added dropwise over 1.5 h a 
solution of oxalyl chloride (4.25 mL, 0.05 mol) in methylene chloride (20 mL). The mixture 
was stirred overnight, and the precipitated triethylammonium chloride was filtered off. The 
volume of the mother liquor was reduced to ca. 30 mL, and then THF (60 mL) was added. 
The precipitated triethylammonium hydrochloride was filtered off. The solvent was removed 
under reduced pressure, and the residue was washed with THF and dried under vacuum. 
Yield: 7.2 g, 27 mmol (49%). 1H NMR (500 MHz, CDCl3): δ (ppm), 7,85 (br. s, 2H, NH), 
3.73–3.75 (m, 4H, OCH2), 3.60 (t, 3JH–H = 5.25 Hz, 4H, OCH2), 3.58–3.60 (m, 4H, OCH2), 
3.51–3.54 (m, 4H, OCH2), 3.11 (q, 3JH–H = 7.3 Hz, 0.6H, [(CH3CH2)3NH]Cl), 3.10 (q, 3JH–H = 
7.2 Hz, 0.6H, [(CH3CH2)3NH]Cl), 2.40 (br.s, 3H, CH2OH + H2O), 1.41 (t, 3JH–H = 7.3 Hz, 
1.7H, [(CH3CH2)3NH]Cl). ESI–MS: m/z = 265 [M + H]+, 287 [M + Na]+. Elemental Analysis 
(%): Calcd. for C10H20N2O6·0.2[(C2H5)3NH]Cl: C, 46.10; H, 8.01; N, 10.56 Found: C, 46.49; 
H, 7.78; N, 10.06. The compound was used without further purification for the synthesis of 
the dinuclear arene ruthenium complex 14c. 
 
Synthesis of the Metalla-Clip [(p-Cymene)2Ru2Cl2(μ-La)] (14a). To a solution of diethyl-1,2-
diazenedicarboxylate (0.35 g, 2.0 mmol) in methanol (10 mL) was added [(p-
cymene)2Ru2Cl2(μ-Cl)2] (1.1 g, 1.8 mmol) and a solution of triethylamine (0.6 mL, 4.3 mmol) 
in methanol (7 mL), and the mixture was left to stand overnight at room temperature. The 
crystalline product formed was filtered off, washed with methanol, and dried in air. Yield: 1.1 
g, 1.6 mmol (85.0%). 1H NMR (500 MHz, CDCl3): δ (ppm), 5.44 (d, 3JH–H = 5.5 Hz, 2H, 
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CHp-cym), 5.37 (d, 3JH–H = 5.5 Hz, 2H, CHp-cym), 5.32 (d, 3JH–H = 5.5 Hz, 2H, CHp-cym), 5.08 (d, 
3JH–H = 5.5 Hz, 2H, CHp-cym), 4.32 and 4.34 (two overlapped q, 3JH–H = 7.0 Hz, 2 H, 
OCH2CH3), 4.19 and 4.21 (two overlapped q, 3JH–H = 7.0 Hz, 2 H, OCH2CH3), 2.74 (sept, 
3JH–H = 6.5 Hz, 2H, CH(CH3)2), 2.17 (s, 6H, CH3), 1.32 (t, 3JH–H = 7.0 Hz, 6H, OCH2CH3), 
1.20 (t, 3JH–H = 6.5 Hz, 12H, CH(CH3)2). IR (cm–1): 1551, 1420, 1337, 1075. ESI–MS: m/z = 
680 [M – Cl]+, 702 [M – HCl + Na]+. Elemental Analysis (%): Calcd. for C26H38Cl2N2O4Ru2: 
C, 43.64; H, 5.35; N, 3.91. Found: C, 43.29; H, 5.29; N, 4.03. 
 
Synthesis of the Metalla-Clip [(p-Cymene)2Ru2Cl2(μ-Lb)] (14b). To a solution of [(p-
cymene)2Ru2Cl2(μ-Cl)2] (1.85 g, 3.0 mmol) in warm methanol (80 mL) were added a solution 
of N,N′-bis(2-hydroxyethyl)oxamide (0.53 g, 3.0 mmol) in warm methanol (25 mL) and 
triethylamine (0.85 mL, 6.1 mmol), and the mixture was refluxed overnight. The volume of 
solvent was reduced to ca. 30 mL, and the precipitate formed was filtered off, washed with 
methanol, and dried in air. Yield: 2.0 g, 2.8 mmol (93.0%). 1H NMR (500 MHz, CDCl3): δ 
(ppm), 5.41 (d, 3JH–H = 6.0 Hz, 2H, CHp-cym), 5.35 (d, 3JH–H = 6.0 Hz, 2H, CHp-cym), 5.33 (d, 
3JH–H = 6.0 Hz, 2H, CHp-cym), 4.99 (d, 3JH–H = 5.5 Hz, 2H, CHp-cym), 4.43–4.47 (m, 2H, 
OCH2), 3.68–3.81 (m, 6H, OCH2), 3.31–3.35 (m, 2H, CH2OH), 2.68 (sept, 3JH–H = 7.0 Hz, 
6H, CH(CH3)2), 2.21 (s, 6H, CH3), 1.21 (d, 3JH–H = 7.0 Hz, 6H, CH(CH3)2), 1.16 (d, 3JH–H = 
7.0 Hz, 6H, CH(CH3)2). IR (cm–1): 3397, 1594, 1055, 1025, 788. ESI–MS: m/z = 680 [M – 
Cl]+, 644 [M – Cl – HCl]+, 322.5 [M – 2Cl]2+. Elemental Analysis (%): Calcd. for 
C26H38Cl2N2O4Ru2: C, 43.64; H, 5.35; N, 3.91. Found: C, 43.60; H, 5.26; N, 3.99. 
 
Synthesis of the Metalla-Clip [(p-Cymene)2Ru2Cl2(μ-Lc)] (14c). To a solution of [(p-
cymene)2Ru2Cl2(μ-Cl)2] (0.2 g, 0.33 mmol) in methanol (12 mL) were added a solution of 
N,N′-bis[2-(2-hydroxyethoxy)ethyl]ethanediamide (0.09 g, 0.33 mmol) in methanol (2 mL) 
and triethylamine (0.12 mL, 0.7 mmol), and the mixture was refluxed for 20 h. The solvent 
was removed, and the residue was washed with THF and water and recrystallized from 
chloroform. Yield: 211 mg, 0.27 mmol (41%). 1H NMR (500 MHz, CDCl3): δ (ppm), 5.41 (d, 
3JH–H = 5.5 Hz, 2H, CHp-cym), 5.37 (d, 3JH–H = 5.5 Hz, 4H, CHp-cym), 5.17 (d, 3JH–H = 5.5 Hz, 
2H, CHp-cym), 4.09–4.15 (m, 2H, OCH2), 3.59–3.77 (m, 14H, OCH2), 3.09 (m, 2H, OH), 2.73 
(sept, 3JH–H = 7.0 Hz, 6H, CH(CH3)2), 2.16 (s, 6H, CH3), 1.22 (d, 3JH–H = 7.0 Hz, 6H, 
CH(CH3)2), 1.20 (d, 3JH–H = 7.0 Hz, 6H, CH(CH3)2). IR (cm–1): 3423, 1597, 1335, 1108, 
1052, 876. ESI–MS: m/z = 768 [M – Cl]+, 733 [M – Cl – HCl]+. Elemental Analysis (%): 
Calcd. for C30H46Cl2N2O6Ru2: C, 44.83; H, 5.77; N, 3.49. Found: C, 45.36; H, 5.71; N, 3.62. 
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General Synthetic Method for the Tetracationic Metalla-Rectangles of the General Formula 
[(p-cymene)4Ru4(μ-bpy)2(μ-L)2]4+ ([15a]4+-[15c]4+), [(p-cymene)4Ru4(μ-bpe)2(μ-L)2]4+ 
([16a]4+-[16c]4+) and [(p-cymene)4Ru4(μ-bpa)2(μ-L)2]4+ ([17a]4+-[17c]4+). 
A mixture of the dinuclear clip (14a-14c) of the general formula [(p-cymene)2Ru2Cl2(μ-L)] 
(0.16 mmol) and 2 equiv of AgCF3SO3 (0.32 mmol) in methanol (20 mL) was stirred at room 
temperature for 2 h and the solution was filtered to remove AgCl. To the filtrate, the 
corresponding 4,4'-bipyridine, 1,2-bis(4-pyridyl)ethylene and 4,4'-azopyridine (0.16 mmol) 
were added. The mixture was stirred at at room temperature for 24 h, and the solvent removed 
under vacuum. The residue was dissolved in dichloromethane (20 mL), the extract filtered 
and concentrated (3 mL) and diethyl ether was slowly added to initiate precipitation of the 
product as a black, brown, yellow, orange or red solid. 
 
 [15a][CF3SO3]4: Orange solid, Yield: 0.055 mmol (68%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.00 (d, 8H, 3JH-H = 5.6 Hz, CHα), 7.81 (d, 4H, 3JH-H = 3.3 Hz, CHβ), 7.67 (d, 4H, 3JH-H 
= 5.8 Hz, CHβ), 5.87 – 5.83 (m, 4H, CHp-cym), 5.83 – 5.79 (m, 4H, CHp-cym), 5.58 – 5.45 (m, 
4H, CHp-cym), 5.30 – 5.17 (m, 4H, CHp-cym), 4.66 (q, 4H,  3JH-H = 3.1 Hz, CH2CH3), 4.62 (q, 
4H, 3JH-H = 3.1 Hz, CH2CH3), 2.70 – 2.63 (m, 4H, CH(CH3)2), 1.66 (s, 6H, CH3), 1.63 (s, 6H, 
CH3), 1.57 (m, 12H, CH2CH3), 1.31 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.28 (d, 12H, 3JH-H = 
6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 165.44 (C=O), 165.36 
(C=O),  152.77 (Cbpy), 152.73 (Cbpy), 124.78 (Cbpy), 123.94 (Cbpy), 86.42 (CHp-cym), 86.22 
(CHp-cym), 85.07 (CHp-cym), 84.97 (CHp-cym), 82.38 (CHp-cym), 82.36 (CHp-cym), 79.71 (CHp-
cym), 79.62 (CHp-cym), 65.97 (CH2CH3), 31.51(CH(CH3)2), 22.61 (CH(CH3)2), 22.58 
(CH(CH3)2), 17.91 (CH3), 17.87 (CH3), 15.39 (CH2CH3), 15.37 (CH2CH3). IR: ʋ (cm-1): 
3073.9 (w, CHp-cym), 1610 (s, C=O), 1262 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 
K): λmax 242 nm (ε = 121 665 M-1 · cm-1), 383 nm (ε = 16 285 M-1 · cm-1). ESI-MS: 2050 [M 
– CF3SO3]+, 950 [M – 2CF3SO3]2+. Elemental Analysis (%): Calc. for C76H92F12N8O20Ru4S4 
·3 CH2Cl2: C, 38.68; H, 4.03; N, 4.57. Found: C, 38.72; H, 4.15; N, 4.76. 
[15b][CF3SO3]4: Yellow solid, Yield: 0.06 mmol (75%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.48 (d, 8H, 3JH-H = 6.5 Hz, CHα), 7.69 (d, 8H, 3JH-H = 6.8 Hz, CHβ), 5.79 (d, 4H, 3JH-H 
= 5.8 Hz, CHp-cym), 5.74 (d, 4H, 3JH-H = 5.8 Hz, CHp-cym), 5.47 (d, 4H, 3JH-H = 5.8 Hz, CHp-
cym), 5.29 (d, 4H, 3JH-H = 5.8 Hz, CHp-cym), 4.51 – 4.46 (m, 8H, CH2CH2), 4.51 – 4.46 (m, 8H, 
CH2CH2), 2.83 – 2.76 (m, 4H, CH(CH3)2), 1.76 (s, 12H, CH3), 1.32 (d, 12H, 3JH-H = 7.0 Hz, 
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CH(CH3)2), 1.23 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ 
(ppm), 177.57 (C=O), 158.31 (Cbpy), 154.84 (Cbpy), 124.03 (Cbpy), 104.11 (Cp-cym), 85.58 
(CHp-cym), 83.54 (CHp-cym), 83.01 (CHp-cym), 80.91 (CHp-cym), 61.98 (CH2CH2), 
31.03(CH(CH3)2), 22.63 (CH(CH3)2), 21.78 (CH(CH3)2), 17.52 (CH3). IR: ʋ (cm-1): 3071.5 
(w, CHp-cym), 1602 (s, C=O), 1258.2 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 
309 nm (ε = 64 003 M-1 · cm-1). ESI-MS: 950 [M – 2CF3SO3]2+, 2049 [M – CF3SO3]+. 
Elemental Analysis (%): Calc. for C76H92O20Ru4F12S4N8 ·2 CH2Cl2: C, 39.56; H, 4.09; N, 
4.73. Found: C, 39.76; H, 4.18; N, 4.86. 
[15c][CF3SO3]4: Brown solid, Yield: 0.051 mmol (63%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.44 (d, 4H, 3JH-H = 6.6 Hz, CHα), 8.35 (d, 4H, 3JH-H = 6.6 Hz, CHα), 7.81 (d, 4H, 3JH-H 
= 6.8 Hz, CHβ), 7.72 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 5.93 (d, 2H, 3JH-H = 5.9 Hz, CHp-cym), 5.81 
(d, 2H, 3JH-H = 5.9 Hz, CHp-cym), 5.78 (d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 5.50 – 5.46 (d, 2H, 3JH-
H = 5.9 Hz, CHp-cym), 5.34 (d, 2H, 3JH-H = 5.9 Hz, CHp-cym), 5.28 (d, 2H, 3JH-H = 5.9 Hz, CHp-
cym), 4.39 – 3.74 (m, 16H, CH2CH2), 2.80 – 2.73 (m, 4H, CH(CH3)2), 1.71 (s, 12H, CH3), 1.32 
(d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.23 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR 
(100 MHz, CD2Cl2): δ (ppm), 176.57 (C=O), 154.80 (Cbpy), 154.13 (Cbpy), 123.75 (Cbpy), 
85.76 (CHp-cym), 84.93 (CHp-cym), 84.73 (CHp-cym), 82.63 (CHp-cym), 80.59 (CHp-cym), 73.66 
(CH2CH2), 70.62 (CH2CH2), 61.79 (CH2CH2), 31.44 (CH(CH3)2), 22.46 (CH(CH3)2), 22.29 
(CH(CH3)2), 17.84 (CH3). IR: ʋ (cm-1): 3069.3 (w, CHp-cym), 1599.3 (s, C=O), 1258.7 (s, 
CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 306 nm (ε = 110 994 M-1 · cm-1). ESI-
MS: 1038 [M – CF3SO3]2+, 2225 [M – CF3SO3]+. Elemental Analysis (%): Calc. for 
C84H108O24Ru4F12S4N8 · 3 CH2Cl2: C, 39.74; H, 4.37; N, 4.26. Found: C, 39.76; H, 4.28; N, 
4.56. 
[16a][CF3SO3]4: Orange solid, Yield: 0.053 mmol (67%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 7.75 (d, 8H, J = 6.1 Hz, CHα), 7.52 – 7.50 (m, 8H, CHβ), 7.49 (d, 4H, 3JH-H = 7.2 Hz, 
CH=CH), 5.86 – 5.74 (m, 8H, CHp-cym), 5.49 – 5.45 (m,4H, CHp-cym), 5.20 – 5.17 (m,4H, 
CHp-cym), 4.78 – 4.49 (m, 8H, CH2CH3), 2.68 – 2.61 (m, 4H, CH(CH3)2), 1.66 (s, 4H, CH3), 
1.64 (s, 4H, CH3), 1.62 (s, 4H, CH3), 1.58 – 1.53 (m, 12H, CH2CH3), 1.30 (d, 12H, 3JH-H = 
6.9, CH(CH3)2), 1.26 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): 
δ (ppm), 165.35 (C=O), 165.28 (C=O),  151.56 (Cbpe), 132.79 (CH=CH), 132.39 (CH=CH), 
124.58 (Cbpe), 86.21 (CHp-cym), 86.05 (CHp-cym), 85.04 (CHp-cym), 84.92 (CHp-cym), 82.26 
(CHp-cym), 79.67 (CHp-cym), 79.56 (CHp-cym),  65.72 (CH2CH3), 31.49 (CH(CH3)2), 22.65 
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(CH(CH3)2), 22.54 (CH(CH3)2), 17.93 (CH3), 17.90 (CH3), 15.42 (CH2CH3), 15.35 
(CH2CH3). IR: ʋ (cm-1): 3071.9 (w, CHp-cym), 1611.6 (s, C=O), 1263.1 (s, CF3). UV-visible: 
(1.0 × 10-5 M, CH3CN, 298 K): λmax 234 nm (ε = 100 117 M-1 · cm-1), 312 nm (ε = 60 999 M-1 
· cm-1). ESI-MS: 2101 [M – CF3SO3]+, 976 [M – 2CF3SO3]2+. Elemental Analysis (%): Calc. 
for C80H96F12N8O20Ru4S4: C, 42.70; H, 4.30; N, 4.98. Found: C, 42.38; H, 4.56; N, 4.88. 
[16b][CF3SO3]4: Yellow solid, Yield: 0.056 mmol (70%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.06 (d, 4H, 3JH-H = 6.8 Hz, CHα), 7.96 (d, 4H, 3JH-H = 6.8 Hz, CHα), 7.60 (d, 4H, 3JH-H 
= 6.8 Hz, CHβ), 7.57 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.50 (d, 4H, 3JH-H = 22.2 Hz, CH=CH), 
5.72 – 5.62 (m, 12H, CHp-cym), 5.31 (d, 2H, 3JH-H = 5.8 Hz, CHp-cym), 5.28 (d, 2H, 3JH-H = 5.8 
Hz, CHp-cym), 4.34 – 4.29 (m, 8H, CH2CH2), 3.99 – 3.89 (m, 8H, CH2CH2), 2.82 – 2.77 (m, 
4H, CH(CH3)2), 1.97 (s, 6H, CH3), 1.91 (s, 6H, CH3), 1.32 (d, 12H, 3JH-H = 7.0 Hz, 
CH(CH3)2), 1.20 (d, 6H, 3JH-H = 6.9 Hz, CH(CH3)2), 1.17 (d, 6H, 3JH-H = 6.9 Hz, CH(CH3)2). 
13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 172.04 (C=O), 153.22 (Cbpe), 153.02 (Cbpe), 
146.49 (Cbpe), 149.39 (Cbpe), 132.73 (CH=CH), 132.67 (CH=CH), 104.11 (Cp-cym), 83.87 
(CHp-cym), 83.84 (CHp-cym), 83.69 (CHp-cym), 83.62 (CHp-cym), 60.86 (CH2CH2), 31.23 
(CH(CH3)2), 31.09 (CH(CH3)2), 22.65 (CH(CH3)2), 22.25 (CH(CH3)2), 17.83 (CH3), 17.53 
(CH3). IR: ʋ (cm-1): 3070.5 (w, CHp-cym), 1601.9 (s, C=O), 1258.1 (s, CF3). UV-visible: (1.0 × 
10-5 M, CH3CN, 298 K): λmax 307 nm (ε = 86 769 M-1 · cm-1). ESI-MS: 976 [M – 2CF3SO3]2+, 
2101 [M – CF3SO3]+. Elemental Analysis (%): Calc. for C80H96F12N8O20Ru4S4 · 2 CH2Cl2: C, 
40.70; H, 4.16; N, 4.63. Found: C, 40.10; H, 4.43; N, 4.67. 
[16c][CF3SO3]4: Yellow solid, Yield: 0.048 mmol (60%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.17 (d, 6H, 3JH-H = 6.1 Hz, CHα), 8.11 (d, 2H, 3JH-H = 6.1 Hz, CHα), 7.64 (d, 8H, 3JH-H 
= 6.1 Hz, CHβ), 7.49 (d, 4H, 3JH-H = 3.2 Hz, CH=CH), 5.90 (d, 1H, 3JH-H = 5.9 Hz, CHp-cym), 
5.81 (d, 3H, 3JH-H = 5.9 Hz, CHp-cym), 5.75 (d, 4H, 3JH-H = 6.2 Hz, CHp-cym), 5.46 (d, 1H, 3JH-H 
= 6.0 Hz, CHp-cym), 5.43 (d, 3H, 3JH-H = 6.0 Hz, CHp-cym), 5.30 (d, 1H, 3JH-H = 6.0 Hz, CHp-
cym), 5.24 (d, 3H, 3JH-H = 6.0 Hz, CHp-cym), 4.45 – 3.52 (m, 32H, CH2CH2), 2.76 – 2.72 (m, 
4H, CH(CH3)2), 1.68 (s, 12H, CH3), 1.29 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.21 (d, 6H, 
3JH-H = 6.9 Hz, CH(CH3)2), 1.17 (d, 6H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, 
CD2Cl2): δ (ppm), 172.04 (C=O), 153.63 (Cbpe), 153.12 (Cbpe), 146.49 (Cbpe), 132.87 
(CH=CH), 104.23 (Cp-cym), 85.90 (CHp-cym), 85.83 (CHp-cym), 85.10 (CHp-cym), 82.41 (CHp-
cym), 79.99 (CH2CH2), 74.05 (CH2CH2), 61.99 (CH2CH2), 31.40 (CH(CH3)2), 22.57 
(CH(CH3)2), 22.23 (CH(CH3)2), 17.81 (CH3). IR: ʋ (cm-1): 3069.1 (w, CHp-cym), 1599.3 (s, 
 Experimental Section 
133 
C=O), 1259.3 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 307 nm (ε = 73 065 
M-1 · cm-1). ESI-MS: 1064 [M – CF3SO3]2+, 2278 [M – CF3SO3]+. Elemental Analysis (%): 
Calc. for C80H96F12N8O20Ru4S4 · 2 CH2Cl2: C, 40.70; H, 4.16; N, 4.63. Found: C, 40.42; H, 
4.49; N, 4.26. 
[17a][CF3SO3]4: Black solid, Yield: 0.056 mmol (70%). 1H NMR (400 MHz, MeOD): δ 
(ppm), 8.25 (d, 8H, 3JH-H = 5.6 Hz, CHα), 7.81 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 7.63 (d, 4H, 3JH-H 
= 6.8 Hz, CHβ), 6.13 – 6.04 (m, 8H, CHp-cym), 5.72 – 5.70 (m, 4H, CHp-cym), 5.44 – 5.41 (m, 
4H, CHp-cym),  4.76 – 4.58 (m, 8H, CH2CH3), 2.76 – 2.72 (m, 4H, CH(CH3)2), 1.68 (s, 6H, 
CH3), 1.65 (s, 6H, CH3), 1.63 – 1.58 (m, 12H, CH2CH3), 1.35 (d, 12H, 3JH-H = 6.9, 
CH(CH3)2), 1.32 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, MeOD): δ 
(ppm), 166.54 (C=O), 166.51 (C=O), 158.52 (Cbpa), 158.19 (Cbpa), 155.48 (Cbpa), 155.42 
(Cbpa), 119.86 (Cbpa), 119.63 (Cbpa), 103.76 (Cp-cym), 103.72 (Cp-cym), 102.94 (Cp-cym), 87.90 
(CHp-cym), 87.81 (CHp-cym), 86.66 (CHp-cym), 86.61 (CHp-cym), 83.33 (CHp-cym), 83.22 (CHp-
cym), 80.53 (CHp-cym), 80.46 (CHp-cym), 66.33 (CH2CH3), 32.49 (CH(CH3)2), 22.86 
(CH(CH3)2), 17.78 (CH3), 17.73 (CH3), 15.60 (CH2CH3). IR: ʋ (cm-1): 3073.9 (w, CHp-cym), 
1602.6 (s, C=O), 1264.2 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 245 nm (ε 
= 144 942 M-1 · cm-1), 308 nm (ε = 52 738 M-1 · cm-1). ESI-MS: 794 [M – 3CF3SO3 – 2L]+. 
Elemental Analysis (%): Calc. for C76H92F12N12O20Ru4S4: C, 40.50; H, 4.11; N, 7.46.  Found: 
C, 40.05; H, 4.16; N, 7.45.   
[17b][CF3SO3]4: Brown solid, Yield: 0.056 mmol (70%). 1H NMR (400 MHz, MeOD): δ 
(ppm), 8.55 (d, 4H, 3JH-H = 6.8 Hz, CHα), 8.50 (d, 4H, 3JH-H = 6.8 Hz, CHα), 7.71 (d, 4H, 3JH-H 
= 6.8 Hz, CHβ), 7.66 (d, 4H, 3JH-H = 6.8 Hz, CHβ), 6.15 (d, 2H, 3JH-H = 5.9 Hz, CHp-cym), 6.12 
(d, 2H, 3JH-H = 5.9 Hz, CHp-cym), 5.99 (d, 4H, 3JH-H = 6.2 Hz, CHp-cym), 5.63 – 5.44 (m, 8H, 
CHp-cym), 4.26 – 4.09 (m, 8H, CH2CH2), 4.10 – 4.00 (m, 8H, CH2CH2), 2.85 – 2.82 (m, 4H, 
CH(CH3)2), 1.76 (s, 6H, CH3), 1.72 (s, 6H, CH3), 1.36 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2), 
1.26 (d, 12H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, MeOD): δ (ppm), 172.79 
(C=O), 156.91 (Cbpa), 156.78 (Cbpa), 146.49 (Cbpa), 149.39 (Cbpa), 119.55 (Cbpa), 119.30 
(Cbpa),  104.11 (Cp-cym), 87.40 (CHp-cym), 87.61 (CHp-cym), 85.56 (CHp-cym), 85.39 (CHp-cym), 
84.48 (CHp-cym), 84.30 (CHp-cym), 81.62 (CHp-cym), 81.57 (CHp-cym), 61.93 (CH2CH2), 61.77 
(CH2CH2), 56.13 (CH2CH2), 56.13 (CH2CH2), 32.40 (CH(CH3)2), 23.13 (CH(CH3)2), 23.05 
(CH(CH3)2), 22.24 (CH(CH3)2), 17.76 (CH3), 17.71 (CH3). IR: ʋ (cm-1): 3072.1 (w, CHp-cym), 
1601.3 (s, C=O), 1258.4 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 285 nm (ε 
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= 86 769 M-1 · cm-1). ESI-MS: 978 [M – 2CF3SO3]2+, 2105 [M – CF3SO3]+. Elemental 
Analysis (%): Calc. for C76H92F12N12O20Ru4S4 · CH2Cl2: C, 39.54; H, 4.05; N, 7.19.  Found: 
C, 39.71; H, 4.33; N, 6.64.   
[17c][CF3SO3]4: Red solid, Yield: 0.048 mmol (60%). 1H NMR (400 MHz, MeOD): δ (ppm), 
8.49 (d, 8H, 3JH-H = 6.1 Hz, CHα), 7.73 (d, 8H, 3JH-H = 6.8 Hz, CHβ), 6.27 (d, 4H, 3JH-H = 5.9 
Hz, CHp-cym), 6.00 (d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 5.62 (d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 5.52 
(d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 4.30 – 3.80 (m, 32H, CH2CH2), 2.87 – 2.80 (m, 4H, 
CH(CH3)2), 1.72 (s, 12H, CH3), 1.37 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.27 (d, 12H, 3JH-H 
= 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, MeOD): δ (ppm), 176.57 (C=O), 154.80 
(Cbpa), 154.13 (Cbpa), 123.75 (Cbpa), 85.76 (CHp-cym), 84.93 (CHp-cym), 84.73 (CHp-cym), 82.63 
(CHp-cym), 80.59 (CHp-cym), 73.66 (CH2CH2), 70.62 (CH2CH2), 61.79 (CH2CH2), 31.44 
(CH(CH3)2), 22.46 (CH(CH3)2), 22.29 (CH(CH3)2), 17.84 (CH3). IR: ʋ (cm-1): 3072 (w, CHp-
cym), 1601.5 (s, C=O), 1258.4 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 284 
nm (ε = 73 905 M-1 · cm-1). ESI-MS: 1066 [M – CF3SO3]2+. Elemental Analysis (%):Calc. for 
C84H108F12N12O24Ru4S4 · CH2Cl2: C, 40.59; H, 4.41; N, 6.68.  Found: C, 40.58; H, 4.48; N, 
6.70. 
 
General Synthetic Method for the Hexacationic Metalla-Prisms of the General Formulas [(p-
cymene)6Ru6(μ-tpt)2(μ-L)3]6+ ([18a]6+-[18c]6+) and [(p-cymene)6Ru6(μ-tpv)2(μ-L)3]6+ 
([19a]6+-[19c]6+).  
A mixture of the dinuclear clip (1a-1c) of the general formula [(p-cymene)2Ru2Cl2(μ-L)] (0.16 
mmol) and 2 equiv of AgCF3SO3 (0.32 mmol) in methanol (20 mL) was stirred at room 
temperature for 2 h and the solution was filtered to remove AgCl. To the filtrate, the 
corresponding 2,4,6-tris(4-pyridyl)-1,3,5-triazine and 1,3,5-tris{2-(4-pyridyl)vinyl}benzene 
(0.11 mmol) were added. The mixture was stirred at 60°C for 24 h, and the solvent removed 
under vacuum. The residue was dissolved in dichloromethane (20 mL), the extract filtered 
and concentrated (3 mL) and diethyl ether was slowly added to initiate precipitation of the 
product as a brown or red solid. 
[18a][CF3SO3]6: Brown solid, Yield: 0.037 mmol (70%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 9.03 (d, 3H, 3JH-H = 4.5 Hz, CHtpt), 8.96 (d, 3H, 3JH-H = 4.7 Hz, CHtpt), 8.84 – 8.77 (m, 
6H, CHtpt), 8.59 – 8.49 (m, 12H, CHtpt), 8.47 – 8.43 (m, 6H, CHtpt), 8.40 – 8.34 (m, 6H, 
CHtpt), 8.04 – 8.00 (m, 6H, CHtpt), 7.78 (d, 6H, 3JH-H = 5.8 Hz, CHtpt), 5.97 –5.93 (m, 6H, 
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CHp-cym), 5.91 (d, 3H, 3JH-H = 5.9 Hz, CHp-cym), 5.88 (d, 3H, 3JH-H = 5.9 Hz, CHp-cym), 5.86 (d, 
6H, 3JH-H = 6.3 Hz, CHp-cym), 5.82 (d, 3H, 3JH-H = 6.2 Hz, CHp-cym), 5.79 (d, 3H, 3JH-H = 6.2 
Hz, CHp-cym), 5.66 (d, 3H, 3JH-H = 6.1 Hz, CHp-cym), 5.56 (d, 3H,3JH-H = 6.2 Hz, CHp-cym), 5.53 
(d, 3H, 3JH-H = 6.2 Hz, CHp-cym), 5.43 (d, 3H, 3JH-H = 6.1 Hz, CHp-cym), 5.34 (d, 3H, 3JH-H = 6.1 
Hz, CHp-cym), 5.25 (d, 3H, 3JH-H = 6.0 Hz, CHp-cym), 5.22 (d, 3H, 3JH-H = 6.0 Hz, , CHp-cym), 
5.13 (d, 3H, 3JH-H = 5.9 Hz, CHp-cym), 4.76 – 4.58 (m, 24H, CH2CH3), 2.79 – 2.60 (m, 12H, 
CH(CH3)2), 1.81 (s, 12H, CH3), 1.66 (s, 12H, CH3), 1.62 (s, 12H, CH3), 1.63 – 1.58 (m, 18H, 
CH2CH3), 1.45 (s, 12H, CH3), 1.33 – 123 (m, 72H, CH(CH3)2). 13C{1H} NMR (100 MHz, 
CD2Cl2): δ (ppm), 170.18 (C=O), 169.95 (C=O), 169.90 (C=O), 169.57 (C=O), 153.70 
(CHtpt), 153.36 (Ctpt), 153.13 (Ctpt), 152.65 (Ctpt), 152.40 (Ctpt), 152.20 (Ctpt), 152.03 (Ctpt), 
143.70 (Ctpt), 143.42 (Ctpt), 143.37 (Ctpt), 143.01 (Ctpt), 125.70 (Ctpt), 125.67 (Ctpt), 125.49 
(Ctpt),125.34 (Ctpt), 125.16  (Ctpt), 125.01 (Ctpt), 125.23 (Ctpt),122.65 (Ctpt), 102.94 (Cp-cym), 
102.60 (Cp-cym), 102.52 (Cp-cym), 102.17 (Cp-cym), 101.89 (Cp-cym), 101.57 (Cp-cym), 101.24 (Cp-
cym), 101.02 (Cp-cym), 86.35 (CHp-cym), 86.25 (CHp-cym), 86.13 (CHp-cym), 85.94 (CHp-cym), 
85.09 (CHp-cym), 84.92 (CHp-cym), 84.85 (CHp-cym), 84.63 (CHp-cym), 81.92 (CHp-cym), 81.86 
(CHp-cym), 81.64 (CHp-cym), 81.57 (CHp-cym), 79.56 (CHp-cym), 79.32 (CHp-cym), 79.16 (CHp-
cym), 78.90 (CHp-cym), 65.71 (CH2CH3), 65.68 (CH2CH3), 31.16 (CH(CH3)2), 31.10 
(CH(CH3)2), 31.04 (CH(CH3)2), 22.24 (CH(CH3)2), 22.22 (CH(CH3)2), 22.19 (CH(CH3)2), 
22.13 (CH(CH3)2), 22.10 (CH(CH3)2), 22.17 (CH(CH3)2), 17.70 (CH3), 17.50 (CH3), 17.39 
(CH3), 17.18 (CH3), 14.90 (CH2CH3), 14.86 (CH2CH3), 14.77 (CH2CH3). IR: ʋ (cm-1): 
3071.9 (w, CHp-cym), 1611.6 (s, C=O), 1263.1 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 
298 K): λmax 242 nm (ε = 179 448 M-1 · cm-1), 347 nm (ε = 40 018 M-1 · cm-1). ESI-MS: 1578 
[M – 3CF3SO3]3+, 1002 [M – 2CF3SO3]2+. Elemental Analysis (%): Calc. for 
C120H138F18N18O30Ru6S6 · 5 CH2Cl2: C, 38.71; H, 3.85; N, 6.50. Found: C, 38.71; H, 4.30; N, 
6.80. 
The number of protons of the compound [18a][CF3SO3]6 is multiplied by two, because of the 
existence of four isomers in solution. 
[18b][CF3SO3]6: Brown solid, Yield: 0.030 mmol (56%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.68 (br, 24H, CHtpt), 5.84 – 5.71 (m, 14H, CHp-cym), 5.66 – 5.60 (m, 5H, CHp-cym), 
5.39 – 5.31 (m, 5H, CHp-cym), 4.39 – 4.32 (m, 12H, CH2CH2), 4.06 – 4.00 (m, 12H, CH2CH2), 
2.88 – 2.80 (m, 6H, CH(CH3)2), 1.91 – 1.83 (m, 18H, CH3), 1.36 – 1.34 (m, 18H, CH(CH3)2), 
1.27 – 1.19 (m, 18H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 172.63 
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(C=O), 172.52 (C=O), 172.26 (C=O), 172.07 (C=O), 154.89 (Ctpt), 84.24 (CHp-cym), 83.69 
(CHp-cym), 83.58 (CHp-cym), 83.55 (CHp-cym), 83.51 (CHp-cym), 83.47 (CHp-cym), 83.21 (CHp-
cym), 82.78 (CHp-cym), 61.84 (CH2CH2), 31.36 (CH(CH3)2), 31.23 (CH(CH3)2), 22.40 
(CH(CH3)2), 22.22 (CH(CH3)2), 17.73 (CH3), 17.68 (CH3). IR: ʋ (cm-1): 3067.7 (w, CHp-cym), 
1606.9 (s, C=O), 1258.4 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 250 nm (ε 
= 155 922 M-1 · cm-1), 310 nm (ε = 56 104 M-1 · cm-1). ESI-MS: 1002 [M – 2CF3SO3]3+, 1578 
[M – CF3SO3]2+. Elemental Analysis (%): Calc. for C120H138F18N18O30Ru6S6 · 7 CH2Cl2: C, 
37.68; H, 3.78; N, 6.23. Found: C, 37.32; H, 3.96; N, 6.59. 
[18c][CF3SO3]6: Yellow solid, Yield: 0.031 mmol (58%). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm), 8.71 (br, 24H, CHtpt), 6.05 – 5.98 (m, 6H, CHp-cym), 5.87 – 5.82 (m, 6H, CHp-cym), 5.60 
– 5.55 (m, 6H, CHp-cym), 5.41 – 5.35 (m, 6H, CHp-cym), 4.21 – 3.89 (m, 48H, CH2CH2), 2.82 – 
2.77 (m, 6H, CH(CH3)2), 1.71 (s, 6H, CH3), 1.67 (s, 4H, CH3), 1.65 (s, 8H, CH3), 1.34 – 1.32 
(m, 18H, CH(CH3)2), 1.27 – 1.24 (m, 18H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ 
(ppm), 176.48 (C=O), 155.83 (Ctpt), 132.02 (Ctpt), 125.66(Ctpt),  86.45 (CHp-cym), 85.35 (CHp-
cym), 82.60 (CHp-cym), 82.34 (CHp-cym), 80.26 (CHp-cym), 80.57 (CHp-cym), 73.92 (CH2CH2), 
70.84 (CH2CH2), 63.94 (CH2CH2), 62.30 (CH2CH2), 55.40 (CH2CH2), 53.75 (CH2CH2), 
31.65 (CH(CH3)2), 22.42 (CH(CH3)2), 17.76 (CH3). IR: ʋ (cm-1): 3071 (w, CHp-cym), 1600.9 
(s, C=O), 1259.3 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 247 nm (ε = 144 
942 M-1 · cm-1), 308 nm (ε = 52 738 M-1 · cm-1). ESI-MS: 1090 [M – 3CF3SO3]3+, 1710 [M – 
2CF3SO3]3+. Calc. for C132H162F18N18O36Ru6S6· 4 CH2Cl2: C, 40.26; H, 4.22; N, 6.21. Found: 
C, 40.19; H, 4.60; N, 6.38. 
[19a][CF3SO3]6: Yellow solid, Yield: 0.039 mmol (73%). 1H NMR (400 MHz, MeOD): δ 
(ppm), ), 7.95 (br, 2H, CHar), 7.88 – 7.80 (m, 12H, CHα), 7.65 (br, 2H, CHar), 7.63 (br, 1H, 
CHar), 7.47 – 7.41 (m, 12H, CHβ), 7.36 (br, 1H, CHar), 7.47 – 7.23 (m, 12H, CH=CH), 6.11 – 
5.88 (m, 12H, CHp-cym), 5.76 – 5.51 (m, 6H, CHp-cym), 5.43 – 5.28 (m, 6H, CHp-cym), 4.68 – 
4.60 (m, 12H, CH2CH3), 2.74 – 2.67 (m, 6H, CH(CH3)2), 1.75 (s, 5H, CH3), 1.68 (s, 8H, 
CH3), 1.63 (s, 5H, CH3), 1.61 – 1.56 (m, 12H, CH2CH3), 1.35 (m, 36H, CH(CH3)2). 13C{1H} 
NMR (100 MHz, MeOD): δ (ppm), 166.54 (C=O), 166.51 (C=O),  158.52 (Ctpv), 158.19 
(Ctpv), 155.48 (Ctpv), 155.42 (Ctpv), 137.78 (CH=CH), 137.59 (CH=CH), 137.45 (CH=CH), 
137.24 (CH=CH), 130.76 (Car), 128.54 (Car), 126.16 (Car), 126.07 (Car), 125.79 (CH=CH), 
125.72 (CH=CH), 125.59 (CH=CH), 125.48 (CH=CH), 123.63(Ctpv), 119.86 (Ctpv), 119.63 
(Ctpv), 103.76 (Cp-cym), 103.72 (Cp-cym), 102.94 (Cp-cym), (Cp-cym), 87.90 (CHp-cym), 87.81 (CHp-
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cym), 86.66 (CHp-cym), 86.61 (CHp-cym), 83.33 (CHp-cym), 83.22 (CHp-cym), 80.53 (CHp-cym), 
80.46 (CHp-cym), 66.33 (CH2CH3), 32.49 (CH(CH3)2), 22.86 (CH(CH3)2), 17.78 (CH3), 17.73 
(CH3), 15.60 (CH2CH3). IR: ʋ (cm-1): 3070 (w, CHp-cym), 1609 (s, C=O), 1263.1 (s, CF3). UV-
visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 237 nm (ε = 125 684 M-1 · cm-1), 337 nm (ε = 
332 425 M-1 · cm-1). ESI-MS: 1052 [M – 3CF3SO3]3+, 1653 [M – 2CF3SO3]2+. Elemental 
Analysis (%):Calc. for C138H156F18N12O30Ru6S6: C, 46.00; H, 4.36; N, 4.66.  Found: C, 45.50; 
H, 4.41; N, 4.54.  
[19b][CF3SO3]6: Brown solid, Yield: 0.038 mmol (71%). 1H NMR (400 MHz, MeOD): δ 
(ppm), 8.10 – 8.05 (m, 12H, CHα), 7.74 – 7.66 (m, 6H, CHar), 7.52 – 7.48 (m, 6H, CH=CH), 
6.12 – 6.10 (m, 6H, CH=CH), 6.12 – 6.10 (m, 6H, CHp-cym), 5.95 – 5.93 (m, 6H, CHp-cym), 
5.51 – 5.47 (m, 12H, CHp-cym), 4.20 – 4.18 (m, 12H, CH2CH2), 4.09 – 4.05 (m, 6H, CH2CH2), 
3.90 – 3.83 (m, 6H, CH2CH2), 2.86 – 2.79 (m, 6H, CH(CH3)2), 1.75 – 1.72 (m, 18H, CH3), 
1.36  (m, 18H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.26 (m, 18H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} 
NMR (100 MHz, MeOD): δ (ppm), 172.65 (C=O), 153.79 (Ctpv), 149.49 (Ctpv), 138.08 
(CH=CH), 137.64 (CH=CH), 128.86 (CHar), 128.43 (CHar), 123.90 (Ctpv), 104.87 (Cp-cym), 
87.27 (CHp-cym), 85.54 (CHp-cym), 84.06 (CHp-cym), 80.98 (CHp-cym), 61.77 (CH2CH2), 56.02 
(CH2CH2), 32.39 (CH(CH3)2), 23.17 (CH(CH3)2), 22.30 (CH(CH3)2), 17.78 (CH3). IR: ʋ (cm-
1): 3067.8 (w, CHp-cym), 1601.3 (s, C=O), 1256.2 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 
298 K): λmax 334 nm (ε = 243 433 M-1 · cm-1). ESI-MS: 1002 [M – 2CF3SO3]3+, 1578 [M – 
CF3SO3]2+. Elemental Analysis (%): Calc. for C138H156F18N12O30Ru6S6 · 2 CH2Cl2: C, 44.56; 
H, 4.27; N, 4.45.  Found: C, 44.08; H, 4.33; N, 4.44. 
[19c][CF3SO3]6: Brown solid, Yield: 0.036 mmol (68%). 1H NMR (400 MHz, MeOD): δ 
(ppm), 8.09 – 8.05 (m, 12H, CHtpv), 7.75 – 7.67 (m, 6H, CHar), 7.55 – 7.53 (m, 12H, CHtpv), 
7.54 – 7.47 (m, 6H, CH=CH), 7.34 – 7.28 (m, 6H, CH=CH), (m, 6H, CHp-cym), 5.87 – 5.82 
(m, 6H, CHp-cym), 5.60 – 5.55 (m, 6H, CHp-cym), 5.41 – 5.35 (m, 6H, CHp-cym), 4.23 – 3.80 (m, 
48H, CH2CH2), 2.88 – 2.81 (m, 6H, CH(CH3)2), 1.74 (s, 6H, CH3), 1.72 (s, 6H, CH3), 1.71 (s, 
6H, CH3), 1.36 (d, 18H, 3JH-H = 6.9 Hz, CH(CH3)2), 1.27 (m, 18H, CH(CH3)2). 13C{1H} NMR 
(100 MHz, MeOD): δ (ppm), 172.71 (C=O), 153.93 (Ctpv), 137.65 (CH=CH), 137.76 
(CH=CH), 138.07 (CH=CH), 141.69 (CH=CH), 127.67 (Car), 128.71(Car), 129.65(Car), 
123.63(Ctpv), 104.67 (Cp-cym), 87.14 (CHp-cym), 85.83 (CHp-cym), 81.01 (CHp-cym), 74.28 
(CH2CH2), 71.46 (CH2CH2), 62.35 (CH2CH2), 54.08 (CH2CH2), 32.39 (CH(CH3)2), 23.23 
(CH(CH3)2), 22.27 (CH(CH3)2), 17.76 (CH3). IR: ʋ (cm-1): 3067 (w, CHp-cym), 1600.2 (s, 
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C=O), 1259.0 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 337 nm (ε = 294 472 
M-1 · cm-1). ESI-MS: 1140 [M – 3CF3SO3]3+, 1785 [M –2CF3SO3]3+. Elemental Analysis (%): 
Calc. for C150H180F12N12O36Ru6S6 · 4 CH2Cl2: C, 43.96; H, 4.50; N, 3.99.  Found: C, 43.57; H, 
4.50; N, 3.87. 
 
7.2.4  Synthesis and Characterisation of the OO∩OO Benzo-quinone Derivatives 
Organic Linkers and the Hexanuclear Arene Ruthenium Host and Host-Guest 
Complexes 
 
Synthesis of 2,5-dihydroxy-3,6-dimesityl-2,4-dimethyl-1,4-benzoquinone (C2H6Lf). Orange 
solid, Yield: 162 mg, 0.43 mmol (43%). A mixture of 2,5-Dibromo-3,6-dimethoxy-1,4-
benzoquinone (326 mg, 1.0 mmol, 1.0 equiv.), dichlorobis(triphenylphosphane) palladium(II) 
(70 mg, 0.1 mmol, 0.1 equiv.), potassium carbonate (690 mg, 5.0 mmol, 5.0 equiv.), and 
phenylboronic acid (533 mg, 4.0 mmol, 4.0 equiv.) in dioxane (10 mL) was stirred at 110 °C 
for 24 h. The resulting dark solution was diluted with CH2Cl2 and dried with anhydrous 
MgSO4. The mixture was filtered through a pad of Celite and concentrated under vacuum. 
The residue was dissolved in dichloromethane (5 mL), the extract filtered and concentrated 
and diethyl ether (50 mL) was slowly added to initiate precipitation of the product. 1H NMR 
(400 MHz, CDCl3): δ (ppm), 7.02 (s, 2H, CHar), 6.92 (s, 4H, CHar), 3.81 (s, 6H, OCH3), 2.04 
(s, 12H, CCH3). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm), 183.69 (C=O), 154.57 (C−O), 
137.39 (CCH3), 130.35 (Car), 128.13 (CHar), 61.49 (OCH3), 21.32 (CCH3). ESI-MS: 399.6 
[M + Na]+. Elemental Analysis (%): Calc. for C24H24O4: C, 76.57; H, 6.43. Found: C, 76.38; 
H, 6.30. 
 
Synthesis of 2,5-dihydroxy-3,6-dimesityl-1,4-benzoquinone (H2Lf). Black solid, Yield: 57 mg, 
0.16 mmol (68%). To a solution of compound (C2H6Lc) (90 mg, 0.24 mmol) in anhydrous 
CH2Cl2 (8.0 mL) was added slowly a solution of BBr3 in CH2Cl2 (1.0 M, 1.0 mL) at –78 °C. 
The reaction mixture was stirred under argon for 12 h until room temperature was attained. 
The reaction was quenched with methanol, and the resulting solution was concentrated under 
vacuum. The compound was obtained from dioxane. 1H NMR (400 MHz, CDCl3): δ (ppm), 
8.15 (br, 2H, OHar), 7.26 – 7.05 (m, 6H, CHar), 2.38 (s, 12H, CCH3). 347.6 [M – H]-. 
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Elemental Analysis (%): Calc. for C22H20O4 · 0.5 Br3: C, 56.43; H, 4.31. Found: C, 56.58; H, 
4.76. 
 
General Synthetic Method for the Arene-Ruthenium Metalla-Clips of the General Formula 
[(p-cymene)2Ru2(μ-Ln)] (20d-20f).  
A mixture of (p-cymene)2Ru2(μ-Cl)2Cl2 (200 mg, 0.33 mmol), 2,5-Dihydroxy-3-phenyl-1,4-
benzoquinone (71 mg, 0.33 mmol), 2,5-Dihydroxy-3,6-diphenyl-1,4-benzoquinone (96 mg, 
0.33 mmol), 2,5-Dihydroxy-3,6-diphenyl-3,5-dimethyl-1,4-benzoquinone (114 mg, 0.33 
mmol) in MeOH (30 mL) was stirred for 15 h at room temperature. The precipitate was 
filtered, washed with diethyl ether, pentane, and dried in vacuo. 
 
[20d]: Black solid, Yield: 185 mg, 0.24 mmol (73%). 1H NMR (400 MHz, CD2Cl2): δ (ppm), 
7.53 – 7.47 (m, 2H, CHar), 7.40 – 7.36 (m, 2H, CHar), 7.30 – 7.26 (m, 1H, CHar), 5.79 (s, 1H, 
CHdobq), 5.66 (d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 5.39 (d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 2.93 – 
2.86 (m, 2H, CH(CH3)2), 2.27 (s, 6H, CH3), 1.37 (d, 6H, 3JH-H = 7.0 Hz, CH(CH3)2), 1.35 (d, 
6H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 184.12 (C=O), 
130.77 (CHar), 127.87 (CHar), 126.89 (CHar), 101.08 (CHdobq) 82.34 (CHp-cym), 79.54 (CHp-
cym), 31.73 (CH(CH3)2), 22.69 (CH(CH3)2), 22.48 (CH(CH3)2), 18.78 (CH3). IR: ʋ (cm-1): 
3042 (w, CHp-cym), 1520 (s, C=O).UV-visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 507 nm (ε 
= 23 910 M-1 · cm-1). ESI-MS: 779.5 [M + Na]+, 723.3 [M – Cl]+. Elemental Analysis (%): 
Calc. for C32H34O4Cl2Ru2 · H2O: C, 49.68; H, 4.69. Found: C, 49.82; H, 4.74. 
[20e]: Black solid, Yield: 192 mg, 0.23 mmol (70%). 1H NMR (400 MHz, CD2Cl2): δ (ppm), 
7.60 – 7.57 (m, 4H, CHar), 7.42 – 7.38 (m, 4H, CHar), 7.31 – 7.29 (m, 2H, CHar), 5.68 (d, 4H, 
3JH-H = 5.9 Hz, CHp-cym), 5.37 (d, 4H, 3JH-H = 5.9 Hz, CHp-cym), 2.70 – 2.63 (m, 2H, 
CH(CH3)2), 2.30 (s, 2H, CH3), 2.26 (s, 4H, CH3), 1.36 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 
13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 180.31 (C=O), 131.02 (CHar), 128.06 (CHar), 
127.19 (CHar), 101.08 (CHdobq), 83.29 (CHp-cym), 79.58 (CHp-cym), 31.52 (CH(CH3)2), 22.86 
(CH(CH3)2), 18.56 (CH3). IR: ʋ (cm-1): 3050 (w, CHp-cym), 1637 (s, C=O). UV-visible: (1.0 × 
10-5 M, CH2Cl2, 298 K): λmax 295 nm (ε = 32 480 M-1 · cm-1), 515 nm (ε = 22 610 M-1 · cm-1). 
ESI-MS: 854.2 [M + Na]+, 796.2 [M – Cl]+. Elemental Analysis (%): Calc. for 
C38H38O4Cl2Ru2: C, 54.87; H, 4.60. Found: C, 54.36; H, 4.78. 
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[20f]: Black solid, Yield: 175 mg, 0.20 mmol (60%). 1H NMR (400 MHz, CDCl3): δ (ppm), 
7.38 – 7.37 (m, 2H, CHar), 7.29 – 7.28 (m, 2H, CHar), 6.90 (br, 2H, CHar), 5.68 – 5.65 (m, 4H, 
CHp-cym), 5.36 – 5.32 (m, 4H, CHp-cym), 2.96 – 2.91 (m, 2H, CH(CH3)2), 2.44 (s, 4H, CH3), 
2.35 (s, 8H, CH3), 2.29 (s, 6H, CH3), 1.43 (d, 12H, 3JH-H = 7.0 Hz, CH(CH3)2). 13C{1H} NMR 
(100 MHz, CDCl3): δ (ppm), 181.13 (C=O), 136.26 (CHar), 130.34 (CHar), 128.37 (CHar), 
99.94 (Cdobq), 96.29 (Cdobq), 83.20 (CHp-cym), 79.22 (CHp-cym), 31.39 (CH(CH3)2), 23.88 
(CH3), 22.69 (CH(CH3)2), 21.49 (CH3), 18.43 (CH3). IR: ʋ (cm-1): 3063 (w, CHp-cym), 1600 
(s, C=O). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 300 nm (ε = 20 262 M-1 · cm-1), 
520 nm (ε = 13 000 M-1 · cm-1). ESI-MS: 852.5 [M – Cl]+, 909.4 [M + Na]+. Elemental 
Analysis (%): Calc. for C42H46O4Cl2Ru2 · CH2Cl2: C, 53.09; H, 4.97. Found: C, 53.00; H, 
4.77. 
 
General Synthetic Method for the Hexacationic Metalla-Prisms of the General Formula [(p-
cymene)6Ru6(μ-tpt)2(μ-Ln)3]6+ ([21d]6+-[21f]6+).  
A mixture of the dinuclear clip (20d-20f) of the general formula [(p-cymene)2Ru2Cl2(μ-Ln)] 
(0.16 mmol) and 2 equiv of AgCF3SO3 (0.32 mmol) in MeOH/ CH2Cl2, (1/1, 30 mL) was 
stirred at room temperature for 2 h and the solution was filtered to remove AgCl. To the 
filtrate 2,4,6-tris(4-pyridyl)-1,3,5-triazine (0.11 mmol) were added. The mixture was stirred at 
60°C for 24 h, and the solvent removed under vacuum. The residue was dissolved in 
dichloromethane (20 mL), the extract filtered and concentrated (3 mL) and diethyl ether was 
slowly added to initiate precipitation of the product as a red solid. 
 
[21d][CF3SO3]6: Red solid, Yield: 111 mg, 0.031 mmol (58%). 1H NMR (400 MHz, 
CD2Cl2): δ (ppm), 8.76 – 8.72 (m, 12H, CHtpt), 8.52 – 8.48 (m, 12H, CHtpt), 7.64 – 7.59 (m, 
6H, CHar), 7.51 – 7.48 (m, 3H, CHar), 7.36 – 7.33 (m, 6H, CHar),  5.97 – 5.95 (m, 3H, 
CHdobq),  5.88 – 5.83 (m, 12H, CHp-cym), 5.73 (d, 6H, 3JH-H = 6.1 Hz, CHp-cym), 5.69 (d, 6H, 
3JH-H = 6.1 Hz, CHp-cym),  2.90 – 2.83 (m, 6H, CH(CH3)2), 2.23 – 2.22 (m, 18H, CH3), 1.38 – 
1.36 (m, 36H, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 184.24 (C=O), 
181.48 (C=O), 170.06 (CHtpt), 154.43 (Ctpt), 144.94 (Ctpt), 130.40 (CHar), 128.69 (CHar), 
128.26 (CHar), 125.61 (CHtpt), 104.81 (Cp-cym), 102.44 (CHdobq), 99.15 (Cp-cym), 83.17 (CHp-
cym), 82.93 (CHp-cym), 82.66 (CHp-cym), 31.83 (CH(CH3)2), 22.49 (CH(CH3)2), 22.37 
(CH(CH3)2), 18.35 (CH3). IR: ʋ (cm-1): 2970 (w, CHp-cym), 1630 (s, C=O), 1258 (s, CF3). UV-
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visible: (1.0 × 10-5 M, CH2Cl2, 298 K): λmax 251 nm (ε = 150 910 M-1 · cm-1), 298 nm (ε = 85 
020 M-1 · cm-1) , 498 nm (ε = 55 370 M-1 · cm-1). ESI-MS: 1041.7 [M – 3 CF3SO3]3+. 
Elemental Analysis (%): Calc. for C138H126F18N12O30Ru6S6 · 7 CH2Cl2: C, 41.79; H, 3.39; N, 
4.03. Found: C, 41.62; H, 3.49; N, 4.43. 
[21e][CF3SO3]6: Red solid, Yield: 124mg, 0.033 mmol (61%). 1H NMR (400 MHz, CD2Cl2): 
δ (ppm), 8.74 (d, 12H, 3JH-H = 6.7 Hz, CHtpt), 8.44 (d, 12H, 3JH-H = 6.6 Hz, CHtpt), 7.65 – 7.62 
(m, 12H, CHar), 7.53 – 7.49 (m, 6H, CHar), 7.43 – 7.40 (m, 12H, CHar),  5.82 (d, 12H, 3JH-H = 
6.6 Hz, CHp-cym), 5.68 (d, 12H, 3JH-H = 6.6 Hz, CHp-cym),  2.83 (sep, 6H, 3JH-H = 6.8 Hz, 
CH(CH3)2), 2.22 (s, 18H, CH3), 1.35 (d, 36H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 
MHz, CD2Cl2): δ (ppm), 181.49 (C=O), 170.10 (C=O), 154.29 (CHtpt), 144.96(Ctpt), 130.41 
(CHar), 129.84 (CHar), 128.59 (CHar), 128.19 (CHar), 125.62 (CHar), 104.52 (Cp-cym), 
99.33(Cp-cym), 84.30 (CHp-cym), 83.17 (CHp-cym), 32.07 (CH(CH3)2), 22.62 (CH(CH3)2), 18.58 
(CH3). IR: ʋ (cm-1): 2970 (w, CHp-cym), 1637 (s, C=O), 1260 (s, CF3). UV-visible: (1.0 × 10-5 
M, CH2Cl2, 298 K): λmax 232 nm (ε = 238 010 M-1 · cm-1), 292 nm (ε = 144 760 M-1 · cm-1), 
508 nm (ε = 76 490 M-1 · cm-1). ESI-MS: 1118.1 [M – 3 CF3SO3]3+. Elemental Analysis (%): 
Calc. for C156H138F18N12O30Ru6S6 · 3 CH2Cl2: C, 47.08; H, 3.58; N, 4.14. Found: C, 47.06; H, 
3.78; N, 4.22. 
[21f][CF3SO3]6: Red solid, Yield: 119 mg, 0.030 mmol (56%). 1H NMR (400 MHz, CD2Cl2): 
δ (ppm), 8.60 (br, 12H, CHtpt), 8.41 (br, 12H, CHtpt), 7.16 – 7.14 (m, 9H, CHar), 7.01 (br, 9H, 
CHar), 5.85 (d, 3JH-H = 5.9 Hz, CHp-cym),  5.74 – 5.70 (m, 12H, CHp-cym), 2.87 – 2.83 (m, 6H, 
CH(CH3)2), 2.61 – 2.59 (m, 12H, CH3), 2.52 – 2.50 (m, 24H, CH3), 2.30 – 2.27 (m, 18H, 
CH3), 1.39 (d, 36H, 3JH-H = 6.9 Hz, CH(CH3)2). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 
180.71 (C=O), 180.60 (C=O), 180.57 (C=O), 180.47 (C=O),153.83 (CHtpt), 143.89 (Ctpt), 
137.34 (Car), 137.02 (Car), 129.67 (CHar), 128.72 (CHar), 127.58 (CHar), 124.13 (CHtpt), 
102.50 (Cp-cym), 102.50 (Cdobq), 98.72 (Cp-cym), 84.24 (CHp-cym), 84.04 (CHp-cym), 30.94 
(CH(CH3)2), 23.13 (CH3), 23.05 (CH3), 21.20 (CH(CH3)2), 20.42 (CH3), 20.37 (CH3), 17.14 
(CH3). IR: ʋ (cm-1): 2969 (w, CHp-cym), 1603 (s, C=O), 1259 (s, CF3). UV-visible: (1.0 × 10-5 
M, CH3CN, 298 K): λmax 298 nm (ε = 158 700 M-1 · cm-1), 398 nm (ε = 214 560 M-1 · cm-1), 
509 nm (ε = 67 460 M-1 · cm-1). ESI-MS: 882.8 [M + 4CH3CN – 4CF3SO3]4+, 1227.1 [M + 
2CH3CN – 3CF3SO3]3+. Elemental Analysis (%): Calc. for C168H160F18N12O30Ru6S6 · 7 
CH2Cl2: C, 46.07; H, 3.84; N, 3.68. Found: C, 46.12; H, 4.01; N, 3.69. 
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Synthesis of Host Guest System of the General Formula [porphin⊂(p-cymene)6Ru6(μ-tpt)2(μ-
L)3]6+ ([22d]6+-[22f]6+). 
A mixture of 3 equiv (0.16 mmol) of dinuclear metalla-clip (20d-20f) of the general formula 
[(p-cymene)2Ru2Cl2(μ-L)], 6 equiv of AgCF3SO3 (0.32 mmol) and 1 equiv of guest molecule 
(porphin, 0.053 mmol), in MeOH/ CH2Cl2, (1/1, 30 mL) was stirred at reflux for 24 h and 
then filtered. The solvent was removed, and the dark residue was dissolved in CH2Cl2 (3 mL), 
before slowly adding diethyl ether to precipitate a red solid. The solid was filtered, washed 
with diethyl ether, and dried under vacuum. 
[22d][CF3SO3]6: Red solid, Yield: 128 mg, 0.033 mmol (62%).  1H NMR (400 MHz, 
CD2Cl2): δ (ppm), 9.03 (s, 4H, CHpo), 8.39 – 7.99 (m, 32H, 12H CHtpt + 8H CHpo + 12H 
CHar), 7.88 – 7.79 (m, 3H, CHar), 6.93 – 6.90 (m, 3H, CHdobq), 6.36 (d, 12H, 3JH-H = 5.8 Hz, 
CHtpt), 5.90 – 5.87 (m, 6H, CHp-cym), 5.82 – 5.80 (m, 6H, CHp-cym), 5.72 – 5.70 (m, 6H, CHp-
cym), 5.64 – 5.61 (m, 6H, CHp-cym), 5.97 – 5.48 (m, 12H, CHp-cym), 2.89 – 2.84 (m, 6H, 
CH(CH3)2), 2.16 – 2.14 (m, 18H, CH3), 1.40 – 1.38 (m, 36H, CH(CH3)2), -6.37 (2H, NHpo). 
13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 184.89 (C=O), 184.85 (C=O), 182.14 (C=O), 
164.43 (C=O), 164.40 (C=O), 153.43 (Ctpt), 153.37 (Ctpt), 153.35 (CHtpt), 153.32 (CHtpt), 
131.15 (CHpo), 129.57 (CHar), 123.80 (CHar), 123.77 (CHar), 123.12 (CHar), 119.93 (CHpo), 
105.10 (Cp-cym), 105.09 (Cp-cym), 104.32 (Cp-cym), 104.29 (Cp-cym), 99.51 (CHdobq), 99.48 
(CHdobq), 84.40 (CHp-cym), 84.37 (CHp-cym), 84.00 (CHp-cym), 83.98 (CHp-cym), 83.95 (CHp-cym), 
83.21 (CHp-cym), 82.83 (CHp-cym), 82.75 (CHp-cym), 32.02 (CH(CH3)2), 22.72 (CH(CH3)2), 
22.59 (CH(CH3)2), 18.49 (CH3). IR: ʋ (cm-1): 3067.7 (w, CHp-cym), 1606.9 (s, C=O), 1258.4 
(s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 298 nm (ε = 112 010 M-1 · cm-1), 
398 nm (ε = 211 320 M-1 · cm-1), 501 nm (ε = 68 380 M-1 · cm-1). ESI-MS: 1793.6 [M – 
2CF3SO3]2+, 1146.1 [M – 3CF3SO3]3+. Elemental Analysis (%): Calc. for 
C158H140F18N16O30Ru6S6 · 6 CH2Cl2: C, 44.84; H, 3.49; N, 5.10. Found: C, 44.93; H, 3.57; N, 
5.16. 
[22e][CF3SO3]6: Red solid, Yield: 151 mg, 0.037 mmol (69%). 1H NMR (400 MHz, CD2Cl2): 
δ (ppm), 8.95 (s, 4H, CHpo), 8.23 – 8.21 (m, 12H, CHar), 8.19 (s, 8H, CHpo), 8.16 – 8.13 (m, 
24H, CHar + CHtpt), 7.91 (t, 6H, 3JH-H = 7.3 Hz, CHar), 6.37 (d, 12H, 3JH-H = 5.3, CHtpt), 5.81 
(d, 12H, 3JH-H = 5.7 Hz, CHp-cym), 5.66 (d, 12H, 3JH-H = 5.8 Hz, CHp-cym), 2.88 – 2.78 (m, 6H, 
CH(CH3)2), 2.20 (s, 18H, CH3), 1.39 (d, 36H, 3JH-H = 6.9 Hz, CH(CH3)2), -6.40 (s, 2H, NHpo). 
13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm), 181.85 (C=O), 164.41 (C=O), 153.31 (Ctpt), 
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140.97, 131.21 (CHar), 129.64 (CHar), 129.64 (CHar), 123.92 (CHar), 116.83 (CHpo), 104.73 
(Cp-cym), 84.53 (CHp-cym), 83.20 (CHp-cym), 32.11 (CH(CH3)2), 22.71 (CH(CH3)2), 18.60 
(CH3). IR: ʋ (cm-1): 3067.7 (w, CHp-cym), 1628 (s, C=O), 1259 (s, CF3). UV-visible: (1.0 × 10-
5 M, CH3CN, 298 K): λmax 292 nm (ε = 174 260 M-1 · cm-1), 401 nm (ε = 226 020 M-1 · cm-1), 
506 nm (ε = 80 460 M-1 · cm-1). ESI-MS: 1907.2 [M – 2CF3SO3]2+, 1221.2 [M – 3CF3SO3]3+, 
879 [M – 4CF3SO3]4+. Elemental Analysis (%): Calc. for C176H152F18N16O30Ru6S6 · 2 CH2Cl2: 
C, 49.93; H, 3.67; N, 5.23. Found: C, 49.81; H, 4.01; N, 5.21.  
[22f][CF3SO3]6: Red solid, Yield: 148 mg, 0.035 mmol (65%). 1H NMR (400 MHz, CD2Cl2): 
δ (ppm), 8.94 – 8.71 (m, 4H, CHpo), 8.17 – 8.12 (m, 23H, CHtpt + CHpo + CHar), 7.97 – 7.96 
(m, 6H, CHar), 7.80 (br, 6H, CHar), 7.57 – 7.56 (m, 3H, CHar), 6.36 – 6.30 (m, 12H, CHtpt), 
5.84 – 5.80 (br, 12H, CHp-cym), 5.73 – 5.68 (m, 12H, CHp-cym), 3.05 – 3.03 (m, 18H, CH3), 
2.93 – 2.92 (m, 18H, CH3), 2.86 – 2.83 (m, 6H, CH(CH3)2), 2.31 – 2.28 (s, 18H, CH3), 1.43 
(d, 36H, 3JH-H = 6.9 Hz, CH(CH3)2), -6.43 (2H, NHpo). 13C{1H} NMR (100 MHz, CD2Cl2): δ 
(ppm), 181.86 (C=O), 181.79 (C=O), 181.75 (C=O), 181.69 (C=O), 153.33 (CHtpt),139.33 
(Car), 138.88 (Car), 138.85 (Car), 130.84 (CHar), 130.74 (CHar), 128.84 (CHar), 123.77 (CHtpt), 
104.10 (CHpo), 103.97 (CHpo), 99.90 (Cp-cym), 85.10 (CHp-cym), 85.05 (CHp-cym), 83.13 (CHp-
cym), 83.07 (CHp-cym), 32.09 (CH(CH3)2), 25.11 (CH3), 25.04 (CH3), 22.43 (CH3), 22.40 
(CH(CH3)2), 18.68 (CH3), 18.66 (CH3), 18.62 (CH3). IR: ʋ (cm-1): 2969 (w, CHp-cym), 1603 
(s, C=O), 1259 (s, CF3). UV-visible: (1.0 × 10-5 M, CH3CN, 298 K): λmax 298 nm (ε = 197 
300 M-1 · cm-1), 398 nm (ε = 232 940 M-1 · cm-1), 511 nm (ε = 84 550 M-1 · cm-1). ESI-MS: 
1329.5 [M + 2CH3OH – 3CF3SO3]3+. Elemental Analysis (%): Calc. for 
C188H176F18N16O30Ru6S6 · 7 CH2Cl2: C, 48.04; H, 3.93; N, 4.60. Found: C, 48.08; H, 3.98; N, 
4.75. 
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Crystal Data and Structure Refinement for Compounds [trans-4](CF3SO3)2 and [trans-
7](CF3SO3)2. 
 
 
          [trans-4](CF3SO3)2                                          [trans-7](CF3SO3)2. 
 
Table 10. Crystallographic data and structure refinement parameters for compounds [trans 
4](CF3SO3)2 · 2 (CH3)2CO and [trans-7](CF3SO3)2. 
 
[a] R1 = ||Fo|  |Fc||/|Fo|. [b] wR2 = {[w(Fo2  Fc2)2]/[w(Fo2)2]}1/2. [c] GOF = {[w(Fo2  Fc2)2]/(n  p)}1/2, 
where n is the number of reflections and p is the total number of parameters refined. 
 [trans-4](CF3SO3)2 [trans-7](CF3SO3)2 
chemical formula  C56H70F6N2O12Ru2S2 C40H44F6N2O10Ru2S2 
formula weight 1343.40 1093.03 
crystal system triclinic monoclinic 
space group P -1 P 21/c 
crystal size (mm3) 0.25  0.24  0.19  0.22  0.21  0.18 
crystal color and shape green block green block 
a (Å) 11.4339(6) 10.1102(6) 
b (Å) 15.2550(8) 9.7424(4) 
c (Å) 17.1872(9) 22.0972(14) 
 (°) 82.734(4) 90 
 (°) 83.408(4) 91.082(5) 
 (°) 80.881(4) 90 
cell volume (Å3) 2922.4(3) 2176.1(2) 
T (K) 173(2) 173(2) 
Z 2 2 
scan range (°) 1.71 < θ < 29.22 1.84 < θ < 29.21 
calcd (g cm-3) 1.527 1.668 
 (mm-1) 0.669 0.874 
unique reflections 15804 5893 
reflections used [I > 2σ(I)] 11073 4174 
Rint 0.0795 0.0632 
final R indices [I > 2σ(I)][a] 0.0385, wR2 0.0873 0.0273, wR2 0.0509 
R indices (all data)[b] 0.0593, wR2 0.0911 0.0512, wR2 0.0536 
GOF[c] 0.893 0.840 
max, min Δρ/e (Å-3) 1.927, -1.127 0.620, -0.524 
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Crystal Data and Structure Refinement for Complexes 14a and 14c (the synthesis of these 
two complexes and the crystals growing was performed by the Arion group at Vienna 
University) 
 
                
                      14a 41c 
 
Table 11. Crystallographic data and structure refinement parameters for complexes 14a and 41c. 
 
 
                                  
 
 
 
 
 
 
 
 
 
[a] R1 = ||Fo|  |Fc||/|Fo|. [b] wR2 = {[w(Fo2  Fc2)2]/[w(Fo2)2]}1/2. [c] GOF = {[w(Fo2  Fc2)2]/(n  p)}1/2, 
where n is the number of reflections and p is the total number of parameters refined. 
 
 
 14a 14c 
chemical formula  C26H38Cl2N2O4Ru2 C30H46Cl2N2O6Ru2 
formula weight 715.62 803.73 
space group P -1 P -1 
a (Å) 8.5335(5) 9.0000(5) 
b (Å) 9.4426(5) 9.1532(5) 
c (Å) 10.4007(6) 9.3851(6) 
 (°) 71.004(3) 96.056(3) 
 (°) 70.609(3) 65.188(3) 
 (°) 65.188(3) 95.327(8) 
Crystal size (mm3) 0.18 × 0.15 × 0.10 0.15 × 0.12 × 0.10 
T (K) 100(2) 100(2) 
Z 1 1 
λ (A°) 0.71073 0.71073 
calcd (g cm-3) 1.697 1.747 
 (mm-1) 1.303 1.210 
R1[a] 0.0341 0.0224 
wR2[b] 0.0891 0.0622 
GOF[c] 1.092 1.032 
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Crystal Data and Structure Refinement for Complexes 20d 
 
 
 
Table 12. Crystallographic data and structure refinement parameters for complex 20d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a] R1 = ||Fo|  |Fc||/|Fo|. [b] wR2 = {[w(Fo2  Fc2)2]/[w(Fo2)2]}1/2. 
 [c] GOF = {[w(Fo2  Fc2)2]/(n  p)}1/2, where n is the number  
of reflections and p is the total number of parameters refined. 
 
 
 20d 
chemical formula  C32H34Cl2O4Ru2 
formula weight 755.63 
crystal system orthorhombic 
space group P na21 
crystal color and shape Red rod 
a (Å) 14.6663(4) 
b (Å) b=11.2056(3) 
c (Å) c=18.1049(7) 
 (°) 90 
 (°) 90 
 (°) 90 
cell volume (Å3) 2975.44(16) 
T (K) 173 K 
Z 4 
scan range (°) 1.93 < θ < 29.220 
calcd (g cm-3) 1.687 
 (mm-1) 1.231 
R1[a] 0.0271 
wR2[b] 0.0632 
GOF[c] 0.969 
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Abbreviations 
 
ethylenediamine: en 
cyclooctene: COT 
isopropyl group: Pri  
porphin: po 
p-Cymene: p-cym 
oxalato: ox 
2,5-dioxydo-1,4-benzoquinonato: : dobq 
5,8-dioxydo-1,4-naphthoquinonato: donq 
2,5-dichlorido-1,4-benzoquinonato: dClobq 
4,4′-bipyridine-D8 : bpy-D8 
4,4′-bipyridine : bpy 
1,2-bis(4-pyridyl)ethylene : bpe  
4,4′-azopyridine: bpa 
4-phenylpyridine: L1 
4-styrylpyridine: L2, 
4-methylpyridine: L3 
4-tert-butylpyridine: L4 
2,4,6-tris(4-pyridyl)-1,3,5-triazine: tpt 
1,3,5-tris{2-(4-pyridyl)vinyl}benzene: tpv  
acetylacetonato: acac 
cis-diamminedichloroplatinum(II): cisplatin  
imidazolium-trans-dimethylsulfoxide-imidazole-tetrachlororuthenate: NAMI-A 
imidazolium-trans-bis(1H-indazole)-tetrachlororuthenate: KP1019  
1,3,5-triaza-7-phosphaadamantane: pta  
pentamethylcyclopentadienyl: Cp* 
metal-to-ligand charge transfer: MLCT 
drug concentration necessary for 50% inhibition of cell viability: IC50  
 Abbreviations 
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enhanced permeability and retention: EPR 
electrospray mass spectrometry: ESI-MS  
diffusion ordered spectroscopy: DOSY 
rotating frame nuclear Overhauser effect spectroscopy: ROESY 
selectivity coefficient: aSC  
photodynamic therapy: PDT 
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The self-assembly process is a natural phenomenon with the ability to organize biological 
systems. Its development by chemists as a synthetic process allowed the formation of 
esthetical structures as well as highly complex supramolecular systems with remarkable 
biological functions. Since 1990, metal directed self-assembly strategy has largely contributed 
to the design and synthesis of discrete architectures. The formation of these specific 
architectures needs some control over the different factors ruling the coordination self-
assembly process. 
The aim of this thesis was to offer an insight into the rules dictating the formation of arene 
ruthenium metalla-assemblies built from stable dinuclear metalla-clips and polypyridyl 
linkers. The characterization of the dynamic ligand exchanges using the 1H/2D isotope 
labeling strategy showed relative stability and inertness of the final structure. In addition, the 
study of the intermediate species involved during the assembly of metalla-cycles by NMR 
experiments highlighted the dynamic nature of the Ru-N bond in solution before the final 
closure of the metalla-cycles. This helped us to describe a plausible thermodynamic 
germination pathway together with the specific reactivity of such metalla-assemblies. 
The promising anticancer-activities of the mononuclear arene ruthenium complexes along 
with the preferential accumulation of macromolecular species in the cancer cells led to more 
interest in the anti-proliferative potential of arene ruthenium metalla-cages. Our strategies in 
order to optimize the biological activity of arene ruthenium metalla-prisms were: 
Functionalization of the bridging linkers resulted in selectivity improvements of the active 
compounds towards target cancer cells; and the modification of the portal’s size of metalla-
cages to control the release of a hydrophobic photosensitizer on the human colon cancer cell 
line HT-29. 
 
 
 
 
	
